

11/03/97

A/

DIVISION-CONTINUATION PROGRAM APPLICATION UNDER 37 CFR 1.60 TRANSMITTAL FORM			ATTORNEY'S DOCKET NO.  LKS94-05A2Z					
PRIOR DOCKET NUMBER  LKS94-05A2	ANTICIPATED CLASSIFICATION OF THIS APPLICATION:  <table border="1"> <tr> <td>CLASS  530</td> <td>SUBCLASS  387.1/388.22</td> </tr> </table>		CLASS  530	SUBCLASS  387.1/388.22	PRIOR APPLICATION:  <table border="1"> <tr> <td>EXAMINER  E. Rabin</td> <td>ART UNIT  1816</td> </tr> </table>		EXAMINER  E. Rabin	ART UNIT  1816
CLASS  530	SUBCLASS  387.1/388.22							
EXAMINER  E. Rabin	ART UNIT  1816							

To the Assistant Commissioner for Patents:

This is a request for filing a: ☐ continuation ☒ divisional application under 37 CFR

1.60, of pending prior application serial no. 08/720,565 filed on 09/30/96, which is a Continuation-in-Part of prior International Application PCT/US96/00608, filed 01/19/96; which is a Continuation-in-Part of prior application U.S.S.N. 08/375,199, filed 01/19/95.

of Craig J. Gerard, Norma P. Gerard, Charles R. Mackay, Paul D. Ponath,  
Theodore W. Post and Shixin Qin

for G PROTEIN-COUPLED RECEPTOR GENE CCR3 AND ANTAGONISTS THEREOF

All of the above applications are incorporated herein by reference in their entirety.

1. ☒ Enclosed is a copy of the latest inventor signed prior application, including the oath or declaration as originally filed. I hereby verify that the attached papers are a true copy of the latest inventor signed prior application serial no. 08/720,565 as originally filed on September 30 1996, and further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: November 3, 1997

EXPRESS MAIL LABEL NO. EM080924642US

2. The filing fee has been calculated on the claims

- a. ☐ as filed in the instant application.
- b. ☒ remaining after the entrance of the Preliminary Amendment.

(Col. 1)		(Col. 2)	SMALL ENTITY		OTHER THAN A SMALL ENTITY	
FOR	NO. FILED	NO. EXTRA	RATE	FEE	RATE	FEE
BASIC FEE	.....	.....	.....	\$ 395	.....	\$ 790
TOTAL CLAIMS	21- 20 =	* 1	X \$11=	\$	X \$22=	\$ 22
INDEP CLAIMS	6- 3 =	** 3	X \$41=	\$	X \$82=	\$ 246
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIM PRESENTED			+ \$135=	\$	+ \$270=	\$
			Assignment Fee	\$	Assignment Fee	\$
			Total:	\$	Total:	\$1058

\*not fewer than 20  
\*\*not fewer than 3

3. ☐ A Verified Statement of Small Entity Status was filed in the prior application on \_\_\_\_\_.
4. ☐ A Verified Statement of Small Entity Status is enclosed.
5. ☒ Cancel in this application original claims 1-37 and 40-48 of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)
6. ☐ This application is being filed by fewer than all the inventors named in the prior application in order to correct inventorship. In accordance with 37 CFR 1.60(b), the Commissioner is requested to delete the name(s) of the following person(s) who are not inventors of the invention being claimed in this application:
7. ☒ Amend the specification as follows:

- a. ☐ Insert the following paragraph before the first line of the specification:

Related Application

This application is a

☐ continuation ☐ division ☐ continuation-in-part  
of co-pending application Serial No. \_\_\_\_\_ filed \_\_\_\_\_,  
which is incorporated herein by reference in its entirety.

- b. ☒ Replace the paragraph after "Related Applications" with the following:

This application is a ☐ continuation ☒ division  
of co-pending application Serial No. 08/720,565 filed September 30, 1996,  
which is a continuation-in-part of International Application  
PCT/US96/00608, (designating the United States), with an International  
filing date of January 19, 1996, which a continuation-in-part of U.S.  
Serial No. 08/375,199, filed January 19, 1995.

All of the above applications are incorporated herein by reference in their  
entirety.

8. ☒ Enclosed are the following:

- a. ☒ Informal drawings as originally filed.  
b. ☐ Formal drawings as originally filed.  
c. ☐ New formal drawings.

9. ☐ Priority of application serial no. \_\_\_\_\_ filed on \_\_\_\_\_ in  
\_\_\_\_\_ is claimed under 35 U.S.C. 119.  
(country)

☐ The certified copy has been filed in prior application serial no.  
\_\_\_\_\_, filed \_\_\_\_\_.

10. ☒ The prior application is assigned of record to  
Brigham and Women's Hospital, Reel 8471, Frame 0353  
Children's Medical Center Corp., Reel 8339 Frame 0757  
LeukoSite, Inc., Reel 8339 Frame 0970

11. ☒ A preliminary amendment is enclosed.

12. ☒ Also enclosed a Substitute Sequence Listing in Paper and CRF, Statement Under 1.825(a),(b)

13. ☒ The power of attorney in the prior application is to  
David E. Brook, Reg. No. 22,592; James M. Smith, Reg. No. 28,043; Leo R.  
Reynolds Reg. No. 20,884; Richard A. Wise, Reg. No. 18,041; Patricia Granahan,  
Reg. No. 32,227; Mary Lou Wakimura, Reg. No. 31,804; Thomas O. Hoover,  
Reg. No. 32,470; Alice O. Carroll, Reg. No. 33,542; N. Scott Pierce, Reg.  
No. 34,900; and Helen E. Wendler, Reg. No. 37,964

- a. ☒ The power appears in the original papers in the prior application.
- b. ☐ An associate power of attorney to \_\_\_\_\_  
\_\_\_\_\_ was filed in the prior application on \_\_\_\_\_.  
\_\_\_\_\_ is enclosed herewith.
- c. ☐ Since the power does not appear in the original papers, a copy of the power  
in the prior application is enclosed.

14. ☒ Address all future communications to:

David E. Brook, Esq.

Hamilton, Brook, Smith & Reynolds, P.C.

2 Militia Drive

Lexington, MA 02173-4799

15. ☐ Please charge my Deposit Account No. 08-0380 in the amount of \$\_\_\_\_\_.  
A copy of this letter is enclosed.

16. ☒ A check in the amount of \$ 1,058.00 to cover the filing fee is enclosed.

17. ☒ Authorization is hereby granted to charge payment of any additional fees associated with this communication, including any fees under 37 CFR 1.16 or under 37 CFR 1.17, or credit any overpayment to Deposit Account No. 08-0380. A copy of this letter is enclosed for accounting purposes.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

*Helen E. Wendler*

By: Helen E. Wendler

Registration No. 37,964

Attorney for Applicant(s)

Telephone (781) 861-6240

Facsimile (781) 861-9540

*November 3, 1997*  
Dated: \_\_\_\_\_  
Two Militia Drive  
Lexington, MA 02173

- ☒ Attorney or Agent of Record  
☐ Filed under Rule \$1.34(a)



94-05A2Z.PLA  
HEW49:WP51  
DEB:HEW:lab  
11/03/97

PATENT APPLICATION  
Attorney's Docket No.: LKS94-05A2Z

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Craig J. Gerard, Norma P. Gerard, Charles R.  
Mackay, Paul D. Ponath, Theodore W. Post and  
Shixin Qin

Divisional Application of: Application No. 08/720,565, filed  
September 30, 1996

For: G PROTEIN-COUPLED RECEPTOR GENE CCR3 AND ANTAGONISTS THEREOF

Date: November 3, 1997  
EXPRESS MAIL LABEL NO. EM080924642US

PRELIMINARY AMENDMENT AND TRANSMITTAL OF  
SUBSTITUTE SEQUENCE LISTING

Assistant Commissioner for Patents  
Washington, D.C. 20231  
Box SEQUENCE

Sir:

Please amend the above-identified application as follows:

In the Specification

At page 17, line 25, please delete the blank space and insert therefor, "HB-12195".

Please replace the Sequence Listing at pages 131-143 of the specification with the attached Substitute "Sequence Listing" pages 131-144, comprising SEQ ID NOS:1-18. Please renumber pages 144-153 of the specification as filed as pages 145-154.

In the Claims

Please add new Claims 53-67 as follows:

- 53. An antibody having binding specificity for a mammalian chemokine receptor 3 protein or portion thereof, wherein the antibody can compete with monoclonal antibody 7B11 for binding to a human chemokine receptor 3 protein or portion thereof.
54. An antigen binding fragment of the antibody of Claim 53.
55. The antibody of Claim 53 wherein the antibody is 7B11.
56. An antigen binding fragment of the antibody of Claim 55.
57. A hybridoma which produces the antibody of Claim 53.
58. The hybridoma of Claim 57 wherein the hybridoma is the 7B11 hybridoma.
59. A method of inhibiting at least one function of a mammalian chemokine receptor 3 protein, comprising the step of contacting said protein with an antibody or antigen binding fragment thereof having binding specificity for a mammalian chemokine receptor 3 protein or portion thereof, wherein said antibody or fragment can compete with monoclonal antibody 7B11 for binding to a human chemokine receptor 3 protein or portion thereof.

60. The method of Claim 59 wherein the antibody or fragment thereof is 7B11 or an antigen binding fragment thereof.
61. A method for treating an inflammatory disease or condition, comprising administering to a mammal a therapeutically effective amount of an antibody or antigen binding fragment thereof having binding specificity for a mammalian chemokine receptor 3 protein or portion thereof, wherein said antibody or fragment can compete with monoclonal antibody 7B11 for binding to a human chemokine receptor 3 protein or portion thereof.
62. The method of Claim 61 wherein the antibody or fragment thereof is 7B11 or an antigen binding fragment thereof.
63. The method of Claim 61 wherein the inflammatory disease or condition is selected from the group consisting of an allergic disease or condition, autoimmune disease, and graft rejection.
64. The method of Claim 61 wherein the inflammatory disease or condition is asthma or allergic hypersensitivity.
65. A method of detecting or measuring human chemokine receptor 3 protein or a portion thereof on the surface of a cell, comprising contacting said cell with an antibody or antigen binding fragment thereof having binding specificity for a mammalian chemokine receptor 3 protein, wherein said antibody or fragment can compete with monoclonal antibody 7B11 for binding to a human chemokine receptor 3 protein.
66. The method of Claim 65 wherein the cell is a leukocyte.
67. The method of Claim 65 wherein the antibody or fragment thereof is 7B11 or an antigen binding fragment thereof.---

REMARKS

*Substitute "Sequence Listing" and Statements Under 37 C.F.R. §§ 1.825(a) and (b)*

Transmitted herewith is a copy of a Substitute "Sequence Listing" in paper form for the above-identified patent application as required by 37 C.F.R. §§ 1.825(a) and 1.821(c), and a copy of the Substitute "Sequence Listing" in computer readable form as required by 37 C.F.R. §§ 1.825(b) and 1.821(e). As required by 37 C.F.R. § 1.825(b), Applicants' Attorney hereby states that the contents of the Substitute "Sequence Listing" in paper form and in computer readable form submitted herewith are the same and, as required by 37 C.F.R. § 1.825(a), also states that the submission includes no new matter.

The Substitute Sequence Listing differs from the Sequence Listing in the specification by the inclusion of (a) complete prior application data, (b) the correct Attorney docket number, and (c) current telephone and facsimile numbers. The specification is being amended in order to incorporate the Substitute Sequence Listing into the application.

*Amendments*

The specification is also being amended in order to include the ATCC Accession Number of the 7B11 hybridoma. New Claims 53-66 have been added. Support for Claims 53 and 55 can be found in the subject application at page 36, lines 4-19, for example. Support for antigen binding fragments as recited in Claims 54, 56, 59, 60-62, 65 and 67 can be found in the specification at page 38, line 5 *et seq.* and in original Claim 52, for example. Support for new Claims 57 and 58 can be found in the subject application at page 17, lines 21-25, and at page 36, line 20 through page 37, line 12, for example.

Support for the methods of Claims 59-64 can be found at page 21, lines 9-18, and at page 63, line 4 *et seq.*, for example. Support for the method of Claims 65-67 can be found at, for

example, page 41, lines 9-16; at page 60, line 30 through page 61, line 25; and Figures 9A-9D, 10A-10C, and 18A-18B, for example.

Applicants' Attorney respectfully requests entry of the Substitute Sequence Listing and amendments to the specification in the subject application.

Respectfully submitted,



---

Helen E. Wendler  
Attorney for Applicants  
Registration No. 37,964  
Telephone (781) 861-6240  
Facsimile (781) 861-9540

Lexington, Massachusetts 02173

Dated: *November 3, 1991*

G PROTEIN-COUPLED RECEPTOR GENE CCR3 AND  
ANTAGONISTS THEREOF

Description

Related Applications

- 5        This application is a continuation-in-part of  
International Application PCT/US96/00608, (designating the  
United States), with an International filing date of  
January 19, 1996, which is a continuation-in-part of U.S.  
Serial No. 08/375,199, filed January 19, 1995, the  
10    teachings of which are each incorporated herein by  
reference in their entirety.

Government Support

- Work described herein was supported in whole or in  
part by a U.S. government grant. The U.S. government has  
15    certain rights in this invention.

Background

- Chemokines, also referred to as intercrines, are  
soluble, low molecular weight members of the cytokine  
family which have chemoattractant function. Chemokines are  
20    capable of selectively inducing chemotaxis of the formed  
elements of the blood (other than red blood cells),  
including leukocytes such as monocytes, macrophages,  
eosinophils, basophils, mast cells, and lymphocytes, such  
as T cells, B cells, and polymorphonuclear leukocytes  
25    (neutrophils)). In addition to stimulating chemotaxis,  
other changes can be selectively induced by chemokines in  
responsive cells, including changes in cell shape,  
transient rises in the concentration of intracellular free  
calcium ( $[Ca^{2+}]$ ), granule exocytosis, integrin

upregulation, formation of bioactive lipids (e.g., leukotrienes) and respiratory burst, associated with leukocyte activation. Thus, the chemokines are early triggers of the inflammatory response, causing inflammatory mediator release, chemotaxis and extravasation to sites of infection or inflammation.

The chemokines characterized to date are related in primary structure. They share four conserved cysteines, which form disulphide bonds. cDNA cloning and biochemical characterization of several chemokines has revealed that the proteins have a leader sequence of 20-25 amino acids, which is cleaved upon secretion to yield a mature protein of approximately 92-99 amino acids. Based on the conserved cysteine motif, the family is divided into two branches, designated as the C-C chemokines ( $\beta$  chemokines) and the C-X-C chemokines ( $\alpha$  chemokines), in which the first two conserved cysteines are adjacent or are separated by an intervening residue, respectively. Baggiolini, M. and C.A. Dahinden, *Immunology Today*, 15: 127-133 (1994)).

The C-X-C chemokines include a number of chemoattractants which are potent chemoattractants and activators of neutrophils, such as interleukin 8 (IL-8), PF4 and neutrophil-activating peptide 2 (NAP-2). The C-C chemokines include molecules such as human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2 and MCP-3), RANTES (Regulated on Activation, Normal T Expressed and Secreted), and the macrophage inflammatory proteins 1 $\alpha$  and 1 $\beta$  (MIP-1 $\alpha$  and MIP-1 $\beta$ ), which have been characterized as chemoattractants and activators of monocytes or lymphocytes, but do not appear to be chemoattractants for neutrophils. For example, recombinant RANTES is a chemoattractant for monocytes, as well as for memory T cells *in vitro* (Schall, T.J. et al., *Nature*, 347: 669-671 (1990)). More recently a chemokine called lymphotactin with a single cysteine pair in the molecule has been

identified which attracts lymphocytes (Kelner, G.S., et al., *Science*, 266: 1395-1359 (1994)).

The C-C chemokines are of great interest because of their potential role in allergic inflammation. For example, MCP-1 induces exocytosis of human basophils, resulting in release of high levels of inflammatory mediators, such as histamine and leukotriene C<sub>4</sub>. Similarly, there is great interest in the receptors for the C-C chemokines, which trigger these cellular events in response to chemokine binding. A receptor for C-C chemokines has recently been cloned and is reported to bind MIP-1 $\alpha$  and RANTES. Accordingly, this MIP-1 $\alpha$ /RANTES receptor was designated C-C chemokine receptor 1 (CKR-1; Neote, K. et al., *Cell*, 72: 415-425 (1993); Horuk, R. et al., WO 94/11504, published May 26, 1994; Gao, J.-I. et al., *J. Exp. Med.*, 177: 1421-1427 (1993)). An MCP-1 receptor has also been cloned (Charo, I.F. et al., *Proc. Natl. Acad. Sci. USA*, 91: 2752 (1994)). This receptor, designated CKR-2, is reported to bind MCP-1 with high affinity and MCP-3 with lower affinity (Charo, I.F., et al., *Proc. Natl. Acad. Sci. USA*, 91: 2752-2756 (1994)). CKR-2 has been shown to exist in two isoforms resulting from the use of an alternative splice site in isoform A producing a distinct cytoplasmic tail. Isoform B, which is not spliced in this region, has been shown to be a functional receptor for MCP-1 and MCP-3 in binding and signal transduction assays (Charo, I.F., et al., *Proc. Natl. Acad. Sci. USA*, 91: 2752-2756 (1994); Myers, S.J., et al., *J. Biol. Chem.*, 270: 5786-5792 (1995)). More recently, a new receptor called CKR-4 has been described; cRNA from this receptor was reported to produce a Ca<sup>2+</sup> activated chloride current in response to MCP-1, MIP-1 $\alpha$ , and RANTES when injected in to *X. laevis* oocytes (Power, C.A., et al., *J. Biol. Chem.*, 270: 19495-19500 (1995)).



The MCP-1 receptor (CKR-2) and C-C chemokine receptor 1 are predicted to belong to a superfamily of seven transmembrane spanning G-protein coupled receptors (Gerard C., and Gerard, N.P., *Annu. Rev. Immunol.*, 12: 775-808 (1994); Gerard C., and Gerard N.P., *Curr. Opin. Immunol.*, 6: 140-145 (1994)). This family of G-protein coupled (serpentine) receptors comprises a large group of integral membrane proteins, containing seven transmembrane-spanning regions. The ligands of these receptors include a diverse group of molecules, including small biogenic amine molecules, such as epinephrine and norepinephrine, peptides, such as substance P and neurokinins, and larger proteins, such as chemokines. The receptors are coupled to G proteins, which are heterotrimeric regulatory proteins capable of binding GTP and mediating signal transduction from coupled receptors, for example, by the production of intracellular mediators.

The cloning and sequencing of two IL-8 receptor cDNAs reveals that these C-X-C receptor proteins also share sequence similarity with seven transmembrane-spanning G protein-coupled receptor proteins (Murphy P.M. and H.L. Tiffany, *Science*, 253: 1280-1283 (1991); Murphy et al., WO 93/06299; Holmes, W.E. et al., *Science*, 253: 1278-1280 (1991)). Additional receptors for chemotactic proteins such as anaphylatoxin C5a and bacterial formylated tripeptide fMLP have been characterized by cloning and been found to encode receptor proteins which also share sequence similarity to these seven transmembrane-spanning proteins (Gerard, N.P. and C. Gerard, *Nature*, 349: 614-617 (1991); Boulay, F. et al., *Biochemistry*, 29: 11123-11133 (1990)). Although a number of other proteins with significant sequence similarity and similar tissue and leukocyte subpopulation distribution to known chemokine receptors have been identified and cloned, the ligands for these

receptors remain undefined. Thus, these proteins are referred to as orphan receptors.

The isolation and characterization of additional genes and the encoded receptors, and the characterization of the  
5 corresponding ligands, is essential to an understanding of the interaction of chemokines with their target cells and the events stimulated by this interaction, including chemotaxis and cellular activation of leukocytes.

#### Summary of the Invention

10 The present invention relates to isolated and/or recombinant nucleic acids which encode a mammalian (e.g., human) receptor protein designated C-C Chemokine Receptor 3 (CKR-3 or CCR3). The invention further relates to recombinant nucleic acid constructs, such as plasmids or  
15 retroviral vectors, which contain a nucleic acid which encodes a receptor protein of the present invention, or portions of said receptor. The nucleic acids and constructs can be used to produce recombinant receptor proteins. In another embodiment, the nucleic acid encodes  
20 an antisense nucleic acid which can hybridize with a second nucleic acid encoding a receptor of the present invention, and which, when introduced into cells, can inhibit the expression of receptor.

Another aspect of the present invention relates to  
25 proteins or polypeptides, referred to herein as isolated, recombinant mammalian CKR-3 receptors. The recombinant CKR-3 receptors or polypeptides can be produced in host cells as described herein. In one embodiment, a receptor protein is characterized by high affinity binding of one or  
30 more chemokines, such as eotaxin, RANTES and/or MCP-3, and/or the ability to stimulate a (one or more) cellular response(s) (e.g., chemotaxis, exocytosis, release of one or more inflammatory mediators).

Antibodies reactive with the receptors can be produced using the receptors or portions thereof as immunogen or cells expressing receptor protein or polypeptide, for example. Such antibodies or fragments thereof are useful  
5 in therapeutic, diagnostic and research applications, including the purification and study of the receptor proteins, identification of cells expressing surface receptor, and sorting or counting of cells.

Also encompassed by the present invention are methods  
10 of identifying ligands of the receptor, as well as inhibitors (e.g., antagonists) or promoters (agonists) of receptor function. In one embodiment, suitable host cells which have been engineered to express a receptor protein or polypeptide encoded by a nucleic acid introduced into said  
15 cells are used in an assay to identify and assess the efficacy of ligands, inhibitors or promoters of receptor function. Such cells are also useful in assessing the function of the expressed receptor protein or polypeptide.

According to the present invention, ligands,  
20 inhibitors and promoters of receptor function can be identified and further assessed for therapeutic effect. Ligands and promoters can be used to stimulate normal receptor function where needed, while inhibitors of receptor function can be used to reduce or prevent receptor  
25 activity. Thus, the present invention provides a new strategy of anti-inflammatory therapy, useful in a variety of inflammatory and autoimmune diseases, comprising administering an inhibitor of receptor function to an individual (e.g., a mammal). In contrast, stimulation of  
30 receptor function by administration of a ligand or promoter to an individual provides a new approach to selective stimulation of leukocyte function, which is useful, for example, in the treatment of parasitic infections.

Brief Description of the Drawings

Figure 1A-1C illustrates the nucleotide sequence determined from a genomic clone encoding a human CKR-3 protein also referred to as Eos L2 receptor (SEQ ID NO:1),  
5 and the predicted amino acid sequence of the protein encoded by the open-reading frame (SEQ ID NO:2).

Figure 2A-2B illustrates the nucleotide sequence determined from the cDNAs encoding a human CKR-3 receptor (SEQ ID NO:3), and the predicted amino acid sequence of the  
10 protein encoded by the open-reading frame (SEQ ID NO:4).

Figure 3 is an illustration of one type of transendothelial chemotaxis assay. A culture insert is placed into a container, such as a well in a 24-well plate, creating a first and second chamber within the well.  
15 ECV304 endothelial cells are grown in a monolayer on the polycarbonate membrane on the inner side of the insert. Cells to be assessed for a response to a substance (e.g., a chemokine) are introduced into the top chamber and the substance is introduced into the bottom chamber.  
20 Chemotaxis can be assessed by detecting cells which migrate through the endothelial layer into the bottom chamber, by removing the insert and detecting or counting cells by a suitable method. For example, cells in the bottom chamber can be collected and assessed by flow cytometry (e.g., FACS  
25 analysis, light scattering).

Figure 4 is a histogram illustrating the chemotaxis of human eosinophils in response to various chemokines. Human eosinophils were purified using a standard protocol, and assessed by microscopy for their response to various  
30 chemokines in a 24 well transendothelial chemotaxis assay (cells per high power field (HPF)).

Figure 5 is an illustration of a FACS analysis of various clones of L1-2 pre-B cells transfected with Eos L2. Cells from over 200 clones were stained with M2 anti-FLAG  
35 Mab followed by anti-mouse Ig-FITC. (Y-axis, number of

cells; X-axis, fluorescence). In the negative control (PAUL 001), transfected cells were stained with an irrelevant antibody.

Figure 6 is a histogram illustrating the binding of RANTES and MIP-1 $\alpha$  to human eosinophils. Purified normal human eosinophils were incubated with 0.1 nM <sup>125</sup>I-labeled MIP-1 $\alpha$  or RANTES ("Hot") in the presence or absence of various cold chemokines (MIP-1 $\alpha$ , RANTES, IL-8, MCP-1, MCP-3) at 250 nM.

Figure 7 is a graph illustrating inhibition of the binding of <sup>125</sup>I-labeled RANTES to human eosinophils by various cold chemokines (RANTES, MIP-1 $\alpha$ , MCP-1 and MCP-3). Human eosinophils were incubated with 0.1 nM radiolabeled RANTES and the indicated concentrations of cold chemokines. The data plotted are the means and standard deviations of duplicates for each sample.

Figure 8 is a histogram illustrating the binding of 0.1 nM <sup>125</sup>I-labeled ("Hot") RANTES or 0.1 nM <sup>125</sup>I-labeled ("Hot") MCP-3 to Eos L2 infected SF9 cells (cpm, counts per minute). (From left to right: Hot Rantes only; Hot Rantes + Cold Rantes; Hot MCP-3 only; Hot MCP-3 + cold MCP-3).

Figures 9A-9D are graphs illustrating CKR-3 expression on leukocytes as determined using MAb LS26-5H12 and flow cytometry. Leukocyte subsets were stained with anti-CKR-3 MAb LS26-5H12 (solid lines) or an IgG<sub>1</sub> isotype-matched control antibody (MOPC-21) (shaded profile). Figure 9A, eosinophils; Figure 9B, T Cells; Figure 9C, monocytes; Figure 9D, neutrophils. Dead cells were excluded based on propidium iodide staining.

Figures 10A-10C are graphs illustrating cell surface staining of L1.2 cells transiently transfected with a CKR-3 receptor (Figure 10A), mock-transfected L1.2 control cells (Figure 10B), or cell line E5 (a stable L1.2 CKR-3 transfectant) (Figure 10C) with an anti-CKR-3 monoclonal

antibody (LS26-5H12, solid line). Background staining with control monoclonal antibody MOPC-21 is also shown (shaded profile).

Figures 11A-11D are graphs illustrating the results of competitive ligand binding of radiolabeled human eotaxin to the E5 cell line (a stable L1-2 cell line transfected with a CKR-3 receptor; Figure 11A) or to human eosinophils (Figure 11B). Cells were incubated with 0.6 nM  $^{125}\text{I}$ -labeled eotaxin and various concentrations of unlabeled eotaxin (O), RANTES ( $\Delta$ ), or MCP-3 ( $\square$ ). After 60 minutes at room temperature, cell pellets were washed and counted. Scatchard plots of unlabeled eotaxin competition were calculated from the data (Figure 11C, E5 cell line; Figure 11D, eosinophils).

Figure 12 is a histogram illustrating the inhibition by various chemokines of human eotaxin binding to the E5 cell line. E5 cells (stable L1-2/CKR-3 transfectants) were incubated with 0.6 nM radiolabeled eotaxin and 250 nM unlabeled chemokines or no competitor as indicated.

Figures 13A-13C are histograms illustrating chemotaxis of L1.2 cells and L1.2 receptor transfectants.  $1 \times 10^6$  cells of the E5 cell line (stable L1-2/CKR-3 transfectants) (Figure 13A), the parental L1.2 cell line (Figure 13B), or an IL-8 RB L1.2 receptor transfectant line LSLW-2 (Figure 13C) were placed in the top chamber and chemokines placed in the bottom chamber at the concentrations specified. Migration was allowed for 4 hours and cells migrating to the bottom chamber were counted. All assays were performed in duplicate and the results representative of at least three separate experiments. Chemokines are listed along the x-axis, number of cells migrated along the y-axis, and concentration of chemokine along the z-axis.

Figures 14A-14B are graphs illustrating the chemotactic response of eosinophils from two different

individuals. The response resembles that of CKR-3 L1.2 transfectants. Donor to donor variation of chemotactic responses of eosinophils to eodaxin, RANTES, MCP-3, and MIP-1 $\alpha$  was observed. Eosinophils were purified from blood, and assessed for their chemotactic response to various concentrations of chemokines. Values are from a representative experiment of at least 4 performed, using the same two blood donors.

Figure 15 is a graph illustrating the binding of  $^{125}\text{I}$ -labeled RANTES to a membranes from a stable cell line (A31-293-20) obtained by transfecting 293 cells with the A31 cDNA clone (square with central dot) as compared with binding to membranes from untransfected 293 cells (filled circles).

Figure 16 is a histogram illustrating the binding of  $^{125}\text{I}$ -labeled MCP-3 to a membranes from a stable cell line (A31-293-20) obtained by transfecting 293 cells with the A31 cDNA clone as compared with binding to membranes from untransfected 293 cells. Binding of labeled MCP-3 to membranes from transfected (A31-20) or untransfected (UT293) cells was determined in the absence of cold MCP-3 (0 nM) or in the presence of cold MCP-3 (100 nM).

Figure 17 is a histogram illustrating the specificity of binding, which was assessed by determining the amount of bound  $^{125}\text{I}$ -labeled MCP-3 which could be displaced by cold MCP-3 from membranes of transfected (A31-20) or untransfected (UT293) cells.

Figure 18A is a FACs profile of the fluorescence intensity of stable L1.2 transfectants expressing either CCR1, CCR2, CCR3, CCR4, CCR5, CXCR1 (IL-8 RA), or CXCR2 (IL-8 RB) which were stained with anti-CCR3 mAb 7B11. Negative control staining for all the L1.2 transfectants (not shown) resembled the staining shown for 7B11 on CCR1 transfectants.

Figure 18B is a FACS profile of human eosinophils, lymphocytes, T cell blasts, monocytes, and granulocytes stained with mAb 7B11. Staining profiles were representative of at least 4 experiments.

5        Figure 18C is a histogram illustrating binding of radiolabeled human eotaxin, RANTES, MCP-2, or MCP-3 to L1.2 CCR3 or CCR1 transfectants, and inhibition by mAb 7B11 or cold chemokines. Cells were incubated with 0.1 nM <sup>125</sup>I-labeled eotaxin, RANTES, or MCP-3, and either 50  $\mu$ l of  
10    100  $\mu$ g/ml of irrelevant mAb (MOPC 21), mAb 7B11, or 250 nM cold chemokine. After 60 minutes at room temperature, cell pellets were washed and counted.

Figure 19 is a graph illustrating inhibition of binding of radiolabeled eotaxin, RANTES, and MCP-3 to human  
15    eosinophils by mAb 7B11. Human eosinophils were incubated with 0.1 nM <sup>125</sup>I-labeled-eotaxin, -RANTES, or -MCP-3, and various concentrations of mAb 7B11. After 60 minutes at room temperature, cell pellets were washed and counted. Data was analyzed by KaleidaGraph, which calculated an IC50  
20    of eotaxin of 25.7 ng/ml, for RANTES of 13.7 ng/ml, and for MCP-3 of 18.8 ng/ml. The level of inhibition using 250 nM cold chemokine is shown at the bottom left of the plot:

• eotaxin,  $\square$  RANTES, and  $\blacktriangle$  MCP-3.

Figure 20A is a graph illustrating the dose response  
25    of mAb 7B11 inhibition of eosinophil chemotaxis to eotaxin. The level of background migration of cells (no chemokine) is shown by the  $\square$  symbol (bottom left of the plot).

Figure 20B is a histogram illustrating inhibition of eosinophil chemotaxis to various chemoattractants by 5  $\mu$ g  
30    or 20  $\mu$ g/ml of 7B11 mAb. For the experiments shown in both 20A and 20B,  $1 \times 10^6$  human eosinophils were placed in the top chamber of the transwell and 10 nM of chemokine was placed in the bottom chamber. Various concentrations of 7B11 mAb were placed in the top well. After 1.5 hours the



cells migrating to the bottom chamber were counted using flow cytometry. The results are representative of at least four separate experiments.

Figure 21 is a series of tracings illustrating that mAb 7B11 inhibits  $[Ca^{2+}]_i$  by human eosinophils in response to eotaxin, RANTES, MCP-2, MCP-3 and MCP-4. Human eosinophils were labeled with Fura-2, and stimulated sequentially with mAb (A), followed 40 sec later with the indicated chemokine (B), and 100 sec following that with C5a (C).  $[Ca^{2+}]_i$  fluorescence changes were recorded using a spectrofluorimeter. The tracings are representative of five separate experiments, performed with eosinophils from different donors. In the top panels, an irrelevant control mAb (MOPC-21) was used, and in the bottom panels, mAb 7B11. Antibodies were used at a final concentration of 6.4  $\mu$ g/ml. Chemokines were used at: eotaxin, 10 nM, RANTES, 20 nM, MCP-2, 200 nM, MCP-3, 200 nM, MCP-4, 10 nM. C5a was used at 400 pM.

Figure 22A is a FACS profile illustrating IL-8 receptor expression on freshly isolated eosinophils from a healthy individual. Eosinophils were stained with mAbs to CXCR1 (solid line), CXCR2 (dotted line) or a control mAb (shaded), and were analyzed by flow cytometry.

Figure 22B is a FACS profile illustrating IL-8 receptor expression on IL-5 treated eosinophils. Eosinophils cultured with IL-5 for 5 days were stained with mAbs, as in Figure 22A.

Figure 22C is a FACS profile illustrating IL-8 receptor expression on eosinophils isolated from an eosinophilic individual, and stained with mAbs, as in Figures 22A and 22B.

Figure 22D are tracings illustrating inhibition of  $[Ca^{2+}]_i$  of day 5 IL-5 primed eosinophils to various chemokines by mAb 7B11. Methods were the same as those

described in the legend of Figure 21. The mAbs and chemokines used were: 1. control mAb, eotaxin, C5a; 2. 7B11, eotaxin, C5a; 3. control mAb, RANTES, C5a; 4. 7B11, RANTES, C5a; 5. control mAb, IL-8, C5a; 6. 7B11, IL-8, C5a. The results are representative of at least three separate experiments.

Figure 23A is a histogram illustrating blockade of eotaxin-, RANTES- and MCP-3-induced eosinophil peroxidase (EPO) release by monoclonal antibody 7B11. Clear bars indicate the amount of EPO released by either 10 nM eotaxin, 100 nM eotaxin, 100nM RANTES or 100 nM MCP-3. Black bars indicate the amount of EPO released when 10 µg/ml of 7B11 was present in the eosinophil degranulation assay. The bar marked "blank" corresponds to a no chemokine, no antibody (buffer) control.

Figure 23B is a histogram illustrating the effect of mAb 7B11 on C5a-induced eosinophil peroxidase release. Clear bars indicate the amount of EPO released by 1 nM C5a. Black bars indicate the amount of EPO released when 10 µg/ml of 7B11 was present in the eosinophil degranulation assay.

Figure 24A is a graph illustrating eosinophil degranulation induced by eotaxin measured by release of eosinophil peroxidase (EPO) and eosinophilic cationic protein (ECP).

Figure 24B is a graph illustrating eosinophil degranulation induced by C5a measured by release of eosinophil peroxidase (EPO) and eosinophilic cationic protein (ECP).

Figure 25 is a graph illustrating stimulation of peroxidase release from eosinophils by eotaxin.

Figure 26 is a graph illustrating stimulation of glucuronidase release from eosinophils by eotaxin.

Figure 27 is a graph illustrating stimulation of arylsulfatase B release from human eosinophils by eotaxin.

Figure 28 illustrates expression of CCR3 on eosinophil and basophils in whole blood. Whole blood was stained with 7B11-FITC and anti-human IgE biotin followed by Streptavidin quantum Red as described in Example 12 and  
5 analyzed by flow cytometry.

Figure 29 is a histogram illustrating histamine release by human basophils in response to chemokines.

Figure 30A is a graph illustrating that basophils chemotax in response to eotaxin and MCP-4.

10 Figure 30B is a histogram illustrating blockade of basophil chemotax in response to eotaxin and MCP-4 using anti-CCR3 mAb 7B11.

#### Detailed Description of the Invention

As described herein, nucleic acids encoding a novel  
15 human receptor, designated Eos L2 or C-C chemokine receptor 3 (CKR-3), also referred to herein as "CCR3", have been isolated. Both human genomic and cDNA clones have been characterized. The cDNA clone was isolated from an eosinophil cDNA library constructed from eosinophils  
20 obtained from a patient with hypereosinophilic syndrome. Sequence analysis of the clones revealed a gene containing an open reading frame of 1065 nucleotides encoding a predicted protein of 355 amino acids (Figures 1A-1C and 2A-2B; SEQ ID NOS: 2 and 4), which shares amino acid sequence  
25 similarity with other C-C chemokine receptors, which are believed to be G protein-coupled receptors and to have a similar structure of seven transmembrane spanning regions.

The predicted proteins encoded by CKR-3 genomic and cDNA clones contain four cysteine residues, one in each of  
30 the extracellular domains at positions 24, 106, 183 and 273 (SEQ ID NOS:2 and 4). Cysteines at these positions are conserved in all chemokine receptors, including CKR-1, CKR-2, CKR-4, IL8-RA and IL8-RB. In addition, this receptor contains an amino acid motif, DRYLAIVHA (residues

130-138) (SEQ ID NOS: 2 and 4), which is also highly conserved among C-X-C and C-C chemokine receptors and is predicted to be intracellular. There are two consensus sites for protein kinase C phosphorylation (Kishimoto, A., et al., *J. Biol. Chem.*, 260: 12492-12499 (1985); Woodgett, J.R., *Eur. J. Biochem.*, 161: 177-184 (1986)), one in the third intracellular loop at AA position 231, and one in the cytoplasmic tail at AA position 333. In addition, there are eight serine/threonine residues in the cytoplasmic tail, which may serve as phosphorylation sites for G-protein coupled receptor kinases such as those isolated from neutrophils (Haribabu, B. and R. Snyderman, *Proc. Natl. Acad. Sci. USA*, 90: 9398 (1993)) or other related family members (Benovic, J.L., and Gomez, J., *J. Biol. Chem.*, 268: 19521-19527 (1993); Kunapuli, P., and Benovic, J.L., *Proc. Natl. Acad. Sci. USA*, 90: 5588-5594 (1993)). Serine/threonine rich cytoplasmic tails are also a common feature of chemokine receptors. Unlike CKR-1, CKR-2, CKR-4, IL-8RA and IL-8RB receptors, CKR-3 does not contain sites for N-linked glycosylation in any extracellular domain. The CKR-3 receptor protein is distinct from C-C chemokine receptor 1, also referred to as the MIP-1 $\alpha$ /RANTES receptor.

The nucleic acid sequences obtained from genomic and cDNA libraries were co-linear, with the following exceptions. Upstream of the initiation codon the two sequences diverge (at position 78 of Figure 2A). The genomic clone appears to have an intron which separates the promoter and most of the 5' untranslated region from the coding region. This genomic arrangement is similar to that found in other seven transmembrane-spanning chemoattractant receptors (Gerard, N.P., et al., *Biochemistry*, 32: 1243-1250 (1993); Murphy, P.M., et al., *Gene*, 133: 285-290 (1993)) including IL-8 RA and RB (Ahuja, S.K., et al., *J. Biol. Chem.*, 269: 26381-89 (1994); Sprenger, H., et al., *J.*

*Biol. Chem.*, 269: 11065-11072 (1994); Sprenger, H., et al.,  
*J. Immunol.*, 153: 2524-2532 (1994)) and CKR-1 (Gao, J.L.,  
et al., *J. Exp. Med.*, 177: 1421-1427 (1993)). Furthermore,  
5 divergence reveals a canonical splice acceptor sequence.

Initial sequence information revealed two regions in  
which the cDNA sequence appeared to be shifted in frame,  
resulting from an insertion of a base followed by the  
deletion of a base, or the deletion of a base followed by  
10 the insertion of a base. These alterations resulted in  
four contiguous amino acid differences in the predicted  
proteins at positions 263-266 and 276-279, respectively.  
Other differences led to amino acid differences at  
positions 182, 196, 197, and 315 of the predicted proteins.  
15 The nucleotide sequence presented in SEQ ID NO:5 is a  
consensus sequence, which includes regions which were  
sequenced in both clones, and was constructed by simple  
alignment (base for base) of the initial nucleic acid  
sequences. SEQ ID NO:6, in which the initial amino acid  
20 differences between the cDNA and genomic clones are  
indicated by Xaa, represents the predicted protein of SEQ  
ID NO:5. However, further sequence analysis revealed that  
nucleotide sequences of the open reading frames appear to  
differ only at a position corresponding to nucleotides 918-  
25 919 of Figure 2B. The genomic clone has a CG at this  
position, while the cDNA clone has a GC at this position.  
Thus, the genomic clone codes for threonine (ACG) at  
position 276 and the cDNA clone codes for serine (AGC) at  
position 276. The difference may be due to a sequencing  
30 ambiguity, or an error introduced into the cDNA during  
reverse transcription. Alternatively, the conservative  
substitution (serine/threonine) could be due to polymorphism  
between individuals. Another alternative is that the  
differences are due to mutation of the receptor gene in the

eosinophils of the patient from which RNA for cDNA library construction was obtained.

Monoclonal and polyclonal antibodies specific for a C-C chemokine receptor 3 of human origin were produced using an N-terminal synthetic peptide of the receptor. FACS (fluorescence activated cell sorting) analysis using one of the monoclonal antibodies (LS26-5H12) revealed significant expression of this receptor on human eosinophils, but not on leukocytes including monocytes, neutrophils, lymphocytes, T cells, T cell blasts (produced by activation with CD3 MAb) (Figures 9A-9D). This pattern of expression was confirmed by Northern analysis with RNA from highly purified leukocyte subsets. However, in some experiments, CKR-3 mRNA or receptor was detected in T lymphocytes; accordingly, it is possible that CKR-3 is expressed on a subset of T lymphocytes (Example 5). In addition, as described herein, a monoclonal antibody specific for the C-C chemokine receptor 3 of human origin was produced (Example 10). The mAb, termed 7B11, is an antibody antagonist of C-C chemokine receptor 3 of human origin and the functions of the receptor. The 7B11 hybridoma cell line was deposited on September 25, 1996 under the terms of the Budapest Treaty at the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD, 20852, under Accession Number \_\_\_\_\_.

Genomic and cDNA clones were also expressed in a variety of systems. Antibody was used to detect expression of receptor from the genomic clone on transfected mammalian cells and baculovirus-transfected insect cells. Stable transfectants of mammalian cells expressing CKR-3 were constructed, and the encoded receptor was shown to bind radiolabeled eotaxin specifically and with high affinity, comparable to the binding affinity observed with eosinophils. Studies with transfected mammalian cells indicated that the receptor also binds RANTES and MCP-3

specifically and with high affinity, but not other CC or CXC chemokines tested. Consistent with the binding data, as shown herein, receptor transfectants generated in a murine B cell lymphoma line migrated in chemotaxis assays  
5 in response to eotaxin, RANTES, and MCP-3, but not to any other chemokines tested. When expressed in several heterologous systems, the human receptor did not significantly bind to MIP-1 $\alpha$  under the conditions used. Moreover, chemotaxis and ligand binding assays using  
10 eosinophils indicate that RANTES and MCP-3 bind eosinophils through a receptor, which is distinct from C-C chemokine receptor 1, the MIP-1 $\alpha$ /RANTES receptor.

The role of MIP-1 $\alpha$  as an eosinophil chemoattractant has been controversial. Some investigators detect  
15 chemotactic responses (Rot, A., et al., *J. Exp. Med.*, 176: 1489-1495 (1995)), whereas others do not (Figure 4, Example 1; Ebisawa, M., et al., *J. Immunol.*, 153: 2153-2160 (1994); and Ponath, P.D., et al., *J. Clin. Invest.*, (1996)(in press)). Interestingly, MIP-1 $\alpha$  is an eosinophil  
20 chemoattractant in the mouse, and this appears to be mediated through the murine CKR-3 homologue, which also binds and signals with murine eotaxin (Post, T.W., et al., *J. Immunol.*, 155: 5299-5305 (1995); the teachings of which are incorporated herein by reference in their entirety).

25 Using the proteins and antibodies of the present invention, additional ligands, as well as additional cell types (e.g., leukocytes, such as basophils) which express CKR-3 receptor, can be identified. For example, as described herein, using 7B11, it has been demonstrated that  
30 basophils express CCR3. The ability of other chemokines to bind mammalian CKR-3 receptors can be assessed according to the present invention.

The cloning and characterization of clones encoding a novel receptor, and the isolation and characterization of  
35 the novel CKR-3 receptor which demonstrably binds and

mediates chemotaxis in response to chemokines such as eotaxin, RANTES and MCP-3, suggests that this receptor is a member of a family of seven transmembrane spanning G protein-coupled receptors which are involved in selective leukocyte chemotaxis and activation in response to chemokines. The CKR-3 or CCR3 receptor and its mammalian homologs are distinct from the MIP-1 $\alpha$ /RANTES receptor and the MCP-1 receptor (i.e., are receptors other than C-C chemokine receptor 1 (CKR-1) and MCP-1 receptor (CKR-2) and their homologs).

Because of the role of chemokine receptors in the selective induction of leukocyte chemotaxis and leukocyte activation in response to chemoattractants, chemokine receptors play a fundamental role in leukocyte migration, and particularly in migration associated with inflammation. Chemokines, produced at sites of inflammation and infection, specifically recruit selected leukocyte subtypes from the circulation to the site of inflammation in the tissues. Subsequent to chemokine binding to a leukocyte chemokine receptor, integrin activation occurs, and leukocytes adhere firmly to the endothelial cell wall via leukocyte integrins and endothelial cell adhesion molecules. The leukocytes become flat in shape, and migrate through the endothelium towards sites of inflammation in the tissues. The specificity of a leukocyte for a tissue or inflammatory site is, in many cases, determined at the level of the chemokine-receptor interaction, rather than at the level of the adhesion interaction between integrin and cellular adhesion molecules.

RANTES and MCP-3 are among the most potent chemotactic cytokines for eosinophils and basophils. In addition, RANTES is reported to be a chemoattractant for memory T cells, a subpopulation of T lymphocytes. As shown herein, RANTES and MCP-3 can induce chemotaxis of eosinophils.



CKR-3 receptor proteins described herein also bind RANTES and MCP-3 with high affinity.

As is further shown herein, CKR-3 binds eotaxin specifically and with high affinity (comparable to the  
5 binding affinity observed with eosinophils), and the CKR-3 receptor is highly restricted in its expression. Although a number of chemoattractants have been identified for eosinophils, such as RANTES and MCP-3 (Baggiolini, M. and Dahinden, C.A., *Immunol. Today*, 15: 127-33 (1994);  
10 Dahinden, C.A., et al., *J. Exp. Med.*, 179: 751-756 (1994); Kameyoshi, Y, et al., *J. Exp. Med.*, 176: 587-592 (1992); Rot, A., et al., *J. Exp. Med.*, 176: 1489-1495 (1995)), as well as PAF, C5a, and IL-16 (Wardlaw, A.J., et al., *J. Clin. Invest.*, 78: 1701-1706 (1986); Gerard, N.P., et al.,  
15 *J. Biol. Chem.*, 264: 1760-1765 (1989); Rand, T.H., et al., *J. Exp. Med.*, 173: 1521-1528 (1991)), these chemoattractants also induce the migration of other leukocyte cell types. In contrast, the chemokine eotaxin, a potent eosinophil chemoattractant originally identified in guinea pigs and  
20 subsequently in mouse and human, is selectively chemotactic for eosinophils (Jose, P.J., et al., *Biochem. Biophys. Res. Commun.*, 205: 788-794 (1994); Jose, P.J., et al., *J. Exp. Med.*, 179: 881-887 (1994); Rothenburg, M.E. et al., *Proc. Natl. Acad. Sci. U.S.A.*, 92: 8960-8964 (1995); Ponath,  
25 P.D., et al., *J. Clin. Invest.*, 97(3):604-612 (1996)). In addition, eotaxin binds to and signals through CKR-3 with a high degree of fidelity, in contrast to chemokines such as MCP-3, which binds CKR-1 and CKR-2 (Ben-Baruch, A., et al., *J. Biol. Chem.*, 270: 22123-22128 (1995)) in addition to  
30 CKR-3, or MIP-1 $\alpha$ , which binds CKR-1 and CKR-4 (Neote, K., et al., *Cell*, 72: 415-425 (1993); Power, C.A., et al., *J. Biol. Chem.*, 270: 19495-19500 (1995)). The restricted expression of CKR-3 on eosinophils, and the fidelity of eotaxin binding to CKR-3, provides a potential mechanism  
35 for the selective recruitment and migration of eosinophils

within tissues. In this regard, the production of eotaxin within a tissue can lead to selective eosinophil recruitment; eotaxin injection into the skin of rhesus monkeys leads to selective eosinophil migration. In addition, eotaxin was shown to recruit eosinophils *in vivo* at a 10-fold lower dose than RANTES, similar to the *in vitro* chemotaxis of CKR-3 transfectants (Ponath, P.D., et al., *J. Clin. Invest.*, 97(3):604-612 (1996)).

Modulation of mammalian CKR-3 receptor function according to the present invention, through the inhibition or promotion of receptor function, such as binding, signalling or stimulation of a cellular response, provides an effective and selective way of inhibiting or promoting leukocyte-mediated inflammatory action, particularly that of eosinophils, basophils, and/or T cells. Ligands, inhibitors and promoters of CKR-3 receptor function, such as those identified as described herein, can be used to modulate leukocyte function for therapeutic purposes.

Eosinophils do not express the MIP-1 $\alpha$  receptor, and do not express significant amounts of MCP-1 receptor. In addition, as noted above, eotaxin and RANTES are some of the most potent chemoattractants for eosinophils, and eotaxin and RANTES bind specifically and with high affinity to the CKR-3 receptor. As a major eosinophil and lymphocyte chemokine receptor, the CKR-3 receptor is an important target for interfering with or promoting eosinophil, basophil, and/or T lymphocyte function. Compounds which inhibit or promote CKR-3 receptor function, such as ligands, inhibitors and promoters identified according to the present method, are particularly useful for modulating eosinophil, basophil, and/or T cell function for therapeutic purposes.

For example, as described herein, anti-CCR3 antibody 7B11, inhibits eosinophil degranulation induced by binding of eotaxin to CCR-3 (Exmaple 11). As also demonstrated

herein, 7B11 inhibits basophil chemotaxis to eotaxin and MCP-4, as well as histamine release by basophils in response to chemokines (Example 13).

	Chemokine 5 receptor	other names	ligands defined to date
	CCR1	CC CKR1	MIP-1 $\alpha$ , RANTES, MCP-3
	CCR2a,b	MCP-1Ra,b	MCP-1, MCP-3, MCP-4
	CCR3	CKR-3	eotaxin, RANTES, MCP-2,3,4
	CCR4		RANTES, MIP-1 $\alpha$ , MCP-1
10	CCR5	CC CKR5	RANTES, MIP-1 $\alpha$ , MIP-1 $\beta$
	CXCR1	IL-8 RA, IL-8 R1	IL-8
	CXCR2	IL-8 RB, IL-8 R2	IL-8, GRO $\alpha$ , NAP-2, ENA-78
	CXCR3	none	IP-10, Mig
	CXCR4	Fusin/humstr/Lestr	SDF-1

#### 15 Nucleic Acids, Constructs and Vectors

The present invention relates to isolated and/or recombinant (including, e.g., essentially pure) nucleic acids having sequences which encode a mammalian (e.g., human) receptor protein designated Eos L2 or C-C Chemokine

20 Receptor 3 (CKR-3, also referred to herein as CCR3) or a portion of said receptor. In one embodiment, the nucleic acid or portion thereof encodes a protein or polypeptide having at least one function characteristic of a mammalian C-C chemokine receptor (e.g., a mammalian CKR-3 receptor),

25 such as a binding activity (e.g., ligand, inhibitor and/or promoter binding), a signalling activity (e.g., activation

of a mammalian G protein, induction of rapid and transient increase in the concentration of cytosolic free calcium  $[Ca^{2+}]_i$ , and/or stimulation of a cellular response (e.g., stimulation of chemotaxis, exocytosis or inflammatory mediator release by leukocytes, integrin activation). The present invention also relates more specifically to isolated and/or recombinant nucleic acids or a portion thereof comprising sequences which encode a mammalian CKR-3 receptor or a portion thereof.

10       The invention further relates to isolated and/or recombinant nucleic acids that are characterized by (1) their ability to hybridize to: (a) a nucleic acid having the sequence SEQ ID NO:1, SEQ ID NO:3 or SEQ ID NO:5, (b) a the complement of any one of SEQ ID NOS:1, 3 or 5, (c) a  
15       portion of the foregoing comprising the coding region (nucleotides 181-1245 of SEQ ID NO:1, nucleotides 92-1156 of SEQ ID NO:3, or nucleotides 15-1079 of SEQ ID NO:5), or the RNA counterpart of any one of the foregoing, wherein U is substituted for T; or (2) by their ability to encode a  
20       polypeptide having the amino acid sequence SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6 or a functional equivalents thereof (i.e., a polypeptide having ligand binding activity for one or more natural or physiological ligand(s) of the receptor and/or stimulatory function responsive to ligand binding,  
25       such that it can stimulate a cellular response (e.g., stimulation of chemotaxis, exocytosis or inflammatory mediator release by leukocytes); or (3) by both characteristics.

30       In one embodiment, the percent amino acid sequence identity between SEQ ID NOS:2, 4 or 6 and functional equivalents thereof is at least about 70% ( $\geq 70\%$ ). In a preferred embodiment, functional equivalents of SEQ ID NOS:2, 4 or 6 share at least about 80% sequence identity with SEQ ID NOS:2, 4 or 6, respectively. More preferably,

the percent amino acid sequence identity between SEQ ID NOS:2, 4 or 6 and functional equivalents thereof is at least about 90%, and still more preferably, at least about 95%. Isolated and/or recombinant nucleic acids meeting  
5 these criteria comprise nucleic acids having sequences identical to sequences of naturally occurring mammalian CKR-3 receptors and portions thereof, or variants of the naturally occurring sequences. Such variants include mutants differing by the addition, deletion or substitution  
10 of one or more residues, modified nucleic acids in which one or more residues is modified (e.g., DNA or RNA analogs), and mutants comprising one or more modified residues.

Such nucleic acids can be detected and isolated by  
15 hybridization under high stringency conditions or moderate stringency conditions, for example. "High stringency conditions" and "moderate stringency conditions" for nucleic acid hybridizations are explained on pages 2.10.1-2.10.16 (see particularly 2.10.8-11) and pages 6.3.1-6 in  
20 *Current Protocols in Molecular Biology* (Ausubel, F.M. et al., eds., Vol. 1, Suppl. 26, 1991), the teachings of which are incorporated herein by reference (see also Example 2). Factors such as probe length, base composition, percent mismatch between the hybridizing sequences, temperature and  
25 ionic strength influence the stability of nucleic acid hybrids. Thus, high or moderate stringency conditions can be determined empirically, depending in part upon the characteristics of the known DNA to which other unknown nucleic acids are being compared for homology.

30 Isolated and/or recombinant nucleic acids that are characterized by their ability to hybridize to a nucleic acid having the sequence SEQ ID NOS: 1, 3 or 5 or the complements of any one of SEQ ID NOS: 1, 3 or 5 (e.g. under high or moderate stringency conditions) may further encode  
35 a protein or polypeptide having at least one function

characteristic of a mammalian C-C chemokine receptor (e.g., a mammalian CKR-3 receptor), such as a binding activity (e.g., ligand, inhibitor and/or promoter binding), a signalling activity (e.g., activation of a mammalian G protein, induction of rapid and transient increase in the concentration of cytosolic free calcium  $[Ca^{2+}]_i$ ), and/or stimulation of a cellular response (e.g., stimulation of chemotaxis, exocytosis or inflammatory mediator release by leukocytes, integrin activation).

10       The signalling function of a protein or polypeptide encoded by hybridizing nucleic acid can be detected by enzymatic assays for G protein activity responsive to receptor binding (e.g., exchange of GTP for GDP on the G protein  $\alpha$  subunit, using membrane fractions). G protein  
15       coupling can be further assessed, for example, using assays in which stimulation by G protein is blocked by treatment or pre-treatment of cells or a suitable cellular fraction (e.g., membranes) with specific inhibitors of G proteins, such as *Bordetella pertussis* toxin (Bischoff, S.C. et al.,  
20       *Eur. J. Immunol.* 23: 761-767 (1993); Sozzani, S. et al., *J. Immunol.* 147: 2215-2221 (1991)).

          The stimulatory function of a protein or polypeptide encoded by hybridizing nucleic acid can be detected by standard assays for chemotaxis or mediator release, using  
25       cells expressing the protein or polypeptide (e.g., assays which monitor chemotaxis, exocytosis (e.g., of enzymes such as eosinophil peroxidase,  $\beta$ -glucuronidase) or mediator release in response to a ligand (e.g., a chemokine such as eotaxin, RANTES or MCP-3) or a promoter.

30       The binding function of a protein or polypeptide encoded by hybridizing nucleic acid can be detected in binding or binding inhibition assays using membrane fractions containing receptor or cells expressing receptor, for instance (see e.g., Example 9; Van Riper et al., *J.*

*Exp. Med.*, 177: 851-856 (1993); Sledziewski et al., U.S. Patent No. 5,284,746 (Feb. 8, 1994)). Thus, the ability of the encoded protein or polypeptide to bind a ligand, such as eotaxin, RANTES or MCP-3, an inhibitor and/or promoter, 5 can be assessed. Functions characteristic of a mammalian CKR-3 receptor may also be assessed by other suitable methods (see below).

These methods, alone or in combination with other suitable methods can also be used in procedures for the 10 identification and/or isolation of nucleic acids which encode a polypeptide having the amino acid sequence SEQ ID NO: 2, 4, 6 or functional equivalents thereof, and having an activity detected by the assay. Portions of the isolated nucleic acids which encode polypeptide portions of 15 SEQ ID NO: 2, 4 or 6 having a certain function can be also identified and isolated in this manner.

Nucleic acids of the present invention can be used in the production of proteins or polypeptides. For example, a nucleic acid containing all or part of the coding sequence 20 for a mammalian CKR-3 receptor, or DNA which hybridizes to the sequence SEQ ID NO: 1, 3 or 5, or the complement of any one of SEQ ID NO: 1, 3 or 5, can be incorporated into various constructs and vectors created for further manipulation of sequences or for production of the encoded 25 polypeptide in suitable host cells.

Nucleic acids referred to herein as "isolated" are nucleic acids separated away from the nucleic acids of the genomic DNA or cellular RNA of their source of origin (e.g., as it exists in cells or in a mixture of nucleic 30 acids such as a library), and may have undergone further processing. "Isolated" nucleic acids include nucleic acids obtained by methods described herein, similar methods or other suitable methods, including essentially pure nucleic acids, nucleic acids produced by chemical synthesis, by 35 combinations of biological and chemical methods, and

recombinant nucleic acids which are isolated. Nucleic acids referred to herein as "recombinant" are nucleic acids which have been produced by recombinant DNA methodology, including those nucleic acids that are generated by procedures which rely upon a method of artificial recombination, such as the polymerase chain reaction (PCR) and/or cloning into a vector using restriction enzymes. "Recombinant" nucleic acids are also those that result from recombination events that occur through the natural mechanisms of cells, but are selected for after the introduction to the cells of nucleic acids designed to allow and make probable a desired recombination event.

#### Antisense Constructs

In another embodiment, the nucleic acid is an antisense nucleic acid, which is complementary, in whole or in part, to a target molecule comprising a sense strand, and can hybridize with the target molecule. The target can be DNA, or its RNA counterpart (i.e., wherein T residues of the DNA are U residues in the RNA counterpart). When introduced into a cell using methods known in the art or other suitable methods, antisense nucleic acid can inhibit the expression of the gene encoded by the sense strand. Antisense nucleic acids can be produced by standard techniques.

In one embodiment, the antisense nucleic acid is wholly or partially complementary to and can hybridize with a target nucleic acid, wherein the target nucleic acid can hybridize to a nucleic acid having the sequence of the complement of SEQ ID NO:1, 3 or 5. For example, antisense nucleic acid can be complementary to a target nucleic acid having the sequence of SEQ ID NO: 5 or a portion thereof sufficient to allow hybridization. In another embodiment, the antisense nucleic acid is wholly or partially complementary to and can hybridize with a target nucleic



acid which encodes a mammalian CKR-3 receptor (e.g., human Eos L2 receptor).

Antisense nucleic acids are useful for a variety of purposes, including research and therapeutic applications.

5 For example, a construct comprising an antisense nucleic acid can be introduced into a suitable cell to inhibit receptor expression. Such a cell provides a valuable control cell, for instance in assessing the specificity of receptor-ligand interaction with the parent cell or other  
10 related cell types. In another aspect, such a construct is introduced into some or all of the cells of a mammal. The antisense nucleic acid inhibits receptor expression, and inflammatory processes mediated by CKR-3 receptors in the cells containing the construct can be inhibited. Thus, an  
15 inflammatory disease or condition can be treated using an antisense nucleic acid of the present invention. Suitable laboratory animals comprising an antisense construct can also provide useful models for deficiencies of leukocyte function, and of eosinophil deficiency in particular, and  
20 provide further information regarding CKR-3 receptor function. Such animals can provide valuable models of infectious disease, useful for elucidating the role of leukocytes, such as eosinophils and/or T lymphocytes, in host defenses.

## 25 Mammalian Nucleic Acids

Because advances in the understanding and treatment of human inflammatory and autoimmune diseases and of parasitic infections would be of tremendous benefit, human CKR-3 or CCR3 was the species selected for most of the experimental  
30 work described herein. However, the approaches described to isolate and manipulate the genomic and cDNAs of human CKR-3 (Eos L2), to construct vectors and host strains, and to produce and use the receptor or fragments thereof, can be applied to other mammalian species, including, but not

limited to primate (e.g., a primate other than a human, such as a monkey (e.g., cynomolgus monkey)), bovine (e.g., cows), ovine (e.g., sheep), equine (e.g., horses), canine (e.g., dog), feline (e.g., domestic cat) and rodent (e.g., guinea pig, murine species such as rat, mouse) species. The human CKR-3 cDNA or genomic clones described here, or sufficient portions thereof, whether isolated and/or recombinant or synthetic, including fragments within the coding sequence produced by PCR, can be used as probes to detect and/or recover homologous CKR-3 genes (homologs) or other related receptor genes (e.g., novel C-C chemokine receptor genes) from other mammalian species (e.g., by hybridization, PCR or other suitable techniques). This can be achieved using the procedures described herein or other suitable methods.

#### Proteins and Peptides

The invention also relates to proteins or polypeptides encoded by nucleic acids of the present invention. The proteins and polypeptides of the present invention can be isolated and/or recombinant. Proteins or polypeptides referred to herein as "isolated" are proteins or polypeptides purified to a state beyond that in which they exist in mammalian cells. "Isolated" proteins or polypeptides include proteins or polypeptides obtained by methods described herein, similar methods or other suitable methods, including essentially pure proteins or polypeptides, proteins or polypeptides produced by chemical synthesis, or by combinations of biological and chemical methods, and recombinant proteins or polypeptides which are isolated. Proteins or polypeptides referred to herein as "recombinant" are proteins or polypeptides produced by the expression of recombinant nucleic acids.

In a preferred embodiment, the protein or polypeptide has at least one function characteristic of a mammalian

CKR-3 receptor, such as a binding activity (e.g., ligand, inhibitor and/or promoter binding), a signalling activity (e.g., activation of a mammalian G protein, induction of rapid and transient increase in the concentration of cytosolic free calcium  $[Ca^{2+}]_i$ ), and/or stimulation of a cellular response (e.g., stimulation of chemotaxis, exocytosis or inflammatory mediator release by leukocytes, integrin activation). As such, these proteins are referred to as CKR-3 proteins of mammalian origin or mammalian chemokine receptor 3 proteins, and include, for example, naturally occurring mammalian CKR-3 receptors, variants of those proteins and/or portions thereof. Such variants include polymorphic variants and natural or artificial mutants, differing by the addition, deletion or substitution of one or more amino acid residues, or modified polypeptides in which one or more residues is modified, and mutants comprising one or more modified residues. An example would be a mammalian CKR-3 receptor protein which binds eotaxin.

In a particularly preferred embodiment, like naturally occurring mammalian CKR-3 receptor proteins or polypeptides, the mammalian CKR-3 receptors of the present invention have ligand binding function for one or more natural or physiological ligand(s) and/or stimulatory function responsive to ligand binding, such that they can stimulate a cellular response (e.g., stimulation of chemotaxis, exocytosis or inflammatory mediator release by leukocytes). For example, in the case of a human chemokine receptor 3 protein, an isolated human CKR-3 protein will bind the one or more natural or physiological ligand(s). As shown herein, an isolated human CKR-3 protein binds eotaxin and RANTES specifically and with high affinity, and specifically binds MCP-3. In one embodiment, a human CKR-3 receptor protein or polypeptide also triggers chemotaxis,

exocytosis or inflammatory mediator release by leukocytes in response to ligand binding.

The invention further relates to fusion proteins, comprising a mammalian CKR-3 receptor protein or polypeptide (as described above) as a first moiety, linked to a second moiety not occurring in the mammalian CKR-3 receptor as found in nature. Thus, the second moiety can be an amino acid or polypeptide. The first moiety can be in an N-terminal location, C-terminal location or internal to the fusion protein. In one embodiment, the fusion protein comprises a human CKR-3 receptor as the first moiety, and a second moiety comprising a linker sequence and affinity ligand (e.g., an enzyme, an antigen, epitope tag).

Fusion proteins can be produced by a variety of methods. For example, some embodiments can be produced by the insertion of a CKR-3 gene or portion thereof into a suitable expression vector, such as Bluescript®II SK +/- (Stratagene), pGEX-4T-2 (Pharmacia) and pET-15b (Novagen). The resulting construct is then introduced into a suitable host cell for expression. Upon expression, fusion protein can be isolated or purified from a cell lysate by means of a suitable affinity matrix (see e.g., *Current Protocols in Molecular Biology* (Ausubel, F.M. et al., eds., Vol. 2, Suppl. 26, pp. 16.4.1-16.7.8 (1991))). In addition, affinity labels provide a means of detecting CKR-3 receptor proteins or polypeptides present in a fusion protein. For example, the cell surface expression or presence in a particular cell fraction of a fusion protein comprising an antigen or epitope affinity label can be detected by means of an appropriate antibody (see, e.g., Example 3).

The invention also relates to isolated and/or recombinant portions of a CKR-3 receptor of mammalian origin, such as a fragment of a human CKR-3 receptor. As is described in more detail below, portions of a mammalian

CKR-3 receptor can be produced (e.g., synthetic peptides) and used to produce antibodies. In one embodiment, an isolated and/or recombinant portion (e.g., a peptide) of a selected mammalian CKR-3 receptor has at least one

5 immunological property. As used herein, with reference to a portion of a receptor, an immunological property includes immunoreactivity (bound by antibodies raised against a mammalian CKR-3 receptor protein of the present invention, including a portion thereof), immunogenicity (induces an

10 antibody response against itself when used in a suitable immunization protocol), and/or cross-reactivity (induces antibodies reactive with a selected mammalian receptor). Furthermore, portions of a CKR-3 receptor having at least one function characteristic of mammalian CKR-3 receptors,

15 such as binding activity, signalling activity, or stimulatory function (stimulation of a cellular response), can also be produced. Extensive studies on the structure and function of mammalian G protein-coupled receptors provide the basis for being able to divide mammalian CKR-3

20 receptors into functional domains (see e.g., Lefkowitz et al., *J. Biol. Chem.*, 263: 4993-4996 (1988); Panayotou and Waterfield, *Curr. Opinion Cell Biol.*, 1: 167-176 (1989)). Furthermore, portions of the receptor can be produced which have full or partial function on their own, or which when

25 joined with another portion of a second receptor (though fully, partially, or nonfunctional alone), constitute a functional protein having at least one function characteristic of a mammalian CKR-3 receptor (e.g., ligand-, inhibitor- or promoter-binding function). (See,

30 e.g., Sledziewski et al., U.S. Patent No. 5,284,746 regarding the construction and use of hybrid G protein-coupled receptors useful in detecting the presence of ligand in a test sample).

Method of Producing Recombinant Mammalian CKR-3 Receptors

Another aspect of the invention relates to a method of producing a mammalian CKR-3 receptor or a portion thereof. Constructs suitable for the expression of a mammalian CKR-3 receptor or a portion thereof are also provided. The constructs can be introduced into a suitable host cell. Cells expressing a recombinant mammalian CKR-3 receptor or a portion thereof can be isolated and maintained in culture. Such cells are useful for a variety of purposes such as the production of protein for characterization, isolation and/or purification, and in binding assays for the detection of ligands, or inhibitors or promoters of ligand binding. Suitable host cells can be procaryotic, including bacterial cells such as *E. coli*, *B. subtilis* and or other suitable bacteria, or eucaryotic, such as fungal or yeast cells (e.g., *Pichia pastoris*, *Aspergillus species*, *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Neurospora crassa*), or other lower eucaryotic cells, and cells of higher eucaryotes such as those from insects (e.g., Sf9 insect cells) or mammals (e.g., 293 cells, Chinese hamster ovary cells (CHO)). (See, e.g., Ausubel, F.M. et al., eds. *Current Protocols in Molecular Biology*, Greene Publishing Associates and John Wiley & Sons Inc., (1993)).

Host cells which produce a recombinant mammalian CKR-3 receptor protein, portion thereof, or fusion protein can be produced as follows. A nucleic acid encoding all or part of the coding sequence for a mammalian CKR-3 receptor or fusion protein can be inserted into a nucleic acid vector, e.g., a DNA vector, such as a plasmid, virus or other suitable replicon for expression. A variety of vectors are available, including vectors which are maintained in single copy or multiple copy, or which become integrated into the host cell chromosome.

The transcriptional and/or translational signals of a selected CKR-3 receptor can be used to direct expression. Alternatively, suitable expression vectors are available. Suitable vectors for expression of a nucleic acid encoding all or part of the coding sequence for a mammalian CKR-3 receptor or fusion protein can contain a number of additional components, including, but not limited to one or more of the following: an origin of replication; a selectable marker gene; one or more expression control elements, such as a transcriptional control element (e.g., a promoter, an enhancer, terminator), and/or one or more translation signals; a signal sequence or leader sequence (for membrane targeting encoded e.g., by the vector, receptor or other source).

A promoter can be provided for expression in a suitable host cell. Promoters can be constitutive or inducible. For example, a promoter can be operably linked to a nucleic acid encoding the receptor protein, portion thereof or fusion protein, such that it is capable of directing expression of the encoded polypeptide. A variety of suitable promoters for procaryotic (e.g., lac, tac, T3, T7 promoters for *E. coli*) and eukaryotic (e.g., yeast alcohol dehydrogenase (ADH1), SV40, CMV) hosts are available.

In addition, the expression vectors typically comprise a selectable marker for selection of host cells carrying the vector and an origin of replication, in the case of replicable expression vector. Genes encoding products which confer antibiotic or drug resistance are common selectable markers and may be used in prokaryotic (e.g.,  $\beta$ -lactamase gene (ampicillin resistance), *Tet* gene for tetracycline resistance) and eukaryotic cells (e.g., neomycin (G418 or geneticin), gpt (mycophenolic acid), ampicillin, or hygromycin resistance genes). Dihydrofolate reductase marker genes permit selection with methotrexate

in a variety of hosts. Genes encoding the gene product of auxotrophic markers of the host (e.g., *LEU2*, *URA3*, *HIS3*) are often used as selectable markers in yeast. Use of viral (e.g., baculovirus) or phage vectors, and vectors  
5 which are capable of integrating into the genome of the host cell, such as retroviral vectors, are also contemplated. The present invention also relates to cells carrying these expression vectors.

When the nucleic acid encoding the receptor protein or  
10 polypeptide is inserted into the vector, operably linked to one or more of these components, and the resulting construct is introduced into host cells maintained under conditions suitable for expression, the receptor protein or polypeptide is produced. The construct can be introduced  
15 into cells by a method appropriate to the host cell selected (e.g., transformation, transfection, electroporation, infection). For production of receptor, host cells comprising the construct are maintained under conditions appropriate for expression, e.g., in the  
20 presence of inducer (e.g., n-butyrate), suitable media supplemented with appropriate salts, growth factors, antibiotic, nutritional supplements, etc.

#### Antibodies

The invention further relates to antibodies reactive  
25 with a CKR-3 receptor or portion thereof. In one embodiment, antibodies are raised against an isolated and/or recombinant mammalian CKR-3 protein including portions thereof (e.g., a peptide). In a preferred embodiment, the antibodies specifically bind CKR-3 (CCR3)  
30 receptor(s) or a portion thereof. Antibodies which can inhibit one or more functions characteristic of a mammalian CKR-3 (CCR3), such as a binding activity, a signalling activity, and/or stimulation of a cellular response are also encompassed by the present invention, such as an



antibody which can inhibit binding of a ligand (i.e., one or more ligands) to CKR-3 (CCR3) and/or one or more functions mediated by CKR-3 (CCR3) in response to a ligand. For example, monoclonal antibody 7B11 can inhibit binding of eotaxin, RANTES, MCP-2, MCP-3 and MCP-4 to human CKR-3 (CCR3). Furthermore, 7B11 can inhibit functions mediated by human CKR-3 (CCR3), including chemokine-induced calcium flux, eosinophil and basophil chemotaxis, histamine release and release of other granule components.

In a particularly preferred embodiment, the antibodies of the present invention have specificity for human CKR-3 (CCR3), and have an epitopic specificity similar to that of murine 7B11 monoclonal antibody described herein.

Antibodies with an epitopic specificity similar to that of murine 7B11 monoclonal antibody can be identified by their ability to compete with murine 7B11 for binding to human CCR3 (e.g., to cells bearing human CCR3, such as eosinophils, basophils, or cells transfected with a nucleic acid of the present invention), for example.

The antibodies of the present invention can be polyclonal or monoclonal (see e.g., Example 5), and the term antibody is intended to encompass both polyclonal and monoclonal antibodies. Antibodies of the present invention can be raised against an appropriate immunogen, including proteins or polypeptides of the present invention, such as isolated and/or recombinant mammalian CKR-3 receptor protein or portion thereof, or synthetic molecules, such as synthetic peptides. In addition, cells which express receptor, such as transfected cells, can be used as immunogens or in a screen for antibody which binds receptor. See for example, Chuntharapai et al., *J. Immunol.* 152: 1783-1789 (1994)).

Preparation of immunizing antigen, and polyclonal and monoclonal antibody production can be performed using any suitable technique. A variety of methods have been

described (see e.g., Kohler et al., *Nature*, 256: 495-497 (1975) and *Eur. J. Immunol.* 6: 511-519 (1976); Milstein et al., *Nature* 266: 550-552 (1977); Koprowski et al., U.S. Patent No. 4,172,124; Harlow, E. and D. Lane, 1988,

5 *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory: Cold Spring Harbor, NY); *Current Protocols In Molecular Biology*, Vol. 2 (Supplement 27, Summer '94), Ausubel, F.M. et al., Eds., (John Wiley & Sons: New York, NY), Chapter 11, (1991)). Generally, a hybridoma can be  
10 produced by fusing a suitable immortal cell line (e.g., a myeloma cell line such as SP2/0) with antibody producing cells. The antibody producing cell, preferably those of the spleen or lymph nodes, are obtained from animals immunized with the antigen of interest. The fused cells  
15 (hybridomas) can be isolated using selective culture conditions, and cloned by limiting dilution. Cells which produce antibodies with the desired specificity can be selected by a suitable assay (e.g., ELISA).

Single chain antibodies, and chimeric, humanized or  
20 primatized (CDR-grafted) antibodies, as well as chimeric or CDR-grafted single chain antibodies, comprising portions derived from different species, are also encompassed by the present invention and the term "antibody". The various portions of these antibodies can be joined together  
25 chemically by conventional techniques, or can be prepared as a contiguous protein using genetic engineering techniques. For example, nucleic acids encoding a chimeric or humanized chain can be expressed to produce a contiguous protein. See, e.g., Cabilly et al., U.S. Patent No.  
30 4,816,567; Cabilly et al., *European Patent No. 0,125,023 B1*; Boss et al., U.S. Patent No. 4,816,397; Boss et al., *European Patent No. 0,120,694 B1*; Neuberger, M.S. et al., WO 86/01533; Neuberger, M.S. et al., *European Patent No. 0,194,276 B1*; Winter, U.S. Patent No. 5,225,539; and  
35 Winter, *European Patent No. 0,239,400 B1*. See also,

Newman, R. et al., *BioTechnology*, 10: 1455-1460 (1992), regarding primatized antibody, and Ladner et al., U.S. Patent No. 4,946,778 and Bird, R.E. et al., *Science*, 242: 423-426 (1988)) regarding single chain antibodies.

5 In addition, functional fragments of antibodies, including fragments of chimeric, humanized, primatized or single chain antibodies, can also be produced. Functional fragments of foregoing antibodies retain at least one binding function and/or modulation function of the full-  
10 length antibody from which they are derived. Preferred functional fragments retain an antigen binding function of a corresponding full-length antibody (e.g., specificity for a mammalian CKR-3 (CCR3)). Particularly preferred functional fragments retain the ability to inhibit one or  
15 more functions characteristic of a mammalian CKR-3 (CCR3), such as a binding activity, a signalling activity, and/or stimulation of a cellular response. For example, in one embodiment, a functional fragment can inhibit the interaction of CKR-3 (CCR3) with one or more of its ligands  
20 (e.g., eotaxin, RANTES, MCP-2, MCP-3, MCP-4) and/or can inhibit one or more receptor-mediated functions, such as eosinophil or basophil chemotaxis and/or degranulation induced by chemokine binding to CKR-3 (CCR3). For example, antibody fragments capable of binding to a mammalian CKR-3  
25 receptor or portion thereof, including, but not limited to, Fv, Fab, Fab' and F(ab')<sub>2</sub> fragments are encompassed by the invention. Such fragments can be produced by enzymatic cleavage or by recombinant techniques. For instance, papain or pepsin cleavage can generate Fab or F(ab')<sub>2</sub>  
30 fragments, respectively. Antibodies can also be produced in a variety of truncated forms using antibody genes in which one or more stop codons has been introduced upstream of the natural stop site. For example, a chimeric gene encoding a F(ab')<sub>2</sub> heavy chain portion can be designed to

include DNA sequences encoding the CH<sub>1</sub> domain and hinge region of the heavy chain.

The term "humanized immunoglobulin" as used herein refers to an immunoglobulin comprising portions of

5 immunoglobulins of different origin, wherein at least one portion is of human origin. Accordingly, the present invention relates to a humanized immunoglobulin having binding specificity for a mammalian CCR3 (e.g., human CCR3), said immunoglobulin comprising an antigen binding

10 region of nonhuman origin (e.g., rodent) and at least a portion of an immunoglobulin of human origin (e.g., a human framework region, a human constant region or portion thereof). For example, the humanized antibody can comprise portions derived from an immunoglobulin of nonhuman origin

15 with the requisite specificity, such as a mouse, and from immunoglobulin sequences of human origin (e.g., chimeric immunoglobulin), joined together chemically by conventional techniques (e.g., synthetic) or prepared as a contiguous polypeptide using genetic engineering techniques (e.g., DNA

20 encoding the protein portions of the chimeric antibody can be expressed to produce a contiguous polypeptide chain). Another example of a humanized immunoglobulin of the present invention is an immunoglobulin containing one or more immunoglobulin chains comprising a CDR of nonhuman

25 origin (e.g., one or more CDRs derived from an antibody of nonhuman origin) and a framework region derived from a light and/or heavy chain of human origin (e.g., CDR-grafted antibodies with or without framework changes). In one embodiment, the humanized immunoglobulin can compete with

30 murine 7B11 monoclonal antibody for binding to human CCR3 (e.g., to cells bearing human CCR3, such as eosinophils, basophils, or cells transfected with a nucleic acid of the present invention). In a preferred embodiment, the antigen binding region of the humanized immunoglobulin is derived

from 7B11 monoclonal antibody. Chimeric or CDR-grafted single chain antibodies are also encompassed by the term humanized immunoglobulin. See, e.g., Cabilly et al., U.S. Patent No. 4,816,567; Cabilly et al., European Patent

- 5 No. 0,125,023 B1; Queen et al., European Patent No. 0,451,216 B1; Boss et al., U.S. Patent No. 4,816,397; Boss et al., European Patent No. 0,120,694 B1; Neuberger, M.S. et al., WO 86/01533; Neuberger, M.S. et al., European Patent No. 0,194,276 B1; Winter, U.S. Patent No. 5,225,539;  
10 Winter, European Patent No. 0,239,400 B1; Padlan, E.A. et al., European Patent Application No. 0,519,596 A1. See also, Ladner et al., U.S. Patent No. 4,946,778; Huston, U.S. Patent No. 5,476,786; and Bird, R.E. et al., *Science*, 242: 423-426 (1988)), regarding single chain antibodies.

- 15 The antibodies of the present invention are useful in a variety of applications, including research, diagnostic and therapeutic applications. In one embodiment, the antibodies are labeled with a suitable label (e.g., fluorescent label, chemiluminescent label, isotope label,  
20 epitope or enzyme label). For instance, they can be used to isolate and/or purify receptor or portions thereof, and to study receptor structure (e.g., conformation) and function.

- The antibodies of the present invention can also be  
25 used to modulate receptor function in research and therapeutic applications. For instance, antibodies can act as inhibitors to inhibit (reduce or prevent) (a) binding (e.g., of a ligand, a second inhibitor or a promoter) to the receptor, (b) a receptor signalling, (c) and/or a  
30 stimulatory function. Antibodies which act as inhibitors of receptor function can block ligand or promoter binding directly or indirectly (e.g., by causing a conformational change). For example, antibodies can inhibit receptor function by inhibiting binding of a ligand, or by

desensitization (with or without inhibition of binding of a ligand).

Antibodies which bind receptor can also act as agonists of receptor function, triggering or stimulating a  
5 receptor function, such as a signalling and/or a stimulatory function of a receptor (e.g., chemotaxis, exocytosis or pro-inflammatory mediator release) upon binding to receptor.

In addition, the various antibodies of the present  
10 invention can be used to detect or measure the expression of receptor, for example, on leukocytes such as eosinophils, basophils, and lymphocytes, or on cells transfected with a receptor gene. Thus, they also have utility in applications such as cell sorting (e.g., flow  
15 cytometry, fluorescence activated cell sorting), for diagnostic or research purposes.

Anti-idiotypic antibodies are also provided. Anti-idiotypic antibodies recognize antigenic determinants associated with the antigen-binding site of another  
20 antibody. Anti-idiotypic antibodies can be prepared against second antibody by immunizing an animal of the same species, and preferably of the same strain, as the animal used to produce the second antibody. See e.g., U.S. Patent No. 4,699,880.

25 In one embodiment, antibodies are raised against receptor or a portion thereof, and these antibodies are used in turn to produce an anti-idiotypic antibody. The anti-Id produced thereby can bind compounds which bind  
30 receptor function, and can be used in an immunoassay to detect or identify or quantitate such compounds. Such an anti-idiotypic antibody can also be an inhibitor of receptor function, although it does not bind receptor itself.

Anti-idiotypic (i.e., Anti-Id) antibody can itself be used to raise an anti-idiotypic antibody (i.e., Anti-anti-Id). Such an antibody can be similar or identical in specificity to the original immunizing antibody. In one embodiment, antibody antagonists which block binding to receptor can be used to raise Anti-Id, and the Anti-Id can be used to raise Anti-anti-Id, which can have a specificity which is similar or identical to that of the antibody antagonist. These anti-anti-Id antibodies can be assessed for inhibitory effect on receptor function to determine if they are antagonists.

Single chain, and chimeric, humanized or primatized (CDR-grafted), as well as chimeric or CDR-grafted single chain anti-idiotypic antibodies can be prepared, and are encompassed by the term anti-idiotypic antibody. Antibody fragments of such antibodies can also be prepared.

#### Identification of Ligands, Inhibitors or Promoters of Receptor Function

As used herein, a ligand is a substance which binds to a receptor protein. A ligand of a selected mammalian CKR-3 receptor is a substance which binds to the selected mammalian receptor. In one embodiment, a ligand can bind selectively to two or more mammalian chemokine receptors, including CKR-3. In a preferred embodiment, ligand binding of a mammalian CKR-3 receptor occurs with high affinity. The term ligand refers to substances including, but not limited to, a natural ligand, whether isolated and/or purified, synthetic, and/or recombinant, a homolog of a natural ligand (e.g., from another mammal), antibodies, portions of such molecules, and other substances which bind receptor. A natural ligand of a selected mammalian receptor can bind to the receptor under physiological conditions, and is of a mammalian origin which is the same as that of the mammalian CKR-3 receptor. The term ligand

encompasses substances which are inhibitors or promoters of receptor activity, as well as substances which bind but lack inhibitor or promoter activity.

As used herein, an inhibitor is a substance which  
5 inhibits at least one function characteristic of a  
mammalian C-C chemokine receptor (e.g., a mammalian CKR-3  
receptor), such as a binding activity (e.g., ligand,  
inhibitor and/or promoter binding), a signalling activity  
(e.g., activation of a mammalian G protein, induction of  
10 rapid and transient increase in the concentration of  
cytosolic free calcium  $[Ca^{2+}]_i$ ), and/or stimulation of a  
cellular response. The term inhibitor refers to substances  
including antagonists which bind receptor (e.g., an  
antibody, a mutant of a natural ligand, other competitive  
15 inhibitors of ligand binding), and substances which inhibit  
receptor function without binding thereto (e.g., an  
anti-idiotypic antibody).

As used herein, a promoter is a substance which  
promotes (induces or enhances) at least one function  
20 characteristic of a mammalian C-C chemokine receptor (e.g.,  
a mammalian CKR-3 receptor), such as a binding activity  
(e.g., ligand, inhibitor and/or promoter binding), a  
signalling activity (e.g., activation of a mammalian G  
protein, induction of rapid and transient increase in the  
25 concentration of cytosolic free calcium  $[Ca^{2+}]_i$ ), and/or  
stimulation of a cellular response. The term promoter  
refers to substances including agonists which bind receptor  
(e.g., an antibody, a homolog of a natural ligand from  
another species), and substances which promote receptor  
30 function without binding thereto (e.g., by activating an  
associated protein).

The assays described below, which rely upon the  
nucleic acids and proteins of the present invention, can be  
used, alone or in combination with each other or other



suitable methods, to identify ligands, inhibitors or promoters of a mammalian CKR-3 receptor protein or polypeptide. Human CKR-3 does not usually exist in cells at levels suitable for high-throughput screening; thus, 5 cells which contain and express a nucleic acid of the present invention are particularly valuable in identifying ligands, inhibitors and promoters of CKR-3 receptor proteins.

Upon isolation of a CKR-3 receptor gene from a mammal, 10 the gene can be incorporated into an expression system to produce a receptor protein or polypeptide as described above. An isolated and/or recombinant receptor protein or polypeptide, such as a receptor expressed in cells stably or transiently transfected with a construct comprising a 15 nucleic acid of the present invention, or in a cell fraction (e.g., membrane fraction from transfected cells) containing receptor, can be used in tests for receptor function. The receptor can be further purified if desired. Testing of receptor function can be carried out *in vitro* or 20 *in vivo*.

An isolated, recombinant mammalian CKR-3 receptor protein, such as a human CKR-3 receptor as that shown in Figure 1A-1C (see also, SEQ ID NO:2), Figure 2A-2B (see also, SEQ ID NO:4) or SEQ ID NO:6, can be used in the 25 present method, in which the effect of a compound is assessed by monitoring receptor function as described herein or using other suitable techniques. For example, stable or transient transfectants, such as A31/293/#20 stable transfectants (see e.g., Example 9), stable 30 transfectants of mouse L1-2 pre-B cells (see e.g., Example 3), baculovirus infected Sf9 cells (see e.g., Example 4), can be used in binding assays. Stable transfectants of mouse L1-2 pre-B cells or of other suitable cells capable of chemotaxis can be used (see e.g., Example 3) in 35 chemotaxis assays, for example.

According to the method of the present invention, compounds can be individually screened or one or more compounds can be tested simultaneously according to the methods herein. Where a mixture of compounds is tested, the compounds selected by the processes described can be separated (as appropriate) and identified by suitable methods (e.g., PCR, sequencing, chromatography). The presence of one or more compounds (e.g., a ligand, inhibitor, promoter) in a test sample can also be determined according to these methods.

Large combinatorial libraries of compounds (e.g., organic compounds, recombinant or synthetic peptides, "peptoids", nucleic acids) produced by combinatorial chemical synthesis or other methods can be tested (see e.g., Zuckerman, R.N. et al., *J. Med. Chem.*, 37: 2678-2685 (1994) and references cited therein; see also, Ohlmeyer, M.H.J. et al., *Proc. Natl. Acad. Sci. USA* 90:10922-10926 (1993) and DeWitt, S.H. et al., *Proc. Natl. Acad. Sci. USA* 90:6909-6913 (1993), relating to tagged compounds; Rutter, W.J. et al. U.S. Patent No. 5,010,175; Huebner, V.D. et al., U.S. Patent No. 5,182,366; and Geysen, H.M., U.S. Patent No. 4,833,092). Where compounds selected from a combinatorial library by the present method carry unique tags, identification of individual compounds by chromatographic methods is possible.

In one embodiment, phage display methodology is used. For example, receptor is contacted with a phage (e.g., a phage or collection of phage such as a library) displaying a polypeptide under conditions appropriate for receptor binding (e.g., in a suitable binding buffer). Phage bound to receptor is selected using standard techniques or other suitable methods. Phage can be separated from receptor using a suitable elution buffer. For example, a change in the ionic strength or pH can lead to a release of phage. Alternatively, the elution buffer can comprise a release

component or components designed to disrupt binding of compounds (e.g., one or more compounds which can disrupt binding of the displayed peptide to the receptor, such as a ligand, inhibitor, and/or promoter which competitively inhibits binding). Optionally, the selection process can be repeated or another selection step can be used to further enrich for phage which bind receptor. The displayed polypeptide is characterized (e.g., by sequencing phage DNA). The polypeptides identified can be produced and further tested for ligand binding, inhibitor and/or promoter function. Analogs of such peptides can be produced which will have increased stability or other desirable properties.

In one embodiment, phage expressing and displaying a fusion proteins comprising a coat protein with an N-terminal peptide encoded by random sequence nucleic acids can be produced. Suitable host cells expressing a receptor protein or polypeptide of the present invention are contacted with the phage, bound phage are selected, recovered and characterized. (See e.g., Doorbar, J. and G. Winter, *J. Mol. Biol.*, 244: 361 (1994) discussing a phage display procedure used with a G protein-coupled receptor).

Other sources of potential ligands, inhibitors and/or promoters of a mammalian CKR-3 receptor include, but are not limited to, substances such as other chemoattractants; other chemokines (e.g., eotaxin), such as a mammalian chemokine from the same mammal as the receptor, from another mammal (e.g., for a human receptor, a homolog of a human chemokine obtained from a non-human source); variants of other chemoattractants or chemokines, such as naturally occurring, synthetic or recombinant variants; other mammalian CKR-3 receptor ligands, inhibitors and/or promoters (e.g., antibodies, antagonists, agonists), and variants thereof; other G-protein coupled receptor ligands,

inhibitors and/or promoters (e.g., antagonists or agonists); and soluble portions of a mammalian CKR-3 receptor, such as a suitable receptor peptide or analog which can inhibit receptor function (see e.g., Murphy, 5 R.B., WO 94/05695).

The in vitro method of the present invention can be used in high-throughput screening. These assays can be adapted for processing large numbers of samples (e.g., a 96 well format). For such screening, use of a host cell 10 expressing receptor, instead of isolated eosinophils, is preferred because of the difficulty in isolating eosinophils.

For binding assays, high level expression of receptor in a suitable host cell is preferred. Expression of 15 receptor can be monitored in a variety of ways. For instance, expression can be monitored using antibodies of the present invention which bind receptor or a portion thereof. Also, commercially available antibodies can be used to detect expression of an antigen- or epitope-tagged 20 fusion protein comprising a receptor protein or polypeptide (e.g., FLAG tagged receptors; see Example 3).

#### Binding Assays

The isolated and/or recombinant receptor proteins, portions thereof, or suitable fusion proteins of the 25 present invention, can be used in a method to select and identify compounds which bind to a (one or more) mammalian CKR-3 receptor protein, such as human CKR-3 receptor, and which are ligands, or potential inhibitors or promoters of receptor activity. Compounds selected by the method, 30 including ligands, inhibitors or promoters, can be further assessed for an inhibitory or stimulatory effect on receptor function and/or for therapeutic utility.

In one embodiment, compounds which bind to an active, isolated and/or recombinant mammalian CKR-3 receptor

protein or polypeptide are identified by the method. In this embodiment, the receptor protein or polypeptide used has at least one function characteristic of a CKR-3 receptor, such as a signalling activity (e.g., activation  
5 of a mammalian G protein), stimulatory function (e.g., stimulation of chemotaxis or inflammatory mediator release), and/or binding function (e.g., ligand, inhibitor and/or promoter binding). In a particularly preferred embodiment, the isolated and/or recombinant mammalian CKR-3  
10 receptor protein or polypeptide has ligand binding function, such that it binds a natural ligand of the receptor.

For example, an isolated and/or recombinant mammalian CKR-3 receptor protein or polypeptide can be maintained  
15 under conditions suitable for binding, the receptor is contacted with a compound to be tested, and binding is detected or measured. In one embodiment, a receptor protein can be expressed in cells stably or transiently transfected with a construct comprising a nucleic acid  
20 sequence which encodes a receptor of the present invention. The cells are maintained under conditions appropriate for expression of receptor. The cells are contacted with a compound under conditions suitable for binding (e.g., in a suitable binding buffer), and binding is detected by  
25 standard techniques. To measure binding, the extent of binding can be determined relative to a suitable control (e.g., compared with background determined in the absence of compound, compared with binding of a second compound (i.e., a standard), compared with binding of compound to  
30 untransfected cells). Optionally, a cellular fraction, such as a membrane fraction, containing receptor can be used in lieu of whole cells (see e.g., Example 9).

In one embodiment, the compound is labeled with a suitable label (e.g., fluorescent label, isotope label),  
35 and binding is determined by detection of the label.

Specificity of binding can be assessed by competition or displacement, for example, using unlabeled compound or a second ligand as competitor.

Ligands of the mammalian receptor, including natural  
5 ligands from the same mammalian species or from another species, can be identified in this manner. The binding activity of a promoter or inhibitor which binds receptor can also be assessed using such a ligand binding assay.

Binding inhibition assays can also be used to identify  
10 ligands, and inhibitors and promoters which bind receptor and inhibit binding of another compound such as a ligand. For example, a binding assay can be conducted in which a reduction in the binding of a first compound (in the absence of a second compound), as compared binding of the  
15 first compound in the presence of the second compound, is detected or measured. The receptor can be contacted with the first and second compounds simultaneously, or one after the other, in either order. A reduction in the extent of binding of the first compound in the presence of the second  
20 compound, is indicative of inhibition of binding by the second compound. For example, binding of the first compound could be decreased or abolished.

In one embodiment, direct inhibition of the binding of a first compound (e.g., a chemokine such as RANTES) to a  
25 human CKR-3 receptor by a second test compound is monitored. For example, the ability of a compound to inhibit the binding of  $^{125}\text{I}$ -labeled RANTES or  $^{125}\text{I}$ -labeled MCP-3 to human CKR-3 can be monitored. Such an assay can be conducted using either whole cells (e.g., eosinophils,  
30 or a suitable cell line containing nucleic acid encoding a human CKR-3 receptor) or a membrane fraction from said cells, for instance.

Other methods of identifying the presence of a compound(s) which bind a receptor are available, such as

methods which monitor events which are triggered by receptor binding, including signalling function and/or stimulation of a cellular response (See below).

It will be understood that the inhibitory effect of antibodies of the present invention can be assessed in a binding inhibition assay. Competition between antibodies for receptor binding can also be assessed in the method in which the first compound in the assay is another antibody, under conditions suitable for antibody binding.

Ligands, as well as receptor-binding inhibitors (e.g., antagonists) and promoters (e.g., agonists), which are identified in this manner, can be further assessed to determine whether, subsequent to binding, they act to inhibit or activate other functions of CKR-3 receptors and/or to assess their therapeutic utility.

#### Signalling Assays

The binding of a ligand or promoter, such as an agonist, can result in signalling by a G protein-coupled receptor, and the activity of G proteins is stimulated.

The induction of induce signalling function by a compound can be monitored using any suitable method. For example, G protein activity, such as hydrolysis of GTP to GDP, or later signalling events triggered by receptor binding, such as induction of rapid and transient increase in the concentration of intracellular (cytosolic) free calcium  $[Ca^{2+}]_i$ , can be assayed by methods known in the art or other suitable methods (see e.g., Neote, K. et al., *Cell*, 72: 415-425 1993); Van Riper et al., *J. Exp. Med.*, 177: 851-856 (1993); Dahinden, C.A. et al., *J. Exp. Med.*, 179: 751-756 (1994).

The functional assay of Sledziewski et al. using hybrid G protein coupled receptors can also be used to monitor the ability a ligand or promoter to bind receptor

and activate a G protein (Sledziewski et al., U.S. Patent No. 5,284,746, the teachings of which are incorporated herein by reference).

A biological response of the host cell (triggered by  
5 binding to hybrid receptor) is monitored, detection of the response being indicative of the presence of ligand in the test sample. Sledziewski et al. describes a method of detecting the presence of a ligand in a test sample,  
10 wherein the ligand is a compound which is capable of being bound by the ligand-binding domain of a receptor. In one embodiment of the method, yeast host cells are transformed with a DNA construct capable of directing the expression of a biologically active hybrid G protein-coupled receptor (i.e., a fusion protein). The hybrid receptor comprises a  
15 mammalian G protein-coupled receptor having at least one domain other than the ligand-binding domain replaced with a corresponding domain of a yeast G protein-coupled receptor, such as a *STE2* gene product. The yeast host cells containing the construct are maintained under conditions in  
20 which the hybrid receptor is expressed, and the cells are contacted with a test sample under conditions suitable to permit binding of ligand to the hybrid receptor. The assay is conducted as described and the biological response of the host cell (triggered by binding to hybrid receptor) is  
25 monitored, detection of the response being indicative of a signalling function.

For instance, an assay is provided in which binding to a hybrid receptor derived from *STE2* gene product leads to induction of the *BAR1* promoter. Induction of the promoter  
30 is measured by means of a reporter gene ( $\beta$ -gal), which is linked to the *BAR1* promoter and introduced into host cells on a second construct. Expression of the reporter gene can be detected by an in vitro enzyme assay on cell lysates or by the presence of blue colonies on plates containing an  
35 indicator (X-gal) in the medium, for example.



In another embodiment, the assay is used to identify potential inhibitors of receptor function. The inhibitory activity of a compound can be determined using a ligand or promoter in the assay, and assessing the ability of the  
5 compound to inhibit the activity induced by ligand or promoter.

Variants of known ligands can also be screened for reduced ability (decreased ability or no ability) to stimulate activity of a coupled G protein. In this  
10 embodiment, although the compound has ligand binding activity (as determined by another method in advance or later), engagement of the receptor does not trigger or only weakly triggers activity of a coupled G protein. Such compounds are potential antagonists, and can be further  
15 assessed using a suitable assay. For instance, the same assay can be conducted in the presence of a ligand or promoter, and the ability of the compound to inhibit the activity of a ligand or promoter is assessed.

#### Chemotaxis and Assays of Cellular Stimulation

20 Chemotaxis assays can also be used to assess receptor function. These assays are based on the functional migration of cells *in vitro* or *in vivo* induced by a compound, and can be used to assess the binding and/or chemoattractant effect of ligands, inhibitors, or  
25 promoters. The use of an *in vitro* transendothelial chemotaxis assay is described in Example 1. Springer et al. describe a transendothelial lymphocyte chemotaxis assay (Springer et al., WO 94/20142, published September 15, 1994, the teachings of which are incorporated herein by  
30 reference; see also Berman et al., *Immunol Invest.* 17: 625-677 (1988)). Migration across endothelium into collagen gels has also been described (Kavanaugh et al., *J. Immunol.* 146: 4149-4156 (1991)). Stable transfectants of mouse L1-2 pre-B cells or of other suitable host cells capable of

chemotaxis can be used (see e.g., Example 3) in chemotaxis assays, for example.

Generally, chemotaxis assays monitor the directional movement or migration of a suitable cell (such as a  
5 leukocyte (e.g., lymphocyte, eosinophil, basophil)) into or through a barrier (e.g., endothelium, a filter), toward increased levels of a compound, from a first surface of the barrier toward an opposite second surface. Membranes or filters provide convenient barriers, such that the  
10 directional movement or migration of a suitable cell into or through a filter, toward increased levels of a compound, from a first surface of the filter toward an opposite second surface of the filter, is monitored. In some assays, the membrane is coated with a substance to  
15 facilitate adhesion, such as ICAM-1, fibronectin or collagen.

For example, one can detect or measure the migration of cells in a suitable container (a containing means), from a first chamber into or through a microporous membrane into  
20 a second chamber which contains a compound to be tested, and which is divided from the first chamber by the membrane. A suitable membrane, having a suitable pore size for monitoring specific migration in response to compound, including, for example, nitrocellulose, polycarbonate, is  
25 selected. For example, pore sizes of about 3-8 microns, and preferably about 5-8 microns can be used. Pore size can be uniform on a filter or within a range of suitable pore sizes.

To assess migration, the distance of migration into  
30 the filter, the number of cells crossing the filter that remain adherent to the second surface of the filter, and/or the number of cells that accumulate in the second chamber can be determined using standard techniques (e.g., microscopy). In one embodiment, the cells are labeled with  
35 a detectable label (e.g., radioisotope, fluorescent label,

antigen or epitope label), and migration can be assessed by determining the presence of the label adherent to the membrane and/or present in the second chamber using an appropriate method (e.g., by detecting radioactivity, 5 fluorescence, immunoassay). The extent of migration induced by a compound can be determined relative to a suitable control (e.g., compared to background migration determined in the absence of the compound, to the extent of migration induced by a second compound (i.e., a standard), 10 compared with migration of untransfected cells induced by the compound).

Chambers can be formed from various solids, such as plastic, glass, polypropylene, polystyrene, etc. Membranes which are detachable from the chambers, such as a Biocoat 15 (Collaborative Biomedical Products) or Transwell (Costar, Cambridge, MA) culture insert, facilitate counting adherent cells.

In the container, the filter is situated so as to be in contact with fluid containing cells in the first 20 chamber, and the fluid in the second chamber. Other than the test compound or additional ligand, inhibitor, or promoter present for the purpose of the assay, the fluid on either side of the membrane is preferably the same or substantially similar. The fluid in the chambers can 25 comprise protein solutions (e.g., bovine serum albumin, fetal calf serum, human serum albumin) which may act to increase stability and inhibit nonspecific binding of cells, and/or culture media.

In a preferred embodiment, particularly for 30 eosinophils, eosinophil-like cells, lymphocytes, or cells expressing a CKR-3 receptor, transendothelial migration is monitored. A transendothelial migration assay is preferred. Such assays are better physiological models, because they more accurately recapitulate in vivo 35 conditions in which leukocytes emigrate from blood vessels

toward chemoattractants present in the tissues at sites of inflammation by crossing the endothelial cell layer lining the vessel wall. In addition, transendothelial assays have lower background (signal to noise ratio).

5 In this embodiment, transmigration through an endothelial cell layer assessed. To prepare the cell layer, endothelial cells can be cultured on a microporous filter or membrane, optionally coated with a substance such as collagen, fibronectin, or other extracellular matrix  
10 proteins, to facilitate the attachment of endothelial cells. Preferably, endothelial cells are cultured until a confluent monolayer is formed. A variety of mammalian endothelial cells can be available for monolayer formation, including for example, vein, artery or  
15 microvascular endothelium, such as human umbilical vein endothelial cells (Clonetics Corp, San Diego, CA) or a suitable cell line, such as the ECV 304 cell line used in Example 1. To assay chemotaxis in response to a particular mammalian receptor, endothelial cells of the same mammal  
20 are preferred; however endothelial cells from a heterologous mammalian species or genus can also be used.

Generally, the assay is performed by detecting the directional migration of cells into or through a membrane or filter, in a direction toward increased levels of a  
25 compound, from a first surface of the filter toward an opposite second surface of the filter, wherein the filter contains an endothelial cell layer on a first surface. Directional migration occurs from the area adjacent to the first surface, into or through the membrane, towards a  
30 compound situated on the opposite side of the filter. The concentration of compound present in the area adjacent to the second surface, is greater than that in the area adjacent to the first surface.

In one embodiment, a chemotaxis is used to test for  
35 ligand or promoter activity of a compound, a composition

comprising cells capable of migration and expressing a mammalian CKR-3 receptor are placed in the first chamber, and a composition comprising the compound to be tested is placed in the second chamber, preferably in the absence of  
5 other ligands or promoters capable of inducing chemotaxis of the cells in the first chamber (having chemoattractant function). However, one or more ligands or promoters having chemoattractant function may be present. Compounds which can bind receptor and induce chemotaxis of the cells  
10 expressing a mammalian CKR-3 receptor in this assay are ligands or promoters of receptor function.

In one embodiment used to test for an inhibitor, a composition comprising cells capable of migration and expressing a mammalian CKR-3 receptor are placed in the  
15 first chamber. A composition comprising one or more ligands or promoters capable of inducing chemotaxis of the cells in the first chamber (having chemoattractant function) is placed in the second chamber. Either shortly before the cells are placed in the first chamber, or  
20 simultaneously with the cells, a composition comprising the compound to be tested is placed, preferably, in the first chamber. Compounds which can bind receptor and inhibit the induction of chemotaxis, by a ligand or promoter, of the cells expressing a mammalian CKR-3 receptor in this assay  
25 are inhibitors of receptor function (i.e., inhibitors of stimulatory function). A reduction in the extent of migration induced by the ligand or promoter in the presence of the test compound, is indicative of inhibitory activity. (see e.g., Example 5). Separate binding studies (see  
30 above) could be performed to determine whether inhibition is a result of binding of the test compound to receptor or occurs via a different mechanism.

In vivo assays which monitor leukocyte infiltration of a tissue, in response to injection of a compound in the  
35 tissue, are described below (see Models of Inflammation).

These models measure the ability of cells to respond to a ligand or promoter by emigration and chemotaxis to a site of inflammation.

In addition to the methods described, the effects of a ligand, inhibitor or promoter on the stimulatory function of the receptor can be assessed by monitoring cellular responses induced by active receptor, using suitable host cells containing receptor. Similarly, these assays can be used to determine the function of a receptor. For instance, exocytosis (e.g., degranulation of eosinophils leading to release of eosinophil cationic protein and/or one or more enzymes, or other granule components; release of histamine from basophils), inflammatory mediator release (such as release of bioactive lipids such as leukotrienes (e.g., leukotriene C<sub>4</sub>)), and respiratory burst (Rot, A. et al., *J. Exp. Med.*, 176: 1489-1495 (1992)), can be monitored by methods known in the art or other suitable methods. See e.g., Bischoff. S.C. et al., *Eur. J. Immunol.*, 23: 761-767 (1993) and Baggiolini, M. and C.A. Dahinden, *Immunology Today*, 15: 127-133 (1994) and references cited therein).

In one embodiment, a ligand, inhibitor and/or promoter is identified by monitoring the release of an enzyme upon degranulation or exocytosis by a cell capable of this function. Cells containing a nucleic acid of the present invention, which encodes an active receptor protein capable of stimulating exocytosis or degranulation are maintained in a suitable medium under suitable conditions, whereby receptor is expressed and degranulation can be induced. The receptor is contacted with a compound to be tested, and enzyme release is assessed. The release of an enzyme into the medium can be detected or measured using a suitable assay, such as in an immunological assay, or biochemical assay for enzyme activity.

The medium can be assayed directly, by introducing components of the assay (e.g., substrate, co-factors, antibody) into the medium (e.g., before, simultaneous with or after the cells and compound are combined).

- 5 Alternatively, the assay can be performed on medium which has been separated from the cells or further fractionated prior to assay.

For example, convenient assays for are available for enzymes such as  $\beta$ -glucuronidase and eosinophil peroxidase  
10 (White, S.R. et al., A kinetic assay for eosinophil peroxidase activity in eosinophils and eosinophil conditioned media, *J. Immunol. Methods*, 144(2): 257-63 (1991)).

Stimulation of degranulation by a compound can be  
15 indicative that the compound is a ligand or promoter of a mammalian CKR-3 receptor. In another embodiment, inhibition of degranulation is indicative of an inhibitor. In this embodiment, the cells expressing receptor are combined with a ligand or promoter, and a compound to be  
20 tested is added before, after or simultaneous therewith.

### Models of Inflammation

A variety of in vivo models of inflammation are available, which can be used to assess the effects of ligands, inhibitors, or promoters in vivo as therapeutic  
25 agents.

For example, primate models with eosinophilic infiltration to the lung, are available for in vivo testing (see e.g., Wegner, C.D. et al., *Science*, 247: 456 (1990)). In one embodiment, an antibody (e.g., a monoclonal  
30 antibody) which reacts with human CKR-3, and which cross-reacts with primate CKR-3, is administered to the animal. A number of parameters can be measured to assess in vivo efficacy including, but not limited to, the number of eosinophils in broncoalveolar lavage fluid, respiratory

compliance, and respiratory rate. A decrease in symptoms of airway hypersensitivity is indicative of therapeutic benefit.

In addition, a sheep model for asthma, a guinea pig  
5 model for passive cutaneous anaphylaxis, or other suitable model can be used to assess compounds in vivo (see e.g., Weg, V.B. et al., *J. Exp. Med.*, 177: 561 (1993); Abraham, W.M. et al., *J. Clin. Invest.*, 93: 776 (1994)).

In addition, leukocyte infiltration upon intradermal  
10 injection of a compound into a suitable animal, such as rabbit, rat, or guinea pig, can be monitored (see e.g., Van Damme J. et al., *J. Exp. Med.*, 176: 59-65 (1992); Zachariae, C.O.C. et al., *J. Exp. Med.* 171: 2177-2182 (1990); Jose, P.J. et al., *J. Exp. Med.* 179: 881-887  
15 (1994)). In one embodiment, skin biopsies are assessed histologically for infiltration of leukocytes (e.g., eosinophils, granulocytes). In another embodiment, labeled cells (e.g., stably transfected cells expressing a CKR-3 receptor, labeled with <sup>111</sup>In for example) capable of  
20 chemotaxis and extravasation are administered to the animal. Infiltration of cells in response to injection of a test sample (e.g., a compound to be tested in a suitable buffer or physiological carrier) is indicative of the presence of a ligand or promoter, such as an agonist, in  
25 the sample. These assays can also be modified to identify inhibitors of chemotaxis and leukocyte extravasation. For example, an inhibitor can be administered, either before, simultaneously with or after ligand or agonist is administered to the test animal. A decrease of the extent  
30 of infiltration in the presence of inhibitor as compared with the extent of infiltration in the absence of inhibitor is indicative of inhibition.



Diagnostic Applications

The present invention has a variety of diagnostic applications. These applications include, but are not necessarily limited to the applications discussed herein.

5        Mutation(s) in genes encoding a mammalian CKR-3  
receptor protein can cause defects in at least one function  
of the encoded receptor, thereby reducing or enhancing  
receptor function. For instance, mutations which produce a  
variant of receptor or alter the level of expression, can  
10    reduce or enhance receptor function, reducing or enhancing,  
the inflammatory processes mediated by receptor.

For example, the methods of detecting or measuring  
receptor function can be used to characterize the activity  
of receptors in cells (e.g., leukocytes) of an individual  
15    or of receptors isolated from such cells. In these assays,  
reduced or enhanced receptor function can be assessed.

The nucleic acids of the present invention provide  
reagents (e.g., probes, PCR primers) which can be used to  
screen for, characterize and/or isolate a defective  
20    mammalian CKR-3 receptor gene, which encodes a receptor  
having reduced or enhanced activity. Standard methods of  
screening for a defective gene can be employed, for  
instance. A defective gene and the activity of the encoded  
receptor can be isolated and expressed in a suitable host  
25    cell for further assessment as described herein for  
mammalian CKR-3 receptors. A number of human diseases are  
associated with defects in the function of a G-protein  
coupled receptor (Clapham, D.E., *Cell*, 75: 1237-1239  
(1993); Lefkowitz, R.J., *Nature*, 365: 603-04 (1993)).

30        The antibodies of the present invention have  
application in procedures in which receptor can be detected  
on the surface of cells. The receptor provides a marker of  
the leukocyte cell types in which it is expressed,  
particularly in eosinophils. For example, antibodies  
35    raised against a receptor protein or peptide can be used to

count cells expressing receptor. Cell counts can be used in the diagnosis of a variety of diseases or conditions in which increased or decreased leukocyte cell types (e.g., hypereosinophilia, for example in hypereosinophilic

5 syndrome; hypoeosinophilia) are observed. The presence of an increased level of eosinophils in a sample obtained from an individual can be indicative of eosinophil infiltration due to an inflammatory disease or condition, such as asthma, or an infection such as a parasitic infections.

10 Alternatively, or in addition, the antibodies can be used to sort cells which express receptor from among a mixture of cells. Suitable methods for counting and/or sorting cells can be used for this purpose (e.g., flow cytometry, fluorescence activated cell sorting).

15 Furthermore, the antibodies can be used to detect or measure decreased or increased expression of receptor in various diseases or conditions in which inflammatory processes of leukocytes are altered (e.g., increased or decreased relative to a suitable control, such as the level

20 of expression in a normal individual). For example, leukocytes (e.g., eosinophils, lymphocytes such as T lymphocytes, monocytes, basophils) can be obtained from an individual and a suitable immunological assay (e.g., ELISA, FACS analysis) can be used to assess the level of

25 expression. The level of expression of a mammalian CKR-3 receptor can be used in the diagnosis of a disease or condition in which increased or decreased expression of a mammalian CKR-3 receptor is present.

#### Transgenic Animals

30 Transgenic animals, in which the genome of the animal host is altered using recombinant DNA techniques, can be constructed. In one embodiment, the alteration is not heritable (e.g., somatic cells, such as progenitor cells in bone marrow, are altered). In another embodiment, the

alteration is heritable (the germ line is altered).  
Transgenic animals can be constructed using standard  
techniques or other suitable methods (see e.g., Cooke. M.P.  
et al., *Cell*, 65: 281-291 (1991) regarding alteration of T  
5 lymphocytes; Hanahan, D., *Science*, 246: 1265-1275, (1989)).

In one aspect, an endogenous mammalian CKR-3 receptor  
gene can be inactivated or disabled, in whole or in part,  
in a suitable animal host (e.g., by gene disruption  
techniques) to produce a transgenic animal. Nucleic acids  
10 of the present invention can be used to assess successful  
construction of a host containing an inactivated or  
disabled CKR-3 gene (e.g., by Southern hybridization). In  
addition, successful construction of a host containing an  
inactivated or disabled CKR-3 gene can be assessed by  
15 suitable assays which monitor the function of the encoded  
receptor.

In another embodiment, a nucleic acid encoding a  
mammalian CKR-3 receptor protein or polypeptide is  
introduced into a suitable host to produce a transgenic  
20 animal. In a preferred embodiment, endogenous CKR-3  
receptor genes present in the transgenic animals are  
inactivated (e.g., simultaneously with introduction of the  
nucleic acid by homologous recombination, which disrupts  
and replaces the endogenous gene). For example, a  
25 transgenic animal (e.g., a mouse, guinea pig, sheep)  
capable of expressing a nucleic acid encoding a mammalian  
CKR-3 receptor of a different mammalian species (e.g., a  
human) in leukocytes (such as eosinophils, lymphocytes  
(e.g., T lymphocytes) can be produced, and provides a  
30 convenient animal model for assessing the function of the  
introduced receptor. In addition, a compound can be  
administered to the transgenic animal, and the effect of  
the compound on an inflammatory process mediated by  
receptor can be monitored in a suitable assay ((see e.g.,  
35 Weg, V.B. et al., *J. Exp. Med.*, 177: 561 (1993); Abraham,

W.M. et al., *J. Clin. Invest.*, 93: 776 (1994)). In this manner, compounds which inhibit or promote receptor function can be identified or assessed for *in vivo* effect.

#### Methods of Therapy

5           Modulation of mammalian CKR-3 receptor function according to the present invention, through the inhibition or promotion of at least one function characteristic of a mammalian CKR-3 receptor, provides an effective and selective way of inhibiting or promoting leukocyte-mediated  
10 inflammatory action. One or more ligands, inhibitors and/or promoters of CKR-3 receptor function, such as those identified as described herein, can be used to modulate leukocyte function for therapeutic purposes.

As major eosinophil and lymphocyte chemokine  
15 receptors, mammalian CKR-3 receptors provide a target for interfering with or promoting eosinophil and/or lymphocyte function in a mammal, such as a human. Consistently, co-localization of T cells and eosinophils is observed in certain inflammatory infiltrates. Thus, compounds which  
20 inhibit or promote CKR-3 receptor function, such as ligands, inhibitors (e.g., 7B11) and promoters identified according to the present method, are particularly useful for modulating eosinophil, basophil, and/or lymphocyte function for therapeutic purposes.

25           Thus, the present invention provides a method of inhibiting or promoting an inflammatory response in an individual in need of such therapy, comprising administering a compound which inhibits or promotes mammalian CKR-3 receptor function to an individual in need  
30 of such therapy.

In one embodiment, a compound which inhibits one or more functions of a mammalian CKR-3 receptor (e.g., a human CKR-3 receptor) is administered to inhibit (i.e., reduce or prevent) inflammation. As a result, one or more

inflammatory processes, such as leukocyte emigration, chemotaxis, exocytosis (e.g., of enzymes, histamine) or inflammatory mediator release, is inhibited. For example, eosinophilic infiltration to inflammatory sites (e.g., in  
5 asthma) can be inhibited according to the present method.

In another embodiment, a compound which promotes one or more functions of a mammalian CKR-3 receptor (e.g., a human CKR-3 receptor) is administered to stimulate (induce or enhance) an inflammatory response, such as leukocyte  
10 emigration, chemotaxis, exocytosis (e.g., of enzymes, histamine) or inflammatory mediator release, resulting in the beneficial stimulation of inflammatory processes. For example, eosinophils can be recruited to combat parasitic infections.

15 In addition to primates, such as humans, a variety of other mammals can be treated according to the method of the present invention. For instance, mammals including, but not limited to, cows, sheep, goats, horses, dogs, cats, guinea pigs, rats or other bovine, ovine, equine, canine,  
20 feline, rodent or murine species can be treated. However, the method can also be practiced in other species, such as avian species (e.g., chickens).

Diseases and conditions associated with inflammation and infection can be treated using the method. In a  
25 preferred embodiment, the disease or condition is one in which the actions of eosinophils and/or lymphocytes are to be inhibited or promoted, in order to modulate the inflammatory response.

Diseases or conditions of humans or other species  
30 which can be treated with inhibitors of CKR-3 receptor function, include, but are not limited to:

- inflammatory or allergic diseases and conditions, including respiratory allergic diseases such as asthma,

allergic rhinitis, hypersensitivity lung diseases,  
hypersensitivity pneumonitis, eosinophilic pneumonias  
(e.g., Loeffler's syndrome, chronic eosinophilic  
pneumonia), interstitial lung diseases (ILD) (e.g.,  
5 idiopathic pulmonary fibrosis, or ILD associated with  
rheumatoid arthritis, systemic lupus erythematosus,  
ankylosing spondylitis, systemic sclerosis, Sjogren's  
syndrome, polymyositis or dermatomyositis); systemic  
anaphylaxis or hypersensitivity responses, drug allergies  
10 (e.g., to penicillin, cephalosporins), insect sting  
allergies; inflammatory bowel diseases, such as Crohn's  
disease and ulcerative colitis; spondyloarthropathies;  
scleroderma; psoriasis and inflammatory dermatoses such as  
dermatitis, eczema, atopic dermatitis, allergic contact  
15 dermatitis, urticaria; vasculitis (e.g., necrotizing,  
cutaneous, and hypersensitivity vasculitis);

- eosinophilic myositis, eosinophilic fasciitis;

- autoimmune diseases, such as rheumatoid arthritis,  
psoriatic arthritis, multiple sclerosis, systemic lupus  
20 erythematosus, myasthenia gravis, juvenile onset diabetes,  
glomerulonephritis, autoimmune thyroiditis, Behcet's  
disease;

- graft rejection (e.g., in transplantation),  
including allograft rejection or graft-versus-host disease;

- 25 • cancers with leukocyte infiltration of the skin or  
organs;

- other diseases or conditions in which undesirable  
inflammatory responses are to be inhibited can be treated,  
including, but not limited to, reperfusion injury,  
30 atherosclerosis, certain hematologic malignancies,

cytokine-induced toxicity (e.g., septic shock, endotoxic shock), polymyositis, dermatomyositis.

Diseases or conditions of humans or other species which can be treated with promoters of CKR-3 receptor function, include, but are not limited to:

- immunosuppression, such as that in individuals with immunodeficiency syndromes such as AIDS, individuals undergoing radiation therapy, chemotherapy, therapy for autoimmune disease or other drug therapy (e.g., corticosteroid therapy), which causes immunosuppression; immunosuppression due congenital deficiency in receptor function or other causes;

- infectious diseases, such as parasitic diseases, including, but not limited to helminth infections, such as nematodes (round worms); (Trichuriasis, Enterobiasis, Ascariasis, Hookworm, Strongyloidiasis, Trichinosis, filariasis); trematodes (fluxes) (Schistosomiasis, Clonorchiasis), cestodes (tape worms) (Echinococcosis, Taeniasis saginata, Cysticercosis); visceral worms, visceral larva migrans (e.g., *Toxocara*), eosinophilic gastroenteritis (e.g., *Anisaki* spp., *Phocanema* ssp.), cutaneous larva migrans (*Ancylostoma braziliense*, *Ancylostoma caninum*).

#### *Eosinophils as the Target Cell in Certain Inflammatory Reactions, Particularly Asthma*

Eosinophils are produced in the bone marrow and circulate to the tissues, predominantly to mucosal tissues, such as the lungs, gastrointestinal tract, and genitourinary tract. Eosinophils typically constitute 1-3% of leukocytes in the blood. However, in people suffering from allergic diseases and helminthic parasitic infections,

increased eosinophil accumulation occurs in the tissues or the blood. Eosinophils accumulation can be both beneficial and detrimental to the host.

For example, eosinophils possess numerous granules, 5 containing cationic proteins. Degranulation of eosinophils, triggered, for example, by the engagement of IgG, IgA, or IgE receptors, or by stimulation by inflammatory mediators such as platelet-activating factor (PAF), leukotrienes, or chemokines, leads to release of the components in the 10 granule. Products from eosinophils also cause damage to host cells. The most damaging are the cationic proteins, which are detectable in elevated concentrations in patients with asthma. Eosinophils also generate a number of inflammatory mediators, including Leukotriene C4, and 15 platelet-activating factor (PAF). These mediators contract airway smooth muscle, promote the secretion of mucus, alter vascular permeability, and elicit further eosinophil and neutrophil infiltration.

Eosinophils are involved in the initiation and 20 maintenance of allergic/asthma diathesis. Thus, in a preferred embodiment, the method can be used to treat asthma or hypersensitivity (allergic) states, particularly those involving mucosal tissues, as well as in other eosinophil-associated diseases. In a particularly 25 preferred embodiment, a compound which inhibits one or more function of a mammalian CKR-3 receptor (e.g., a human CKR-3 receptor) is administered to an individual with asthma.

Eosinophils are clearly important in the host defense against and destruction of, large, nonphagocytatable 30 organisms, such as multicellular helminthic parasites. Eosinophils are also important effector cells in immune reactions against other pathogens that induce high levels of IgE antibodies. Accordingly, the method can be used to treat infectious diseases, such as parasitic diseases, to



stimulate or promote inflammatory defenses, or to suppress inflammatory responses which are destructive to the host.

### *Eosinophils and Asthma Pathogenesis*

Asthma is characterized by the obstruction of the  
5 airways or bronchi, and results from a bronchial  
hyperresponsiveness and rapid constriction in response to a  
wide range of pharmacological mediators. Chronic  
inflammation of the bronchial mucosal lining is widely  
believed to play a fundamental role in the development of  
10 asthma.

Intense infiltration of the bronchial mucosa with  
eosinophils, macrophages and lymphocytes is observed in  
asthma and other hypersensitivities. Often the selective  
migration of eosinophils to inflamed airways can be  
15 striking, and appears to result from the selective binding  
of eosinophils to endothelium and extraction from the  
blood. Eosinophils in particular are implicated as the  
causative agents of bronchial mucosal injury. Studies of  
asthmatic patients suggest that blood eosinophil counts  
20 correlate with the degree of bronchial hyperresponsiveness.  
In addition, bronchial biopsies and bronchoalveolar lavage  
fluid from asthmatics show a clear relationship between the  
degree of eosinophilia and clinical severity. Thus, there  
is a strong connection between the presence of eosinophils  
25 and adverse immune reactions, particularly in asthma.

A major chemokine receptor on eosinophils and  
lymphocytes, that functions in selective leukocyte  
chemotaxis, extravasation and activation in response to  
chemoattractant, provides an excellent target for  
30 interfering with eosinophil recruitment. For example,  
administration of an inhibitor of at least one function of  
a mammalian (e.g., human) CKR-3 receptor, such as by  
inhibiting chemokine binding thereto, can provide an  
effective and selective way of treating asthma. By

reducing or preventing recruitment (extravasation, infiltration) of leukocytes, particularly eosinophils, to inflamed lung and airway tissues, and/or reducing leukocyte function in those tissues, the destructive inflammatory processes of asthma can be inhibited, and the symptoms alleviated.

There is evidence that the blockage of eosinophil recruitment to the lung can alleviate the symptoms of asthma. Administration of a monoclonal antibody reactive with  $\alpha 4$  integrin was reported to inhibit the accumulation of eosinophils into the lung and airways, and blocked the airway hyperresponsiveness to antigen challenge in sheep. In a primate model of asthma, a monoclonal antibody to ICAM-1 is reported to attenuate airway eosinophilia and hyperresponsiveness. In addition, in a guinea pig model for passive cutaneous anaphylaxis, *in vitro* pretreatment of eosinophils with the anti- $\alpha 4$  monoclonal was reported to suppress eosinophil accumulation. (see Wegner, C.D. et al., *Science*, 247: 456 (1990); Weg, V.B. et al., *J. Exp. Med.*, 177: 561 (1993); and Abraham, W.M. et al., *J. Clin. Invest.*, 93: 776 (1994) regarding these models).

#### *Modes of Administration*

According to the method, one or more compounds can be administered to the host by an appropriate route, either alone or in combination with another drug. An effective amount of a compound (e.g., a receptor peptide which inhibits ligand binding, an antibody or antibody fragment) is administered. An effective amount is an amount sufficient to achieve the desired therapeutic effect, under the conditions of administration, such as an amount sufficient for inhibition or promotion of a CKR-3 receptor function, and thereby, inhibition or promotion, respectively, of an inflammatory response.

A variety of routes of administration are possible including, but not necessarily limited to oral, dietary, topical, parenteral (e.g., intravenous, intraarterial, intramuscular, subcutaneous injection), inhalation (e.g., intrabronchial, intranasal or oral inhalation, intranasal drops), routes of administration, depending on the disease or condition to be treated. For respiratory allergic diseases such as asthma, inhalation is a preferred mode of administration.

- 10 Formulation of a compound to be administered will vary according to the route of administration selected (e.g., solution, emulsion, capsule). An appropriate composition comprising the compound to be administered can be prepared in a physiologically acceptable vehicle or carrier. For
- 15 solutions or emulsions, suitable carriers include, for example, aqueous or alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles can include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated
- 20 Ringer's or fixed oils. Intravenous vehicles can include various additives, preservatives, or fluid, nutrient or electrolyte replenishers (See, generally, Remington's Pharmaceutical Science, 16th Edition, Mack, Ed. 1980). For inhalation, the compound can be solubilized and loaded into
- 25 a suitable dispenser for administration (e.g., an atomizer, nebulizer or pressurized aerosol dispenser).

#### EXEMPLIFICATION

- The present invention will now be illustrated by the following Examples, which are not intended to be limiting
- 30 in any way.

EXAMPLE 1

Chemotactic Properties of Human Eosinophils

Chemotaxis of Human Eosinophils

To identify antagonists of eosinophilic chemokine  
5 receptor(s), it is necessary to identify the important  
chemokines for eosinophil chemotaxis, and determine the  
receptor(s) that these chemokines are binding to.  
Chemotaxis experiments were performed in a sensitive and  
improved chemotaxis assay, which employs an endothelial  
10 cell line grown on the polycarbonate membrane of the  
chemotaxis well.

Isolation of Eosinophils

100 ml of heparinized blood was diluted 1:1 with PBS.  
20 ml aliquots were layered over 65%, 75% Percoll step  
15 gradients. The gradients were centrifuged at 1500 rpm, 25  
min at room temp. The eosinophil/neutrophil layers were  
transferred to a new tube and erythrocytes lysed by  
addition of 20 mls 0.2% NaCl for 1 min followed by the  
addition of 30 mls 1.8% NaCl. Cells were washed twice with  
20 a buffer consisting of PBS, 0.5% BSA, 0.5 mM EDTA. Cells  
were resuspended at  $5 \times 10^7$  cells/50  $\mu$ l in cold buffer  
(PBS, 0.5% BSA, 0.5 mM EDTA) and 50  $\mu$ l CD16 microbeads were  
added to the cells. The mixture was incubated at 4°C for  
25 min followed by the addition of 900  $\mu$ l cold buffer. The  
25 miniMACS™ separation unit (Miltenyi Biotec, Inc., Auburn CA  
95603) was used to deplete CD16 positive cells  
(neutrophils). Cells were loaded onto the column in 200  $\mu$ l  
aliquots. Flow-through cells were collected and assessed  
histologically. The eosinophil prep was > 99% pure.

### Chemotaxis Assay

Chemokines were obtained from Peprotech, Inc. (Rocky Hill, N.J.). Chemotaxis experiments were performed using 3.0 micron Biocoat cell culture inserts (Collaborative Biomedical Products), in 24 well plates. Endothelial cells were grown to confluency on the inserts for two days prior to chemotaxis experiments. The endothelial cells used were a cell line termed ECV 304 (European Collection of Animal Cell Cultures, Porton Down, Salisbury, U.K.), which expresses endothelial cell markers such as von Willebrand factor, as well as ICAM-1 and VCAM-1. This endothelial cell line greatly facilitates these assays, since human umbilical vein endothelial cells can be variable in nature, can be used for only several passages, and grow much more slowly than ECV 304. The assay was conducted at 37°C for 1.5 hours, and migrated cells were counted using an inverted microscope.

### Results

The results, presented in Figure 4, are representative of at least five experiments. Growth of ECV 304 endothelial cells on the polycarbonate membrane reduced the background migration almost completely. Eosinophils applied to transendothelial chemotaxis assays showed migration to a number of chemokines, particularly RANTES, MCP-3, and to a lesser degree MCP-1. MIP-1 $\beta$ , IL-8, MCP-2, and IP-10 had little effect on eosinophil chemotaxis. MIP-1 $\alpha$  was chemotactic for eosinophils in some experiments, although generally was inactive. In these experiments, a range of chemokine concentrations was used, because of the variability in responsiveness of leukocytes to different chemokines, and uncertainties about the quality of chemokine preparations. A consistent finding was the high level of eosinophil chemotaxis to RANTES and MCP-3.

EXAMPLE 2

Identification of a Major Eosinophilic  
Chemokine Receptor

Primer Selection and Design

5        Five chemokine receptor genes were aligned and  
compared to generate a set of degenerate oligonucleotides  
for use in PCR (Polymerase Chain Reaction) cloning of novel  
chemokine receptors from eosinophils. The selection of  
these five receptor genes was based on either the type of  
10 chemokine ligand with which they bind (Il-8 receptor A  
(IL8RA), Il-8 receptor B (IL8RB), MIP-1 $\alpha$  receptor (MIP1 $\alpha$ R))  
or orphan receptors with significant sequence similarity to  
these receptors whose expression is reported to be  
restricted to lymphoid cells or tissue (Epstein Barr  
15 Inducible receptor-1 (EBI1R) and Burkitt's Lymphoma  
Receptor-1 (BLR1)). Receptor sequences were aligned by  
hand based on a number of published alignments (IL-8RA,  
Holmes et al., *Science*, 253: 1278-1280 (1991); IL-8RB,  
Murphy, P.A. et al., *Science*, 253: 1280-1283 (1991);  
20 MIP1 $\alpha$ /RANTES, Neote, K. et al., *Cell*, 72: 415-425 (1991);  
EBI1R, Birkenbach, M. et al., *J. Virol.*, 67: 2209-2220  
(1993); and BLR1 (Dobner, T. et al., *Eur. J. Immunol.*, 22:  
2795-2799 (1992)).

Sequences within transmembrane (TM) regions 2, 6 and 7  
25 as well as a region just C-terminal to TM3 were selected as  
targets for degenerate oligonucleotide design based on the  
high degree of sequence similarity. The nucleotide  
sequences of the degenerate oligonucleotide primers are  
illustrated in the Table below.

TABLE

Primer Set 2

SEQ ID NO:

TM2a

7 Primer 2a-1 (forward) 5'- TAC CTG CTS AAC CTG GCC ITG GCI G  
8 Nested primer 2a-2 (forward) 5'- AC CTG GCC ITG GCI GAC CTM CTC TT

TM3

9 Primer 3F (forward) 5'- GAC CGY TAC CTG GCC ATI GTC CAY GCC  
10 Primer 3R (reverse) CTG GCR ATG GAC CGG TAI CAG GTR CGG - 5'

TM6b

11 Primer 6b-1 (reverse) GAR AMR ACC IRI GGG ATG TTR IAC CAI - 5'  
12 Nested primer 6b-2 (reverse) AAG RAI GAR GAR AMR ACC IRI GGG ATG T - 5'

TM7

13 Primer 7-1 (reverse) ACG SAG TTG GGI IAS IAG ATG CGG AAG - 5'  
14 Nested primer 7-2 (reverse) GTG WCG ACG SAG TTG GGI IAS IAG A - 5'

Nucleotide Abbreviations:

K = G/T  
M = A/C  
R = A/G  
S = C/G  
W = A/T  
Y = C/T

### Eosinophil Isolation and Purification

100 ml of heparinated blood was diluted 1:1 with PBS. 20 ml aliquots were layered over 65%, 75% Percoll step gradients. The gradients were centrifuged at 1500 rpm, 25 min at room temperature. The eosinophil/neutrophil layers were transferred to a new tube and erythrocytes lysed by addition of 20 mls 0.2% NaCl for 1 minute followed by the addition of 30 mls 1.8% NaCl. Cells were washed twice with a solution of phosphate buffered saline (PBS), 0.5% Bovine Serum Albumin (BSA), 0.5 mM ethylenediaminetetraacetic acid (EDTA). Cells were resuspended at  $5 \times 10^7$  cells/50  $\mu$ l in cold buffer (PBS, BSA, EDTA solution), and 50  $\mu$ l CD16 microbeads were added to the cells. The mixture was incubated at 4°C for 25 min followed by the addition of 900  $\mu$ l cold buffer. The miniMACS™ separation unit (Miltyeni Biotec, Inc., Auburn, CA 95603) was used to deplete CD16 positive cells (neutrophils). Cells were loaded onto the column in 200  $\mu$ l aliquots. Flow-through cells were collected and assessed histologically. By this criteria, the eosinophil prep was > 99% pure.

### mRNA isolation and PCR

mRNA for RT-PCR (Reverse transcription-polymerase chain reaction) was extracted directly from purified cells using the Micro-FastTrack™ mRNA isolation kit purchased from Invitrogen. Quality of the mRNA was evaluated by PCR amplification of  $\beta$ -actin and/or GAPDH (glyceraldehyde-3-phosphate dehydrogenase) mRNA prior to use with 7TMS degenerate primers.

20-50 ng of mRNA was reverse transcribed using a GeneAmp® RNA PCR kit (Perkin-Elmer) with oligo dT and/or random hexamers as primers in a 20  $\mu$ l final volume as specified by the manufacturer. 2-5  $\mu$ l of this cDNA (reverse transcribed eosinophil message) was mixed with 200



$\mu$ M dNTPs and 50-100 pmol of degenerate primers in a 50  $\mu$ l volume. Magnesium concentration and pH were optimized for each primer pair. The magnesium concentration ranged from 1.0 to 3.0 mM and pH ranged from 8.5 to 10.0. Although  
5 various cycle parameters were also evaluated, the conditions generally used were similar to the following: 3 cycles: 94°C, 30 sec; 37°C, 30 sec; 2 min ramp to 72°C, 1 min, followed by 30 cycles: 94°C, 45 sec; 48°C, 1 min; 72°C, 1 min. (ramp = gradual increase).

10 With regard to the 201 bp fragment isolated (see below), primer pairs 2a-1 and 7-1, or primer pairs 2a-1 and 3R, were used in a PCR reaction (as described above) in 60 mM Tris-HCl, pH 9.5 and 1.5 mM MgCl<sub>2</sub>. One  $\mu$ l of product  
15 from each reaction was used in a separate (second) round of PCR with "nested" primers 2a-2 and 3R. ("Nested" primers are primers which hybridize to sequences within the outside primers.) Reaction conditions for the nested PCR were exactly as described for the first PCR.

PCR products were assessed and separated by agarose  
20 gel electrophoresis, and appropriately sized fragments were purified and subcloned using the pCR-Script™ SK+ cloning kit (Stratagene). (Appropriate fragment sizes are as follows: for PCR with primer pairs from regions 2a and 7 (see Table above), ~700 bp; for PCR with primers from  
25 region 2a and primer 3R, ~200 bp; for PCR with primer 3F and primers from region 6b, ~400 bp, and for PCR with primer 3F and region 7 primers, ~550 bp.) Expected fragment sizes were predicted based upon the hypothesis that a related receptor protein would share some structural  
30 similarity.

#### Rapid Screening Assay

In order to screen a large number of clones quickly for novel members of the 7TMS family, the inserts of

bacterial colonies obtained as described above (i.e., transformants of plasmids comprising appropriately sized fragments subcloned into pCR-Script SK+), were screened by PCR using T3 and KS primers complementary to the sequence flanking the polylinker of pCR-Script™. In particular, a portion of a bacterial colony from an overnight transformation was mixed directly with 40 µl of a PCR mixture containing 200 µM dNTPs, 20 mM Tris, pH 8.5, 50 mM KCl, 2.5 mM MgCl<sub>2</sub>, 50 pmol each primers and 0.25 units Taq polymerase. Cycle conditions were 25 cycles: 94°C, 20 sec; 55°C, 20 sec; 72°C, 30 sec. Inserts of the correct size were identified by evaluating 20 µl of PCR product on 1.5% agarose gels. The remaining 20 µl of the reaction was digested with Alu I, Hha I, and Rsa I (triple digestion) and resolved on a 12% polyacrylamide gel to screen for different digestion patterns. Clones of different patterns were then selected for sequence analysis.

### Results

Sequence analysis of PCR fragment, generated from degenerate oligos, identified a 201 bp partial cDNA clone in pCR-Script. (The degenerate oligos were 2a-1, 2a-2, 3F, 3R and 7-1). This partial clone, designated Eos L2 (also referred to as L2 and EL2), was found to have 78.3% amino acid similarity (81.1% nucleic acid similarity) to the MIP1α/RANTES receptor and 60.8% amino acid similarity (61.6% nucleic acid similarity) to the MCP-1 receptor. A search of the most current sequence data bases revealed this partial clone to be unique.

### Southern and Northern Analysis

The PCR fragment was labeled and used to probe both Southern and Northern blots. To prepare the PCR probe, the 201 bp fragment was released from the pCR-Script vector

with restriction enzymes EcoRI and Not I. This digested  
resulted in a fragment of 240 bp comprised of the 201 bp  
fragment plus 39 base pairs of polylinker from the vector.  
The fragment was separated from vector by electrophoresis  
5 through agarose gel, and purified by (Magic Mini Prep,  
Promega Corp. Madison, WI) exactly as recommended by the  
manufacturer. Approximately 200 ng of material was labeled  
with the Random Primed DNA Labeling Kit purchased from  
Boehringer Mannheim following the manufacturer's  
10 recommended labeling protocol.

For Southern blots, genomic DNA (purchased from  
Clontech Laboratories, Inc., Palo Alto, CA) was digested  
with restriction enzyme overnight and separated by  
electrophoresis on a 0.7% agarose gel followed by capillary  
15 transfer to Hybond-N nylon membrane (Amersham).  
Hybridization was in 6x SSC (1x SSC is 0.15 M sodium  
chloride, 0.015 M sodium citrate) containing 5x Denhardt's  
solution (1x Denhardt's solution is 0.02% bovine serum  
albumin, 0.02% ficoll, 0.02% polyvinylpyrrolidone), 10% w/v  
20 dextran sulfate, 2% SDS, and sheared salmon sperm DNA (100  
 $\mu$ g/ml) overnight at 65°C. The membrane was rinsed twice in  
2X SSC, 0.5% SDS at 65°C followed by two washes (15 min  
each) in 0.2X SSC, 0.5% SDS at 65°C.

The Southern hybridization revealed a single strongly  
25 hybridizing fragment and a single weakly hybridizing  
fragment with each enzyme used. The weakly hybridizing  
fragment is likely to be the MIP1 $\alpha$ 1/RANTES receptor.

Multiple Tissue Northern Blots were purchased from  
Clontech Laboratories, Inc., Palo Alto, CA). ExpressHyb™  
30 Solution was also purchased from Clontech Laboratories,  
Inc. The Multiple Tissue Northern Blots were carried out  
as recommended by the manufacturer. The probe was as  
described above for Southern blots. The results of the  
Northern hybridization showed high levels of a ~ 1.6 kb

message in spleen, peripheral blood leukocytes and thymus. Additional Northern analyses are presented in Example 5.

#### Genomic Library Screening

A human genomic phage library constructed in the EMBL3  
5 SP6/T7 vector, purchased from CLONTECH Laboratories, Inc.  
(Palo Alto, CA), was screened with the 201 bp PCR fragment  
to obtain a full-length clone. Approximately 25,000 plaque  
forming units were mixed with 600  $\mu$ l of an overnight  
bacterial culture of *E. coli* strain K802 provided with the  
10 library in NZCYM top agarose and plated on 150 mm petri  
dishes containing NZCYM agar (NZCYM broth, Agar and Agarose  
were purchased from Gibco/BRL). After incubation at 37°C  
for 7 hours, the plates were overlaid with BA-85  
nitrocellulose membranes (Schleicher and Schuell, Keene,  
15 NH) for 5 minutes to allow transfer of phage to membrane.  
The membranes were then soaked for 5 minutes in Denturing  
Solution (1.5 M sodium chloride, 0.5 N sodium hydroxide)  
followed by neutralization in 1.5 M sodium chloride, 0.5 M  
Tris, pH 8.0. The filters were allowed to air dry for 15  
20 minutes and then baked for two hours at 80°C under vacuum.  
The filters were then hybridized as described above for the  
Southern Blot. The 201 bp PCR fragment contained the  
nucleotides between oligonucleotide primers 2a-2 (TM2) and  
3R (TM3).

25 One genomic phage clone, designated Eos L2.8,  
contained an insert which comprises the 1.8 kb Hind III  
fragment seen on Southern blots (complete insert size was  
not determined, but is ~17 kb).

Phage clone Eos L2.8 was digested with Hind III  
30 restriction enzyme and electrophoresed on an agarose gel.  
A Hind III fragment of approximately 1.8 kb was cut out,  
electroeluted from agarose, phenol/chloroform extracted and  
precipitated with ethanol. The 1.8 kb fragment was  
resuspended in water and ligated into the Hind III site of

the pBluescript II KS+ vector (Stratagene) followed by transformation into DH5 $\alpha$  competent cells purchased from Gibco/BRL.

Both strands of this Hind III fragment were  
5 sequenced, and the fragment was found to contain the entire amino acid coding region for the Eos L2 receptor (a human CKR-3 receptor). Comparison of this sequence and the cDNA clone described below indicates that the clone is a full-length clone. The open reading frame of 1065 nucleotides  
10 encodes a protein of 355 amino acids (SEQ ID NO:2) with a predicted molecular mass of 41 Kd.

Comparison of the sequence of the full-length Eos L2 receptor with MIP1 $\alpha$ /RANTES and MCP-1 receptors revealed a 73.4% and 60.5% amino acid similarity, respectively. For  
15 this comparison, sequences were aligned by hand and the number of similar amino acids, divided by the total number of amino acids was multiplied by 100.)

The sequences were also aligned by the Clustal method using MegAlign<sup>TM</sup> (DNASTAR, Inc.). Comparison with other  
20 chemokine receptor sequences revealed a 62%, 47%, and 41% amino acid sequence similarity to CKR-1, CKR-2B, and CKR-4, respectively. In contrast, the amino acid sequence similarity to IL-8 receptors A and B was only 27% for both receptors. The sequence similarity of this receptor to  
25 MIP1 $\alpha$ /RANTES and MCP-1 receptors, both C-C chemokine receptors, is consistent with the results reported herein which indicate that Eos L2 is a C-C chemokine receptor.

### EXAMPLE 3

#### Expression of Eos L2 in Transfected Cell Lines

##### 30 FLAG-tagged Eos L2 (CKR-3) Receptor construct

An Eos L2 receptor fusion protein was constructed as follows:

1. A FLAG-PAF receptor construct in pCDM8 (constructed as reported in Kunz, D. et al., *J. Biol. Chem.*, 267: 9101-9106 (1992)) was double digested with Hind III and EcoRI to release a 48 bp fragment containing  
5 nucleotides which encode the FLAG peptide. The nucleotide sequence is AAGCTTCCA GCA GCC ATG GAC TAC AAG GAC GAC GAT GAC AAA GAATTC (SEQ ID NO:15). The amino acid sequence is MDYKDDDDKEF (SEQ ID NO:16). The 48 bp Hind III/EcoRI fragment containing the FLAG nucleotides subcloned into the  
10 HindIII/EcoRI sites of the pcDNA3 vector (Invitrogen, San Diego, CA) giving rise to pcDNA3/FLAG.

2. The pBluescript II KS+ vector containing the 1.8 kb Eos L2 Hind III fragment was digested with BamHI and Xho I to release a 1.261 kb fragment. This BamHI-XhoI  
15 fragment contains nucleotides encoding Eos L2 amino acids 91 through the stop codon plus the same 3' untranslated region and 21 bp of pBluescript II KS+ vector.

3. Two PCR primers were generated to amplify the 5' end of the Eos L2 gene, but removing the first Met  
20 and engineering in an EcoRI site which will be compatible with the EcoRI site described above in step 1. The 5' primer (SEQ ID NO:17) was:

EcoRI  
5'-TTAA GAATTC ACA ACC TCA CTA GAT AC  
25 This primer contains an EcoRI site and the first 17 nucleotides of the EosL2 gene except for the Met codon.

The 3' primer (SEQ ID NO:18) was:

BamHI  
30 5'-CATAGT GGATCC AGAATG  
This primer primes in the Eos L2 gene just 3' to the BamHI site. Amplification with these two primers using the pBluescript II KS+ vector containing the 1.8 kb Eos L2 fragment as template will amplify a 280 bp fragment  
35 containing the 5' end of the Eos L2 which can be digested

with EcoRI and BamHI to give a fragment for ligation as described below.

Conditions for amplification were: 100 ng of pBluescript II KS+ containing the 1.8kb EosL2 fragment was  
5 combined with 200  $\mu$ M dNTPs and 50 pmol of primers in a 50  $\mu$ l reaction volume. The final magnesium concentration was 2.5  $\mu$ M and the pH was 8.0. The fragment was amplified with 25 cycles of 94°C, 30 sec; 55°C, 30 sec; 72°C, 30 sec. The amplified product was separated on agarose gel and purified  
10 by electroelution as described above. The fragment was digested with EcoRI and BamHI purified again on agarose gel.

4. For construction of the Flag-tagged EosL2 gene, the pCDNA3 vector containing the FLAG fragment  
15 (described in step 1) was digested with EcoRI and Xho I. The vector fragment (an EcoRI-XhoI fragment comprising the FLAG coding sequence) was separated from the polylinker fragment by electrophoresis, and the vector fragment was purified as described for other electroeluted fragments.  
20 The vector fragment was combined with the EcoRI-BamHI fragment generated by PCR in step three. These two fragments were combined with the 1.261 kb BamHI-XhoI fragment from step two. All three fragments were triple ligated together to yield the FLAG-tagged Eos L2 receptor  
25 in pCDNA3. Ligated DNA was transformed into DH5 $\alpha$ .

#### Transient Transfectants

293 cells (ATCC Accession No. CRL 1573) were grown in Minimal Essential Medium (MEM) Alpha Medium obtained from Gibco/BRL and supplemented with 10% fetal Calf Serum,  
30 Glutamine, and Penicillin/Streptomycin (all from Gibco/BRL). For each transient transfection,  $2 \times 10^6$  293 cells were plated 1 day before transfection in a 35-mm tissue culture dish. On the day of transfection, the cells

(which grow attached to the dish) were washed 1 x with Phosphate Buffered Saline (PBS, Gibco/BRL) and a mixture of DNA and lipofectAMINE™ Reagent (Gibco/BRL) were applied to the cells.

5        The DNA/lipofectAMINE™ reagent mixture was made by incubating 2 µg of Flag-tagged Eos L2 receptor expression vector in a final volume of 100 µl OptiMEM™ (Gibco/BRL) with 12 µl of LipofectAMINE™ reagent in a 100 µl volume for 45 minutes at room temp. The final mixture volume is 200  
10 µl. After the 45 minute incubation, 800 µl of OptiMEM™ is added to the 200 µl of DNA/lipofectAMINE™ reagent and the 1 ml of solution is layered over the cells as described above. The cells were then incubated at 37°C for 5 hours at which time 1 ml of MEM Alpha Medium supplemented as  
15 described above is added. The cells are incubated for an additional 12 hours at which time all medium is removed and the cells washed 2 x with PBS and 2 mls of MEM Alpha medium supplemented as described above is added. The transfected cells are then incubated for an additional 72 hours. The  
20 cells are harvested by gently pipetting them after incubation in PBS 10 mM EDTA.

Cell surface expression of a FLAG-tagged Eos L2 receptor was demonstrated in the transiently transfected 293 cells. Approximately 2.6% of the cells express the  
25 receptor on the surface as determined by immunofluorescent staining and FACS analysis. Levels of expression in some cells were found to be as much as 2 logs greater than background indicating that high levels of expression can be achieved in this cell line. As the Eos L2 gene is carried  
30 by the pcDNA3 expression vector (Invitrogen Corp., San Diego, CA), which contains the neomycin resistance gene, stable 293 transfectants can be selected using geneticin (G418) selection.



### Stable Cell Lines

Over 500 stable lines of mouse L1-2 pre-B cells have been generated with the FLAG-tagged receptor. L1-2 pre-B cells were obtained from (Dr. Eugene Butcher, Stanford University, Stanford, CA), and were maintained in RPMI-1640 (Gibco/BRL), supplemented with 10% bovine serum albumin, and Pen/Strep, sodium pyruvate and  $\beta$ -mercaptoethanol. Cells from over 200 clones were screened for surface expression by staining with M2 anti-FLAG monoclonal antibody (International Biotechnologies, Inc., New Haven, CT), followed by anti-mouse Ig-FITC (Jackson ImmunoResearch Laboratories, Inc.), and analyzed by fluorescence activated cell sorting (FACS). Immunofluorescent staining and FACS analysis was performed as described in Current Protocols in Immunology, Vol. 1, Coligan, J. et al., Eds., (John Wiley & Sons, Inc.; New York, NY). Results of the FACS analysis for several cell lines revealed a number of clones which express high levels of the Eos L2 flagged receptor (Figure 5). Untransfected cells (not shown) were negative for staining. Stable cell lines with high level expression can be used as immunogens for the production of antibodies reactive with the Eos L2 receptor. In addition, these cell lines are useful for studying chemotaxis and ligand binding.

### 25 Baculovirus Expression

For construction of a baculovirus expression vector, the Flag-tagged Eos L2 receptor in pCDNA 3 was digested with HindIII to remove the Flag-tagged gene. The HindIII fragment containing the gene was blunt ended by filling in the overhangs with Klenow fragment and dNTP's. The blunt ended fragment was subcloned into the Sma I site of pVL1393 (Invitrogen). 2.0  $\mu$ g of the pVL1393 vector containing the Eos L2 gene was mixed with 0.5  $\mu$ g of AcMNPV viral DNA (Invitrogen) and co-transfected into Sf9 insect cells

(Invitrogen) with Insectin™ (Invitrogen) according to the manufacturer's instructions. The SF-900 media (serum free) was replaced with 5 ml of SF-9 culture medium (Grace's Supplemented Insect Media (Gibco/BRL) containing 10% fetal calf serum) on the following day, and the cells were allowed to grow for five days. Recombinant virus was plaque purified as described in D.R. O'Reilly, L.K. Miller, and V.A. Luckow (1994) *Baculovirus expression vectors: A Laboratory Manual*, Oxford University Press, pp. 149-158.

10        Expression of the Eos L2 receptor was obtained on Sf9 cells by infecting Sf9 cells with the plaque purified recombinant virus described above. The Sf9 cells ( $2 \times 10^6$  cells/ml) were infected at a multiplicity of infection of 10:1. The infection proceeded for 72 hours at which time  
15        the cells were stained with the M2 anti-FLAG antibody.

          Successful expression of this receptor was also achieved with a baculovirus expression system in Sf9 cells. Good levels of expression have been achieved based on staining with anti-FLAG antibody (see Example 5). Ligand  
20        binding was also achieved with the same cells Sf9 transfectants shown by FACS to be expressing receptor. While definitive cell surface expression was shown by propidium iodide exclusion, expression on these cells appeared to be low, as compared with a negative control  
25        (i.e., Sf9 cells transfected with expression vector lacking the Eos L2 gene insert). Length of infection can be decreased, and MOI can be further optimized, for higher cell surface expression.

EXAMPLE 4

Ligand Binding Studies

Ligand Binding Procedure

Cells transfected with Eos L2 receptors or normal  
5 human eosinophils purified (see above) were washed in Hanks  
Balanced Saline Solution (HBSS), then resuspended in  
binding buffer: 50 mM HEPES, 1 mM  $\text{CaCl}_2$ , 5 mM  $\text{MgCl}_2$ , 0.5%  
Bovine Serum Albumin (BSA), pH 7.3. In microfuge tubes, 5  
x  $10^5$  cells were incubated with 0.1 nM radiolabeled  
10 chemokine (purchased from New England Nuclear,  
Massachusetts) in 200  $\mu\text{l}$  aliquots at room temperature for  
60 minutes. The cells were either incubated with  
radiolabeled chemokine alone, or together with unlabeled  
chemokines (from PeproTech) as competitors, which were used  
15 at the indicated concentrations. At the end of incubation,  
cells were washed 3 times in the binding buffer, each wash  
consisting of centrifugation in a microfuge at 7,000 x g  
for 2 minutes. After the wash, the pellets were  
transferred into LP3 tubes and the radioactivity of the  
20 cells, which represented the amount of binding was measured  
in a gamma counter. All samples were in duplicates and all  
the experiments were repeated at least 3 times. Scatchard  
Plot was calculated from the binding data by MicroSoft  
Excell and CricketGraph on a Macintosh computer.

25 Binding to Human Eosinophils

Based on the findings from chemotaxis assays (see  
Example 1), the ligand binding studies focused on RANTES,  
MIP-1 $\alpha$  and MCP-3. The ligand binding studies were carried  
out using radiolabeled chemokines and various 'cold'  
30 chemokines as competitors. Purified normal human  
eosinophils were incubated with either 0.1 nM  $^{125}\text{I}$ -labeled  
MIP-1 $\alpha$  or RANTES in the presence or absence of various cold

chemokines (250 nM MIP-1 $\alpha$ , RANTES, IL-8, MCP-1 or MCP-3). After extensively washing the cells, the binding was measured by a gamma counter.

Figure 6 is a histogram illustrating the binding of human eosinophils to RANTES and MIP-1 $\alpha$ . These results suggest that eosinophils bind only weakly to MIP-1 $\alpha$ , and that this binding can be inhibited by MIP-1 $\alpha$  itself and by other  $\beta$ -family chemokines, e.g., MCP-1, MCP-3 and RANTES (Figure 6). In contrast, eosinophils bound RANTES more abundantly (Figure 6). Binding by RANTES could not be inhibited efficiently by excess amount of 'cold' MIP-1 $\alpha$  (Figure 7), suggesting that on eosinophils, there could be distinguished receptors for MIP-1 $\alpha$  and RANTES.

Scatchard plot analysis revealed that there are  $1.8 \times 10^3$  MIP-1 $\alpha$  binding sites with an affinity of 91 pM. The analysis also revealed a lower affinity (883 pM) receptor for RANTES, having more binding sites ( $3.6 \times 10^4$ /cell). Under the conditions used, there was no significant MCP-1 binding to eosinophils (not shown), and MCP-1 did not inhibit RANTES binding except at very high concentrations (2500-fold excess, Figure 7).

#### Eos L2 Receptor Transfectants

Following the cloning and expression of the Eos L2 receptor, transfected cells were used to test binding to a number of chemokines. The first attempts using 293 transfectants were unsuccessful, as the addition of cold chemokines interfered with binding, a phenomenon observed by other investigators. In contrast, using baculovirus infected SF9 cells, good RANTES binding could be detected (Figure 8). The assay conditions for SF9 cells were different from that of mammalian cells. Binding of 0.1 nM  $^{125}$ I-labeled RANTES took place in 50 mM HEPES, pH 7.3, 5 mM MgCl<sub>2</sub> and 1 mM CaCl<sub>2</sub>, supplemented with 0.5% BSA. After 60

minutes at room temperature, the cells were washed three times in the binding buffer containing 0.5 M NaCl, and the radioactivity in the cell pellets was counted using a gamma counter.

5 In these ligand binding assays, the most effective heterologous competitor of MIP-1 $\alpha$  or RANTES binding was MCP-3. In fact, MCP-3 also effectively inhibited MCP-1 binding to activated T cells. Thus, MCP-3 appears to bind to CKR-1, CKR-2 and CKR-3 (CKR-1, Gao, J.L., et al., *J. Exp. Med.*, 177: 1421-1427 (1993) and Neote, K., et al., *Cell*, 72: 415-425 (1993); CKR-2, Charo, I.F., et al., *Proc. Natl. Acad. Sci. USA*, 91: 2752-2756 (1994) and Myers, S.J., et al., *J. Biol. Chem.*, 270: 5786-5792 (1995)).

10 Radiolabeled MCP-3 (Peprotech, Inc. Rocky Hill, N.J.) was also used for binding studies. MCP-3 binding was carried out as described above with the following modifications. Cells were incubated with 0.1 nM <sup>125</sup>I-labeled MCP-3. The binding buffer used was HBSS plus 0.5% BSA and 0.1% sodium azide. Binding took place at 37°C for 20 30 min. The unbound isotope was separated by spinning cells through 800  $\mu$ l of 20% sucrose, at 12,000 x g for 2 min. The tubes were then snap-frozen in dry ice, the tips cut off with a pair of pliers and counted.

#### EXAMPLE 5

#### 25 Expression of the Eosinophilic Chemokine Receptor

To confirm that the Eos L2 receptor is the functional receptor on eosinophils, the expression of the receptor was assessed by (a) Northern blot analyses, and (b) flow cytometry using monoclonal antibodies anti-peptide 30 antibodies reactive with the receptor.

Purification of Human Eosinophils, Neutrophils, and PBMC

Eosinophils were isolated from heparinized blood of individuals with high levels of circulating blood eosinophils (5-17%) by combined density gradient centrifugation and negative selection with anti-CD16 magnetic beads (Hansel, T.T. et al., *J. Immunol. Meth.*, 122: 97 (1989)). Briefly, the granulocyte fraction from the Percoll centrifugation was incubated with CD16 microbeads (Miltenyi Biotec, Inc., Sunnyvale, CA) for 30 minutes. Cells were then passed through a MACS column (Miltenyi Biotec, Inc.), and eosinophils were collected in the flow-through. Eosinophils were shown histologically to be > 99% pure as determined by analysis of Diff-Quick-stained cytocentrifugation preparations by light microscopy.

Human neutrophils were isolated from heparinized venous blood by Percoll density gradient centrifugation ( $d = 1.088$ ) at room temperature (Coligan et al., Eds., 1992, *Current Protocols in Immunology*, (John Wiley & Sons: New York, NY)). RBCs were removed by hypotonic lysis.

PBMCs were also isolated as described (Coligan et al., Eds., 1992, *Current Protocols in Immunology*, (John Wiley & Sons: New York, NY)). Monocytes were purified by CD14 positive selection with magnetic beads and T cells were purified by passage of lymphocytes over nylon wool. To generate CD3 blasts,  $2 \times 10^6$  PBMCs/ml in RPMI-1640 plus 10% FCS were added to tissue culture plates first coated with the anti-CD3 antibody TR77. After 4-6 days blasts were removed to fresh media and supplemented with IL-2 (Genzyme) at 50 units/ml.

Northern Analyses: CKR-3 Is Expressed Selectively in Eosinophils

Although eotaxin is a selective chemoattractant for eosinophils, the CKR-3 receptor also binds RANTES and MCP-3, which are known to attract monocytes and T cells. Message expression of the receptor was examined in various leukocyte populations.

The results of initial Northern hybridization (see Example 2) showed expression of a ~ 1.6 kb message in spleen, peripheral blood leukocytes, and thymus, and a number of leukocyte subpopulations, such as eosinophils and T cells, as well as in the HL-60 cell line. Message levels increased dramatically in the HL-60 cell line upon butyric acid induction down the eosinophilic pathway.

This message is likely to be that of Eos L2, since the message for the MIP1 $\alpha$ /RANTES receptor which cross-hybridizes on Southern blots is weak and is reported to be approximately 3.0 kb. When the original 201 bp PCR fragment is used as a probe in Southern blots, a strongly hybridizing 1.8 kb HindIII fragment is seen. This is the fragment that was cloned and discussed here. In addition to this fragment, a very weakly hybridizing fragment at about 10 kb is observed. This 10 kb fragment corresponds to the reported HindIII fragment size of the MIP1 $\alpha$ /RANTES receptor. This MIP1 $\alpha$ /RANTES receptor produces a message of approximately 3 kb which is not observed on Northern blots. Therefore, the ~1.6 kb message seen on Northern blots probably derives from Eos L2 gene. By far the most abundant expression of Eos L2 was observed in a preparation of purified eosinophils from a patient with hyper-eosinophilic syndrome (see Example 8).

Because of the high sequence similarity of CKR-3 to other CC chemokine receptors and the fact that the full-length clone hybridizes to multiple sequences in Southern blots, additional Northern analyses used a 250 bp fragment

from the 3'-untranslated region of the genomic clone which does not cross-hybridize with other sequences in Southern blots. For hybridization, a 3'-untranslated region probe specific for CKR-3 was used encompassing nucleotides

5 1203-1453 (Figure 1C).

A Northern blot panel was prepared using RNA from different leukocyte populations, including monocytes, neutrophils, lymphocytes, T cells, T cell blasts produced by activation with CD3 MAb, and eosinophils. RNA was  
10 isolated using TriZOL<sup>TM</sup> reagent (Gibco/BRL) following the manufacturer's recommended protocol. 15 µg of total RNA isolated from each highly purified leukocyte population was separated on 1.2% formaldehyde agarose gels and transferred to Nytran-Plus<sup>TM</sup> nylon membrane (Schleicher and Schuell)  
15 and cross-linked using a Stratalinker®. Hybridization with radiolabeled 3'-untranslated region probe was with ExpressHyb<sup>TM</sup> Solution (Clontech) using the manufacturer's suggested protocol. Northern blots were exposed to X-OMAT AR film for 3-5 days with intensifying screen. CKR-3  
20 specific probe was removed by boiling in 0.5% SDS and the blot re-probed with β-actin to control for variation in loading.

The only cell population which gave a detectable signal was eosinophils, where a message 1.8 kb in size was  
25 found. These results are consistent with the pattern of surface expression detected immunologically in Figures 13A-13D. Although message was not detected in resting or activated T cells in this experiment, it is possible that a subset of T cells may express the receptor.

### 30 Monoclonal Antibodies (MAbs) Reactive with the Eosinophilic Chemokine Receptor

MAbs reactive with the Eos L2 receptor were generated by immunizing mice with a synthetic peptide corresponding



to the N-terminal 35 amino acids. The N-terminal 35 amino acids of Eos L2, deduced from the nucleotide sequence (see Figures 1A-1C; see also, SEQ ID NO:2), were synthesized and coupled to the carrier protein PPD (Purified Protein  
5 Derivative of *Mycobacterium tuberculosis*; Severn Biotech Ltd., Cambridge, U.K.).

Female Balb/C mice were immunized with 50  $\mu$ g of this peptide peptide-carrier conjugate in PBS 4 times at 2 week intervals. Mice were injected intra-peritoneally with the  
10 peptide conjugate, using Freund's complete (first injection) and incomplete adjuvant (subsequent injections). The final immunization was injected intravenously without adjuvant. Polyclonal antiserum was also collected from mice immunized with synthetic peptide.

15 Two successful fusions were performed which generated over 15,000 hybridomas. Four days after the final injection, the spleen was removed and a single cell suspension prepared in serum free DMEM media. These cells were fused with the hybridoma fusion partner SP2/0,  
20 according to Galfre, G. et al. (Galfre, G. et al., *Nature*, 266: 550-552 (1977)). 20 ml of spleen cells and 20 ml of SP2/0 were combined, spun at 800g for 5 min and the media removed. A solution of 50% Polyethylene glycol 1500 (Boehringer Mannheim, Indianapolis, IN) prewarmed to 37°C  
25 was added to the cell pellet over 2 min, followed by 10 ml of DMEM media over 3 min. The cell suspension was spun at 400g for 3 min and the supernatant removed. The pellet was resuspended gently in DMEM media containing 20% fetal calf serum, 2 mM L-glutamine, 100 units/ml penicillin, 100  $\mu$ g/ml  
30 streptomycin sulfate, and HAT selection media (Boehringer Mannheim, Indianapolis, IN). Cells were plated into 96 well flat bottom microtiter plates at 200  $\mu$ l/well.

10-14 days later, supernatants from the wells were screened for reactivity against the peptide using an  
35 enzyme-labeled anti-mouse antibody (Horseradish peroxidase-

labeled anti-mouse IgG (Jackson) in an ELISA assay. Approximately 200 mAbs were selected that showed strong reactivity against the synthetic peptide. Hybridomas of interest were subcloned using limiting dilution.

5 To determine which antibodies could recognize the native, surface expressed molecule, the MABs were screened against Sf9 insect cells infected with AcMNPV virus carrying human Eos L2 genomic DNA. These insect cells expressed Eos L2 (CKR-3) receptor on the cell surface, as  
10 judged by strong anti-FLAG staining of approximately 10% of cells. Staining was performed using M2 anti-FLAG antibody, followed by anti-mouse Ig-FITC (Jackson ImmunoResearch Laboratories, Inc.), and analyzed by fluorescence activated cell sorting, using FACScan analysis to quantitate  
15 expression. (Current Protocols in Immunology, Vol. 1, Coligan, J. et al., Eds., (John Wiley & Sons, Inc.; New York, NY)).

Approximately 33% of the anti-peptide hybridomas reacted with the Eos L2 transfected insect cells, with a  
20 staining pattern identical to that of the FLAG antibody, as determined by FACS analysis using anti-mouse Ig-FITC (Jackson ImmunoResearch Laboratories, Inc.) as second antibody. Untransfected insect cells stained with anti-FLAG were completely negative. Anti-peptide antibody also  
25 tested against untransfected cells, which were negative for staining.

MABs that were found to stain the transfected insect cells were examined using FACS analysis for their reactivity with human eosinophils, peripheral blood  
30 lymphocytes, monocytes, neutrophils, and activated T cells (activated T cells; lymphocytes were treated with an anti-CD3 antibody to activate T cells). Cells were stained with mAb LS26-5H12 and then FITC-anti-mouse Ig (Jackson ImmunoResearch Laboratories, Inc.). Fc receptor binding

was controlled for by using an excess of normal human serum.

All eosinophils were stained with a selected anti-Eos L2 mAb, LS26-5H12. Neutrophils were not significantly  
5 stained by LS26-5H12 antibody under the conditions of the assay. Based on the expected distribution of the Eos L2 receptor, and that it functions in RANTES binding, MAb LS26-5H12 appears to recognize the naturally expressed form of this receptor. In addition to the LS26-5H12 MAb, ~ five  
10 additional Mabs behaved similarly.

The LS26-5H12 hybridoma was further purified by limiting dilution. In another experiment, highly purified leukocyte subsets (purified as described in Example 5) were stained with MAb LS26-5H12 and analyzed by flow cytometry  
15 (Figures 9A-9D). Staining profiles were representative of at least 4 experiments. T Cells were identified based on CD3 staining. Monocytes and neutrophils were identified by forward and side scatter.

Highly purified eosinophils stained strongly with  
20 LS26-5H12 (Figure 9A), suggesting abundant expression of the receptor on the surface of eosinophils, and consistent with a high receptor number determined by ligand binding and Scatchard analysis. Neutrophils, blood T cells, and monocytes showed little or no staining with this MAb  
25 (Figures 9B-9D). These latter results, using antibody from the recloned hybridoma, suggest CKR-3 is selectively expressed on eosinophils, and is not appreciably expressed on other leukocyte types tested. However, it is possible that a subset of T cells expresses the receptor.

EXAMPLE 6

Selection of Stable L1.2 Cell Transfectants

2% - 5% of transiently transfected COS, HEK-293 and CHO cells were surface positive as assessed using  
5 antibodies to FLAG-tagged receptor (see above), while substantial intracellular protein could be detected, suggesting inefficient protein trafficking. The L1.2 mouse pre-B cell line was used to select lines with higher levels of surface expression (see Figure 5) for further assessment  
10 of ligand binding specificity and signal transduction by CKR-3. This cell line has been used successfully for the study of other chemoattractant receptors (Honda, S., et al., *J. Immunol.*, 152: 4026-4035 (1994)), and the expression of transfected human chemokine receptors confers  
15 specific chemotactic ability to various ligands (see below).

To monitor surface expression of CKR-3, a monoclonal antibody (MAb) was produced to the N-terminal region of the receptor, by immunizing mice with a synthetic peptide  
20 having a sequence corresponding to the N-terminal 35 amino acids of CKR-3. Anti-peptide MAbs were detected by ELISA, and MAbs that recognize the native receptor were identified by their reactivity with human eosinophils, as well as their staining of transient transfectants.

25 Construction of CKR-3/pcDNA3

PCR was used to modify the CKR-3 gene contained in the 1.8 kb genomic fragment by inserting a HindIII restriction site and optimal Kozak sequence immediately 5' to the initiation codon. The coding region and 448 bp of  
30 3'-untranslated region were inserted into the HindIII site of pcDNA3 (Invitrogen), placing the gene under the control of the human CMV immediate early gene promoter of the vector. The details of the construction of this FLAG-

tagged Eos L2 (CKR-3) receptor construct (also referred to herein as CKR-3/pcDNA3) are provided in Example 3.

#### Transfection and Stable Cell Line Selection

The murine pre-B lymphoma cell line L1.2 was obtained from Dr. Eugene Butcher (Stanford University) and maintained in RPMI-1640 supplemented with 10% bovine serum. 20 µg of linearized, CKR-3/pcDNA3 was used to transfect the cell line as follows. L1.2 cells were washed twice in HBSS and resuspended in 0.8 ml of the same. The plasmid DNA was mixed with the cells and incubated for 10 minutes at room temperature then transferred to a 0.4 cm electroporation cuvette and a single pulse applied at 250 V, 960 µF. The electroporation was followed by a 10 minute incubation at room temperature. G418 was added to a final concentration of 0.8 mg/ml 48 hr post-transfection and the cells plated in 96 well plates at 25,000 cells/well. After 2-3 weeks under drug selection, G418 resistant cells were stained with 5H12 anti-receptor mAb (see below) and analyzed by FACScan®.

Lines with detectable surface staining were expanded and cloned several times by limiting dilution. Clones with the brightest surface staining were further analyzed by Northern hybridization to confirm the presence of transfected receptor as well as by RT-PCR using a T7 primer complementary to the pcDNA3 vector as the 5' primer and a CKR-3 specific primer as the 3' primer (not shown). No amplification was seen without addition of reverse transcriptase.

For transient transfection, 20 µg of supercoiled DNA was used in the electroporation exactly as described for stable cell line production. Cell surface staining was assessed after 48-72 hrs.

L1.2 cells transfected with CKR-3/pcDNA3 were diluted to  $1 \times 10^6$  cells/ml in tissue culture media. n-butyric acid (sodium salt, Sigma Chemical Corp., Cat. No. B5887) was added to a final concentration of 5 mM (diluted from a 1M stock solution made in tissue culture media). Cells were grown overnight (18-24 hours) at 37°C, 5% CO<sub>2</sub> prior to use. Lower concentrations have been used successfully (e.g., 2.5 mM and 1 mM n-butyric acid). n-butyrate treatment has been reported to induce protein levels up to about 10-fold relative to uninduced controls (see, e.g., Palermo, D.P., et al., *J. Biotech.*, 19: 35-48 (1991) and references cited therein). CKR-3 mRNA levels driven by the human CMV immediate early gene promoter were elevated dramatically by n-butyrate treatment.

#### 15 Monoclonal Antibody Production and Flow Cytometry

MAbs reactive with synthetic peptide were produced as described above in Example 5. MAbs were screened by ELISA as follows. 50 µl of peptide, at a concentration of 2 µg/ml in carbonate buffer, was used to coat NUNC 96-well Maxisorp plates for at least 4 hours at 4°C. 300 µl/well of blocking buffer (PBS + 1% BSA) was added for at least 2 hours. Plates were washed four times with PBS/Tween 20, and 50 µl of MAb supernatant was added to each well and incubated at 37°C for one hour. Plates were washed four times with PBS/Tween 20 and alkaline phosphatase-conjugated second antibody (Jackson ImmunoResearch Laboratories, West Grove PA) diluted 1:500 in PBS was added to each well. After an incubation at 37°C for 30 minutes, plates were washed four times with PBS/Tween 20. The substrate used for the color reaction was p-nitrophenylphosphate dissolved in diethanolamine buffer (Bio-Rad). Plates were read at 410 nm on an ELISA reader.

To determine which anti-peptide MAb could recognize native, surface expressed CKR-3, the anti-peptide MAb were screened against transiently transfected cells and eosinophils. For MAb staining, cells were washed once with  
5 PBS, and resuspended in 100  $\mu$ l PBS containing 2% FCS, 0.1% sodium azide (FACS buffer), 5  $\mu$ g/ml purified antibody, 5  $\mu$ g/ml MOPC-21 IgG, isotype matched control MAb (Sigma) or 100  $\mu$ l hybridoma culture supernatant. After 30 min at 4°C, cells were washed twice in FACS buffer, and resuspended in  
10 100  $\mu$ l of FITC-conjugated affinity purified F(ab')<sub>2</sub> goat anti-mouse IgG (Jackson). After incubating for 30 minutes at 4°C, cells were washed twice in FACS buffer and analyzed by FACScan\* to determine the level of surface expression. Propidium iodide was used to exclude dead cells.

15 Surface Expression of Receptor on Stable Transfectants of the L1.2 Cell Line

Figure 10A shows detectable surface staining of the transiently transfected receptor on a subpopulation of L1.2 cells, using an anti-receptor MAb, LS26-5H12.  
20 Untransfected L1.2 cells were negative (Figure 10B). A stable cell line was constructed by limiting dilution cloning of the transfectants and selection for higher surface staining as described above. This process yielded lines that had much higher levels of receptor expression  
25 (Figure 10C). Northern blot analysis confirmed the presence of transfected CKR-3 mRNA in one of the subclones, designated E5, and its absence in untransfected L1.2 cells (not shown).

EXAMPLE 7

Ligand Binding Specificity of Stable L1.2 Transfectants

Chemokines

Recombinant human chemokines were obtained from  
5 Peprotech, Inc. (Rocky Hill, NJ), except for human eotaxin  
which was synthesized using solid-phase methods that were  
optimized and adapted to a fully automated peptide  
synthesizer (model 430A; Applied Biosystems, Inc., Foster  
City, CA) as described (Clark-Lewis, I., et al.,  
10 *Biochemistry*, 30: 3128-3135 (1991)). Human eotaxin is also  
commercially available from Peprotech.

<sup>125</sup>I-Labeling

<sup>125</sup>I-labeled eotaxin was produced using the Bolton  
Hunter reagent (NEN), as described (Coligan, J.E., et al.,  
15 *Eds.*, 1992, *Current Protocols in Immunology* (New York: John  
Wiley and Sons)). The specific activity of radiolabeled  
eotaxin was calculated to be 180 Ci/mM.

Ligand Binding

Chemokine binding to target cells was carried out  
20 using a modification of a previously reported method (Van  
Riper, G., et al., *J. Exp. Med.* 177: 851-856 (1993)).  
Cells were washed once in PBS and resuspended in binding  
buffer (50 mM HEPES, pH 7.5, 1 mM CaCl<sub>2</sub>, 5 mM MgCl<sub>2</sub>, 0.5%  
BSA and 0.05% azide) at a concentration of 1 x 10<sup>7</sup>/ml.  
25 Aliquots of 50 µl (5 x 10<sup>5</sup> cells) were dispensed into  
microfuge tubes, followed by the addition of cold  
competitor and radiolabeled chemokines. The final reaction  
volume was 200 µl. Non-specific binding was determined by  
incubating cells with radiolabeled chemokines in the  
30 presence of 250-500 nM of unlabeled chemokines. After 60  
minutes incubation at room temperature, the cells were



washed 3 times with 1 ml of binding buffer containing 0.5 M NaCl. Cell pellets were then counted.

Competition is presented as the percentage of specific binding as calculated by  $100(S-B)/(T-B)$ , where S is the radioactivity of the sample, B as background binding and T as total binding without competitors. Background binding was obtained by incubating cells with radiolabeled chemokine and at least 400-fold excess of unlabeled chemokines. The total binding of eotaxin to E5 cells was  $11611 \pm 119$  cpm and background binding  $2248 \pm 745$  cpm. The total binding of eotaxin to eosinophils was  $7866 \pm 353$  cpm and background binding  $1148 \pm 518$  cpm. Duplicates were used throughout the experiments and the standard deviations were always less than 10% of the mean. All experiments were repeated at least three times. Curve fit was calculated by KaleidaGraph software.

The E5 cell line described in Example 6 was tested for its ability to bind radiolabeled eotaxin. Cells were incubated with 0.6 nM  $^{125}\text{I}$ -labeled eotaxin and various concentrations of cold competitor. Figure 11A shows that the transfected cells bound  $^{125}\text{I}$ -labeled eotaxin specifically and with high affinity. Scatchard analysis of the binding data indicated a dissociation constant ( $K_d$ ) of 1.5 nM (Figure 11C), similar to the value of 0.5 nM obtained using purified human eosinophils (Figure 11D). In addition, both RANTES and MCP-3 were able to specifically compete for binding. None of the other chemokines tested, including MIP-1 $\alpha$ , MIP-1 $\beta$ , or IL-8 were able to specifically compete for radiolabeled ligand (Figure 12).

### 30 Chemotaxis Assays

Chemotaxis with human eosinophils was assessed using a modification of a transendothelial assay (Carr, M.W. et al., *Proc. Natl. Acad. Sci. USA*, 91: 3652-3656 (1994)).

The endothelial cells used for this assay were the endothelial cell line ECV 304, obtained from the European Collection of Animal Cell Cultures (Porton Down, U.K.). Endothelial cells were cultured on 6.5-mm diameter Biocoat®

- 5 Transwell tissue culture inserts (Costar Corp., Cambridge MA) with a 3.0  $\mu$ M pore size. Culture media for ECV 304 cells consisted of M199 + 10% Fetal Calf Serum, L-glutamine, and antibiotics.

- 10 Assay media consisted of equal parts RPMI 1640 and M199, with 0.5% BSA. 24 hours before the assay,  $2 \times 10^5$  ECV 304 cells were plated onto each insert of the 24-well chemotaxis plate, and incubated at 37 °C. Chemotactic factors (diluted in assay medium) were added to the 24-well tissue culture plates in a final volume of 600  $\mu$ l.

- 15 Endothelial-coated tissue culture inserts were inserted into each well and  $10^6$  cells were added to the top chamber in a final volume of 100  $\mu$ l. The plate was incubated at 37°C in 5% CO<sub>2</sub>/95% air for 4 hours.

- 20 The cells that had migrated to the bottom chamber were counted using flow cytometry. 500  $\mu$ l of the cell suspension from the lower chamber was placed in a tube, and relative cell counts were obtained by acquiring events for a set time period of 30 seconds. This counting method was found to be reproducible, and enables gating on the
- 25 leukocytes and the exclusion of debris or other cells. Counts obtained in this way match closely those obtained by counting with a microscope.

- 30 The same assay was used to assess chemotaxis of L1.2 cells or L1.2 receptor transfectant cell lines, except that endothelial cells were not used to coat the Biocoat® Transwell tissue culture inserts.

CKR-3 expression in L1.2 cells confers chemotactic  
responsiveness for eotaxin, RANTES and MCP-3

L1.2 receptor transfectants were tested for their ability to migrate in response to a panel of chemokines over a range of concentrations. The CKR-3 expressing cell line E5 showed a chemotactic response to eotaxin, RANTES, and MCP-3 with a peak response to eotaxin at 100 ng/ml, although specific migration could be detected as low as 10 ng/ml (Figure 13A). While a response to RANTES was evident at both 10 ng/ml and 100 ng/ml, the magnitude of the response was not as great as with eotaxin. MCP-3 appeared to be a less potent chemoattractant on the E5 cell line than on eosinophils, with no detectable migration below 100 ng/ml. No significant response to other chemokines tested was seen with this cell line. In other control experiments, cells did not migrate to the bottom chamber when chemokine was added to the top well alone, confirming that cell migration was chemotactic rather than chemokinetic (not shown).

The untransfected L1.2 cell line did not migrate in response to any chemokines tested (Figure 13B). Indeed, a striking feature of the L1.2 cell line was the very low background chemotaxis to non-specific ligands. As a specificity control, L1.2 cells transfected with IL-8 RB migrated specifically in response to IL-8 and GRO $\alpha$  (Figure 17C), as well as NAP-2 and ENA-78 (not shown), but not to other CXC or CC chemokines. Other chemokine receptors which were introduced into L1.2 cells by transfection also confer chemotactic ability to their specific ligands, including CKR-2 transfectants (which respond to MCP-1 and MCP-3), CKR-1 transfectants (which respond to MIP-1 $\alpha$ ), and IL-8 RA transfectants (which respond to IL-8) (not shown). Pertussis toxin completely abrogated the chemotactic response of both eosinophils and the CKR-3 transfectants to eotaxin indicated that the receptor was signaling through

the G $\alpha$  subclass (Simon, M.I., et al., *Science*, 252: 802-808 (1991)) in both normal and transfected cells (not shown).

The chemotactic profile of eosinophils resembles that of CKR-3 transfectants

5        In order to assess whether the function of normal eosinophils resembled that of CKR-3 L1.2 transfectants, chemotaxis experiments were performed using eosinophils from a number of normal individuals (humans), having high levels of eosinophils (~6 to 8% of WBC) (purified as  
10 described in Example 5). Figures 14A-14B show two characteristic patterns of eosinophil chemotaxis observed in two different individuals. One pattern was characterized by a robust migration to eotaxin, and a lesser response to RANTES and MCP-3 (Figure 14A). The  
15 other pattern showed essentially equivalent chemotaxis in response to eotaxin, RANTES and MCP-3 (Figure 14B). These patterns were not due to variations in the assay, since within each individual, they were highly reproducible over a long period of time. MIP-1 $\alpha$  showed only weak chemotactic  
20 activity for eosinophils in the second class of individuals.

EXAMPLE 8

Cloning of a cDNA encoding Eos L2

Construction of an Eosinophil cDNA Library

25        Eosinophils were obtained from a patient (M.V.) diagnosed with idiopathic hyper-eosinophilic syndrome (Costa, J.J. et al., *J. Clin. Invest.*, 91: 2673 (1993)). RNA was isolated using a standard guanidinium isothiocyanate/cesium chloride method (In: *Current*  
30 *Protocols In Molecular Biology*, Vol. 1, Ausubel, F.M. et al., Eds., (John Wiley & Sons: New York, NY) page 4.2.2-4.2.3 (1991)). mRNA was obtained using Dynabeads® (Dynal,

Inc.), and the bacteriophage library was constructed using the SUPERScript™ Lambda System for cDNA Synthesis and  $\lambda$  Cloning (Gibco BRL, Life Technologies) which comes with  $\lambda$ gt22A, NotI-SalI arms.

## 5 Library Screening

We screened approximately 750,000 bacteriophage plaques of the resulting human eosinophil cDNA library in duplicate. The probe used was a full-length radiolabeled cDNA probe (p4 cDNA) which encodes the MIP-1 $\alpha$ /RANTES receptor (CKR-1) (Gao et al., *J. Exp. Med.*, 177: 1421 (1993)). The p4 cDNA was cloned into the BamHI (5') and XhoI (3') sites of pcDNAI (Invitrogen). A BamHI-XhoI fragment of this clone (i.e., p4 cDNA in pcDNAI) was obtained by restriction digestion, and isolated using Gene Clean (Bio101). The fragment was labeled with  $^{32}$ P using a random primer labeling kit (Boehringer Mannheim Biochemicals).

Filters were prehybridized by incubation for two hours at 42 °C, in a solution of 50% formamide, 5 X SSC, 1X Denhardt's, 10% Dextran Sulfate, 20 mM TRIS, pH 7.5, 0.1% SDS (sodium dodecyl sulfate). Hybridization was performed overnight at 42 °C in the same solution. Eosinophil cDNA library filters were then washed two times with 2X SSC/0.1% SDS at room temperature, and two times with 2X SSC/0.1% SDS at 42 °C. Each wash was for 30 minutes. Filters were exposed overnight and positive plaques were picked in duplicate. Clones were further evaluated when positive in duplicate after the low stringency washes.

## Characterization of cDNA Clones

Plaques were plaque purified, and DNA was isolated by a small scale phage lysis protocol (In: *Current Protocols In Molecular Biology*, Vol. 1, Suppl. 10, Ausubel, F.M. et

al., Eds., (John Wiley & Sons: New York, NY), page 1.13.7  
(1991). The bacteriophage DNA was digested with EcoRI  
(site in arm of vector) and NotI. The inserts released by  
digestion were visualized on a gel, and were found to be  
5 approximately 1.6 kb in length. The ~1.6 kb insert present  
in a plaque designated Mip-16 or M-16, was isolated using  
Gene Clean (Bio101), and was cloned into the EcoRI and NotI  
sites of Bluescript® vector KS (Stratagene), which had been  
digested with both EcoRI and NotI to produce asymmetric  
10 ends. The ligated plasmid was introduced into XL1-Blue *E.*  
*coli* cells (Stratagene) made competent as described by  
Hanahan (Hanahan, D., (1985), In: DNA Cloning, Volume 1,  
D.M. Glover, Ed. (IRL Press: Washington, D.C.), pp. 109-  
135).

15 Dideoxy sequencing of the M-16/Bluescript construct  
was performed using a dideoxynucleotide sequencing kit  
obtained from USB (United States Biochemical, Cleveland,  
OH). The nucleotide sequence of this clone was determined  
to encode a novel protein with a high degree of homology to  
20 the MIP-1 $\alpha$ /RANTES receptor; however, from the sequence  
data, the clone did not appear to be full-length.

In order to identify a full-length clone, 15-20  
additional plaques were isolated and purified, and the  
inserts present in the phage were characterized by  
25 restriction enzyme analysis and/or sequencing. Another  $\lambda$   
clone, designated M31, which was isolated was found to  
contain a ~1.8 kb insert. The insert was cloned into the  
EcoRI and NotI sites of Bluescript® vector KS (Stratagene),  
and introduced into XL1-Blue *E. coli* cells (Stratagene) as  
30 described above. DNA sequencing of this clone (M31 insert  
in Bluescript, referred to as M31/Bluescript construct) was  
performed as described above, and revealed that it encoded  
a full-length receptor.

The M31 insert was released from the M31/Bluescript  
35 construct by digestion with EcoRI and NotI. The resulting

fragment was isolated using Gene Clean (Bio101), and was inserted into the EcoRI and NotI sites of vector Ap<sup>M</sup>9, which had been digested with both EcoRI and NotI to produce asymmetric ends. Vector Ap<sup>M</sup>9 (de Fougerolles, A.R. et al., *J. Exp. Med.*, 177: 1187-1192 (1993)) is a derivative of CDM8 (Invitrogen) containing the  $\beta$ -lactamase from pBluescript and a polylinker from pSP64. The resulting construct, designated A31, was introduced into competent XL1-Blue cells.

10       The nucleotide sequence of the full-length cDNA and the predicted amino acid sequence of the encoded protein are shown in Figures 2A-2B (see also SEQ ID NO:3 and SEQ ID NO:4). The cDNA sequence shown in Figures 2A-2B was determined from clones A31 (bases 15-365 (numbering as in  
15       Figures 2A-2B)), and the M-16/Bluescript construct (bases 366 to 1152 (numbering as in Figures 2A-2B)). A comparison of the amino acid sequence of the novel receptor with other proteins revealed that the novel receptor and the  
20       MIP-1 $\alpha$ /RANTES receptor share 62% sequence identity, and the novel receptor and the MCP-1 receptor share 50.57% sequence identity. Sequence identity was determined using the Wisconsin UW GCG package (program gap), with the Needleman and Wunsch algorithm (Needleman and Wunsch, *J. Mol. Biol.* 48:443-453 (1970)).

## 25       Northern Analysis

RNA for Northern analysis was obtained from a patient having hyper-eosinophilia. The eosinophils were isolated as described (Costa, J.J., et al., *J. Clin. Invest.*, 91: 2673 (1993)). Total eosinophil RNA was isolated using  
30       standard procedures (In: *Current Protocols In Molecular Biology*, Vol. 1, Ausubel, F. M. et al., Eds., (John Wiley & Sons: New York, NY) page 4.2.2-4.2.3 (1991)). The total RNA was fractionated on a 1% agarose gel, and then blotted

onto GeneScreen filters (New England Nuclear). Filters were probed at high stringency according to the manufacturer's protocol for high stringency washing of Gene Screen blots (New England Nuclear).

5        Several Northern blots were prepared. One involved probing with the EcoRI-NotI fragment of the M16/Bluescript construct, and others were probed with the EcoRI-NotI fragment from clone A31. Both EcoRI-NotI fragments include the 3' untranslated regions. Probes were labeled with <sup>32</sup>P  
10        using a random primer labeling kit (Boehringer Mannheim Biochemicals).

15        The Northern blots each revealed a very strong signal of approximately 1.8 kb in total human eosinophil RNA. This result indicates that the A31 RNA is expressed at very high levels in eosinophils from this patient.

#### EXAMPLE 9

#### Expression of cDNA encoding Eos L2 receptor and Ligand Binding Studies

##### Constructs

20        Vectors A31 (described above) and A31-pcDNA3 were used for expression and binding analyses. To construct A31-pcDNA3, vector A31 was digested with EcoRI and NotI, the ~1.8 kb insert was isolated using Gene Clean (Bio101), and was inserted into the EcoRI and NotI sites of vector  
25        pcDNA-3 (Invitrogen), which had been digested with both EcoRI and NotI. The ligated construct, designated A31-pcDNA3, was introduced into competent XL1-Blue cells.

##### Transient Transfections

30        Transient transfections using A31 in the kidney cell line 293 initially suggested high affinity binding of A31 with radioactive RANTES. These initial binding studies



have been difficult to reproduce. Accordingly, stable cell lines have subsequently been produced with A31/pcDNA3 stably integrated into both RBL (rat basophilic leukemia) and 293 cells. RBL cells (Accession No. ATCC CRL 1378) were obtained from the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, MD 20852, and 293 cells (Accession No. ATCC CRL 1573) were a gift from I. Charo, Gladstone Cardiovascular Institute.

#### Stable Cell Lines

Stable cell lines were constructed as follows. A31-pcDNA3 was linearized by digestion with NotI. The linearized plasmid was introduced into RBL and 293 cells by electroporation. Confluent 293 and RBL cells growing in 100 X 20 mm plates were trypsinized, resuspended in 1 cc of phosphate buffered saline (PBS) and electroporated in a 0.4 cm cuvette (BioRad) with settings of 960 microfarads and 250 volts. Stable transfectants were isolated by positive selection in medium containing geneticin. Specifically, the cells were first cultured in DMEM (BRL), 10% fetal calf serum for several days, and then were switched to DMEM, 10% fetal calf serum with 0.9 mg/cc of Geneticin (BRL). (DMEM, Dulbecco's Modified Eagle's Medium). After 3 weeks, surviving colonies were isolated sterilely with cloning cylinders, and individual clones were grown in individual wells in DMEM, 10% fetal calf serum with 0.9 mg/cc of Geneticin (BRL).

Surviving clones which expressed A31 RNA at high levels were detected by Northern analysis. 120 stable transfectants of the RBL line, and 38 stable transfectants of the 293 cell line, were screened. Specifically, RNA from individual clones was isolated using the acid phenol method (Chomczynski, P. and N. Sacchi, *Anal. Biochem.*, 162: 156-159 (1987)). RNA was fractionated by electrophoresis, blotted onto GeneScreen (New England Nuclear), and Northern

blots were probed according to the manufacturer's suggestion for high stringency wash. The EcoRI-NotI insert from plasmid A31 was isolated, radiolabeled with  $^{32}\text{P}$  using the random primer labeling kit (Boehringer Mannheim Biochemicals), and used as a probe. RNA was quantified by ethidium bromide staining on gels. Untransfected 293 or RBL cells were used as negative controls for the corresponding transfectants.

Stable cell lines designated A31-293-#8, A31-293-#9, A31-293-#17, and A31-293-#20 were subsequently found to express A31 RNA at very high levels relative to other lines. Clone A31-293-#20 which highly expresses the A31 message by Northern analysis, was selected for further study.

One RBL line was found to express low-medium amounts of RNA, but did not appear to bind RANTES under the conditions used (not shown).

#### Ligand Binding

Stable clone A31-293-#20 was grown in quantities sufficient for binding assays. In particular, cells were grown in 100 mm plates in DMEM, 10% fetal calf serum, 0.9 mg/cc geneticin. Plates were grown to confluence, and membranes were prepared as follows. Culture medium was removed, and the cells were washed with phosphate buffered saline. Cells were harvested by washing with TEN (40 mM TRIS, pH 7.5, 1 mM EDTA, and 150 mM NaCl). The cells were frozen in liquid nitrogen, thawed at room temperature, and the membrane fraction was collected by centrifugation in a conical tube for 10 minutes at 18,000 rpm. Each binding point was determined using one-half of the membranes harvested from a single 100 mm plate grown to confluence.

$^{125}\text{I}$ -labeled RANTES was purchased from New England Nuclear, and cold RANTES was purchased from Peprotech

(Princeton, N.J.).  $^{125}\text{I}$ -labeled MCP-3 was a gift from New England Nuclear, and cold MCP-3 was a gift from J. Van Damme, Rega Institute for Medical Research, University of Leuven, B-3000 Leuven, Belgium (see also, Opdenakker, G. et al., *Biochem. Biophys. Res. Commun.*, 191(2): 535-542 (1993)). Binding assays were performed as described by Van Riper, G. et al., *J. Exp. Med.*, 177: 851 (1993), with the following modifications. In particular, the binding to membranes of 0.125 nanomolar of  $^{125}\text{I}$ -RANTES was performed in the presence of varying concentrations of unlabeled ligand. Binding buffer was 50 mM Hepes, 1 mM  $\text{CaCl}_2$ , 5 mM  $\text{MgCl}_2$ , 0.5% BSA, pH 7.2. Radiolabeled and cold ligand were added simultaneously to the membranes (see above), and incubated for 1.5 hours at room temperature. The binding reaction was added to 2 cc of wash buffer (0.5 M NaCl, 50 mM Hepes, 1 mM  $\text{CaCl}_2$ , 5 mM  $\text{MgCl}_2$ , 0.5% BSA, pH 7.2), mixed by vortexing, and then placed on polyethyleneimine-treated Whatman GFC filters. Filters were washed with an additional two ccs of wash buffer. Activity retained on filters after washing was determined by scintillation counting. Filters were placed in 5 cc of scintillation fluid and were then counted in a miniaxi-beta liquid scintillation counter (United Technologies, Packard, Downers Grove, IL). All points were determined in triplicate, except for the point at 2 nM, which was determined in duplicate.

The results of the assay indicated high affinity binding of RANTES to the receptor encoded by the A31 clone (Figure 15). Scatchard analysis of the data indicated a  $K_d$  of ~ 2.5 nM for RANTES, which is what is expected in normal cells.

Binding of MCP-3 to membranes from clone A31-293-#20 was also assessed using the ligand binding assay described above for RANTES binding to A31-293-#20 membranes (Figure

16). Binding reactions contained 0.125 nanomolab  $^{125}\text{I}$ -labeled MCP-3.

In addition, specificity of binding was assessed by determining the extent to which labeled MCP-3 (bound in the absence of cold MCP-3), could be displaced by cold MCP-3 (Figure 17). All points were taken in duplicate.

The MCP-3 bound to membranes from untransfected cells could not be displaced by  $^{125}\text{I}$ -labeled MCP-3, indicating non-specific binding. In comparison, the MCP-3 bound to membranes from A31-293-#20 cells could be displaced by hot MCP-3, which is indicative of specific binding.

The results of these assays indicate that the receptor encoded by the A31 cDNA specifically binds human MCP-3.

Example 10 Human eosinophils respond to numerous CC chemokines through one predominant receptor

**Cells, Cell Lines, and Tissue Culture.** Eosinophils were isolated from heparinized blood using CD 16 microbeads (Miltenyi Biotec, Auburn, CA), as described in Ponath, P.D., et al., *J. Clin. Invest.*, 97:604-612 (1996) and were shown cytologically to be  $\geq 99\%$  pure. Neutrophils and PBMCs were isolated as described in Ponath, P.D., et al., *J. Clin. Invest.*, 97:604-612 (1996). To generate CD3 blasts,  $2 \times 10^6$  PBMC/ml in RPMI-1640 plus 10% FCS were added to tissue culture plates first coated with the anti-CD3 antibody TR66. After 4-6 days blasts were removed to fresh media and supplemented with IL-2 (provided by Antonio Lanzavecchia, Basel) at 50 units/ml. Other cell lines used included transfectants of the L1.2 murine pre B cell lymphoma, expressing high levels of either CCR3 (see below; Ponath, P.D., et al., *J. Exp. Med.*, 183:2437-2448 (1996)), IL-8 RA (Ponath, P.D., et al., *J. Exp. Med.*, 183:2437-2448 (1996)), IL-8 RB (Ponath, P.D., et al., *J. Exp. Med.*,

183:2437-2448 (1996)), CCR2b, CCR4 and CCR5, and CCR1  
(Campbell, J.J., et al., *J. Cell Biol.*, 134:255-266  
(1996)). Transfectants were maintained in RPMI-1640  
supplemented with 10% bovine serum and 800 µg/ml G418. The  
5 different transfectants were monitored for expression of  
the relevant receptors, using mAbs specific for CCR3  
(Ponath, P.D., et al., *J. Exp. Med.*, 183:2437-2448 (1996)),  
IL-8 RA, IL-8 RB, or CCR2 (Qin, S., et al., *Eur. J.*  
*Immunol.* 26:640-647 (1996); (Ponath, P.D., et al., *J. Clin.*  
10 *Invest.*, 97:604-612 (1996)). For CCR4 and CCR5, expression  
was monitored using the anti-flag mAb M2, since these  
receptors were constructed with this epitope at the  
N-terminus.

Human eosinophils were cultured in RPMI 1640 with 10%  
15 FCS and 5 ng/ml of recombinant human IL-5 (Genzyme Corp.,  
Cambridge, MA), for 5-7 days, using tissue culture flasks  
containing subconfluent monolayers of ECV304 cells.

MAbs to IL-8 RA, IL-8 RB, and CCR2 (MCP-IR) have been  
described (Qin, S., et al., *Eur. J. Immunol.* 26:640-647  
20 (1996)). mAb staining of cells was performed using standard  
procedures, as described previously (Ponath, P.D., et al.,  
*J. Exp. Med.*, 183:2437-2448 (1996)). To enumerate antibody  
binding sites per cell, the F/P ratio of 7B11-FITC was  
determined with Simply Cellular beads (Flow Cytometry  
25 Standards Corp., San Juan, PR) and the FACScan<sup>®</sup> was  
calibrated with Quantum 26 beads (Flow Cytometry Standards  
Corp.), according to the manufacturer's instructions. 100  
µl of whole blood from donors was reacted with a  
supersaturating amount (400 ng) of 7B11-FITC in PBS with  
30 0.5% azide. Red cells were lysed with ammonium chloride  
lysing solution and the mean channel fluorescence of 7B11  
stained cells was determined by flow cytometry.

### Expression Vector Construction and Generation of CCR3 Stable Transfectants

The 1.8 kb CKR-3 (CCR3) genomic fragment, which was ligated into the HindIII site of the pBluescript II KS+ vector (Stratagene) (Example 2), was modified for expression by insertion of a HindIII restriction site and optimal Kozak sequence immediately 5' to the initiation codon in a four-stage process as described in Example 3 (Construction of FLAG-tagged Eos L2 (CKR-3) Receptor Construct).

The murine pre-B lymphoma cell line L1.2 was maintained in RPMI-1640 supplemented with 10% bovine serum. 20 µg of the FLAG-tagged CKR-3/pcDNA3 construct (Example 3) were linearized by digestion with ScaI and used to transfect the L1.2 cell line as follows. L1.2 cells were washed twice in HBSS and resuspended in 0.8 ml of the same buffer. The plasmid DNA was mixed with the cells and incubated for 10 minutes at room temperature, transferred to a 0.4-cm electroporation cuvette, and a single pulse was applied at 250 V, 960 µF. The electroporation was followed by a 10 minute incubation at room temperature. G418 was added to a final concentration of 0.8 mg/ml 48 hours after transfection and the cells were plated in 96-well plates at 25,000 cells/well. After 2-3 weeks under drug selection, G418-resistant cells were stained with 5H12 anti-receptor monoclonal antibody, and analyzed by FACScan® (Becton Dickinson & Co., Mountain View, CA). For mAb staining, cells were washed once with PBS, and resuspended in 100 µl PBS containing 2% FCS, 0.1% sodium azide (FACS® buffer), 5 µg/ml affinity purified antibody or 5 µg/ml MOPC-21 IgG<sub>1</sub>-isotype matched control mAb (Sigma Chemical Co., St. Louis, MO), or 100 µL hybridoma culture supernatant. 5H12 antibody was used as hybridoma culture supernatant. After 30 minutes at 4°C, cells were washed twice with FACS®

buffer, and resuspended in 100  $\mu$ l FITC-conjugated,  
affinity-purified F(ab')<sub>2</sub> goat anti-mouse IgG (Jackson  
ImmunoResearch Laboratories). After incubation for 30  
minutes at 4°C, cells were washed twice in FACS® buffer and  
5 analyzed by FACScan®. Propidium iodide was used to exclude  
dead cells. Stable transfectants were treated with 5mM n-  
butyric acid (Sigma Chemical Co., St. Louis, MO, Catalog  
No. B 5887) 24 hours prior to analysis (FACS staining or  
binding) or immunization. All stable transfectants,  
10 including the L1.2 transfectants described in Figures 18A  
and 18C were treated with n-butyric acid. Lines with  
detectable surface staining were expanded and cloned  
several times by limiting dilution. As a negative control,  
CKR-3 transfected cells were stained with an irrelevant  
15 control IgG1 MAb (MOPC-21) and the same second antibody.  
In addition, control L1.2 cells transfected with IL-8RB,  
which were processed in parallel, were stained with 5H12  
and second antibody. A CKR-3 transfected clone having the  
brightest surface staining as assessed by fluorescence  
20 intensity was used as immunogen as described below.  
Generally, the mean channel fluorescence intensity of the  
5H12-stained cell preparation was 2-3 logs higher than  
staining of the controls. The transfectants used in the  
immunization which yielded the monoclonal antibody  
25 designated 7B11, displayed a fluorescence intensity two  
logs higher than the MOPC-21-stained and the IL-8RB  
controls.

Clones with the brightest surface staining were  
further analyzed by Northern hybridization to confirm the  
30 expression of transfected receptor as well as by RT-PCR  
using a T7 primer complementary to the pcDNA3 vector as the  
5' primer and a CKR-3-specific primer as the 3' primer. No  
amplification was seen without addition of reverse  
transcriptase.

### Monoclonal Antibody Production and Flow Cytometry

L1.2 CCR3 transfected cells prepared as described above were washed three times in PBS and resuspended in 200  $\mu$ l PBS/ $10^7$  cells. Monoclonal antibodies reactive with CCR3  
5 were generated by immunizing C57BL6 mice with  $10^7$  L1.2 CCR3 transfected cells, intraperitoneally, five to six times at 2 week intervals. The final immunization was injected intravenously. Four days later, the spleen was removed and cells were fused with the SP2/0 cell line as described  
10 (Coligan, J.E. et al., 1992, In: *Current Protocols In Immunology* (John Wiley and Sons, New York), Unit 2.5.4).

Monoclonal antibodies reactive with CCR3 were identified using untransfected and CCR3 transfected L1.2 cells, and immunofluorescent staining analysis using a  
15 FACScan® (Becton Dickinson & Co., Mountain View, CA). Hybridoma culture supernatants were used in an indirect immunofluorescence assay in a 96-well format using anti-mouse Ig-FITC. Untransfected and CCR3 transfected L1.2 cells were washed once with PBS, and resuspended in 50  $\mu$ l  
20 PBS containing 2% FCS, 0.1% sodium azide (FACS® buffer). 50  $\mu$ L hybridoma culture supernatant was added. After 30 minutes at 4°C, cells were washed twice with FACS® buffer, and resuspended in 100  $\mu$ l FITC-conjugated, affinity-purified F(ab')<sub>2</sub> goat anti-mouse IgG (Jackson  
25 ImmunoResearch Laboratories). After incubation for 30 minutes at 4°C, cells were washed twice in FACS® buffer and analyzed by FACScan®. Antibodies which stained CCR-3 transfectants but not untransfected L1.2 cells were selected. Two monoclonal antibodies reactive with CCR3  
30 were obtained from two different fusions. One of these antibodies, produced by the 7B11 hybridoma, was designated 7B11.

**Chemokines, Chemotaxis Assays, and Ligand-binding Assay.** Recombinant human chemokines were obtained from



Peprotech (Rocky Hill, NJ), except for eotaxin, described previously (Ponath, P.D., et al., *J. Clin. Invest.*, 97:604-612 (1996)), which was a gift of Dr. Ian Clark-Lewis. Chemotaxis of human eosinophils was assessed using a modification of a transendothelial assay (Carr, M.W., et al., *Proc. Nat'l. Acad. Sci. USA*, 91:3652-3656 (1994)), using the cell line ECV304 as described (Ponath, P.D., et al., *J. Clin. Invest.*, 97:604-612 (1996)). Cells that had migrated to the bottom chamber were placed in a tube, and relative cell counts were obtained using the FACScan.

<sup>125</sup>I-labeled eotaxin was obtained from Amersham (Arlington Heights, IL), and its specific activity was stated to be 2000 Ci/mM. Chemokine binding to target cells was carried out as described previously (Ponath, P.D., et al., *J. Clin. Invest.*, 97:604-612 (1996); Van Riper, G., et al., *J. Exp. Med.*, 177: 851-856 (1993)). Duplicates were used throughout the experiments and the standard deviations were always <10% of the mean. All experiments were repeated at least three times. Curve fit and concentrations that inhibit 50% specific binding (IC<sub>50</sub>) were calculated by KaleidaGraph software (Synergy Software, Reading, PA).

**Measurement of intracellular calcium concentration**  
([Ca<sup>2+</sup>]<sub>i</sub>). 50 µg Fura-2 AM (Molecular Probes, Eugene OR) was dissolved in 44 µl of DMSO, and this was diluted to 4.4 ml with loading buffer (Hanks Balanced Salt Solution, Gibco/BRL, catalogue # 14025-092 containing 2% BSA). Eosinophils were resuspended in loading buffer at 10<sup>7</sup> cells/ml, and 1.5 ml of cells was mixed with 300 µl of the Fura-2 solution for 30 minutes at 37°C. Following labeling, excess dye was removed by centrifugation and cells were resuspended at a concentration of 10<sup>6</sup>/ml in 125 mM NaCl, 5 mM KCl, 1 mM MgCl<sub>2</sub>, 1 mM CaCl<sub>2</sub>, 0.5 mM glucose,

0.025% BSA and 20 mM HEPES, pH 7.4.  $[Ca^{2+}]_i$  was measured using excitation at 340 and 380 nm on a Hitachi F-2000 fluorescence spectrometer. Calibration was performed using 1% NP-40 for total release and 25  $\mu$ M EGTA to chelate free  $Ca^{2+}$ .

## Results

Complete blocking of eotaxin, RANTES and MCP-3 binding to CCR3 transfectants using a mAb, 7B11. L1.2 transfectants expressing high levels of CCR3 were selected using the anti-CCR3 peptide mAb 5H12 (Example 5, also referred to herein as LS26-5H12; Ponath, P.D., et al., *J. Clin. Invest.*, 97:604-612 (1996)). mAbs were produced to surface expressed CCR3 and one mAb, 7B11, was identified that reacted with L1.2 cells transfected with CCR3, but not with L1.2 cells transfected with CCR1, CCR2b, CCR4, CCR5, CXCR1, or CXCR2 (Figure 18A). mAb 7B11 stained human eosinophils intensely (Figure 18B). This mAb was unreactive with lymphocytes, CD3 activated T cells, and monocytes. Staining on neutrophils was largely negative, although a small percentage of these cells may express very low levels of the receptor. The small subset of granulocytes stained intensely by 7B11 (Figure 18A) were eosinophils which were contained in the granulocyte gate.

mAb 7B11 was assessed for its ability to inhibit  $^{125}I$ -labeled-eotaxin,  $^{125}I$ -RANTES,  $^{125}I$ -MCP-2 and  $^{125}I$ -MCP-3 binding to CCR3 transfectants. mAb 7B11 inhibited binding completely of  $^{125}I$ -labeled eotaxin to the transfectants (Figure 18C), and this inhibition was as efficient as that obtained with 100 nM cold eotaxin. This indicated that mAb 7B11 was able to completely block eotaxin binding to CCR3. This mAb also completely inhibited  $^{125}I$ -labeled RANTES,  $^{125}I$ -labeled MCP-3 and  $^{125}I$ -labeled MCP-2 binding to CCR3 transfectants (Figure 18C), indicating that the epitope

recognized by 7B11 was involved in the binding of numerous CC chemokines. In contrast, mAb 7B11 failed to inhibit RANTES binding to CCR1 transfectants (Figure 18C).

mAb 7B11 blocks binding of radiolabeled eotaxin, RANTES and MCP-3 to eosinophils. To test if eotaxin, RANTES and MCP-3 binding to eosinophils was occurring through CCR3, binding of radiolabeled chemokines to eosinophils was performed in the presence of various concentrations of the blocking mAb 7B11, or a control mAb (Figure 19).

<sup>125</sup>I-labeled eotaxin binding to eosinophils could be completely inhibited using an appropriate amount of 7B11 mAb, consistent with results indicating that eotaxin binds only to CCR3 on eosinophils (Ponath, P.D., et al., *J. Exp. Med.*, 183:2437-2448 (1996)). However RANTES and MCP-3 are known to bind chemokine receptors in addition to CCR3 (Neote, K., et al., *Cell* 72:415-425 (1993); Gao, J.L., et al., *J. Exp. Med.*, 177:1421-1427 (1993); Ponath, P.D., et al., *J. Exp. Med.*, 183:2437-2448 (1996)). Figure 19 shows that mAb 7B11 also inhibited <sup>125</sup>I-labeled RANTES and <sup>125</sup>I-labeled MCP-3 binding to eosinophils. 50 ng/ml of mAb 7B11 was sufficient to achieve complete blockade of all chemokine binding to normal eosinophils, similar to the inhibition achieved with 2500-fold excess of cold chemokines. Slightly lower amounts of mAb 7B11 were required to block RANTES and MCP-3 binding, which is consistent with the lower affinity of RANTES and MCP-3 for CCR3 (Ponath, P.D., et al., *J. Exp. Med.*, 183:2437-2448 (1996)).

Inhibition of eosinophil chemotaxis to CC chemokines using anti-CCR3 mAb. Chemotaxis experiments were performed using eosinophils from normal individuals with moderately high levels of eosinophils (~3 to 6% of WBC). Figure 20A shows that mAb 7B11 was able to inhibit completely the chemotaxis of eosinophils to eotaxin in a dose dependent

manner. 5-10 ug/ml was required to achieve 100% inhibition, using 100 ng/ml (12.5 nM) of chemokine in the bottom well. Figure 20B shows that the eosinophil chemotactic responses to RANTES, MCP-2, MCP-3, and MCP-4 could be inhibited

5 totally using 5-10 ug/ml of mAb 7B11. 7B11 was unable to inhibit eosinophil chemotaxis to C5a (Figure 20B).

Moreover, mAb 7B11 was unable to inhibit PBMC chemotaxis to RANTES, which occurs through chemokine receptors other than CCR3. Donor to donor variation in eosinophil chemotactic

10 responses to chemokines has been observed (Ponath, P.D., et al., *J. Exp. Med.*, 183:2437-2448 (1996)). However, in all individuals examined thus far (n=8), mAb 7B11 was able to inhibit by >95% the migration of eosinophils to eotaxin, RANTES, MCP-2, MCP-3, and MCP-4.

15 mAb 7B11 inhibits changes in  $[Ca^{2+}]_i$  by eosinophils in response to CC chemokines. Eotaxin, RANTES, MCP-2, MCP-3 and MCP-4 induce changes in  $[Ca^{2+}]_i$  by human eosinophils (Ponath, P.D., et al., *J. Clin. Invest.*, 97:604-612 (1996); (Uguccioni, M., et al., *J. Exp. Med.*, 183:2379-2384  
20 (1996)). To examine the agonist/antagonist function of mAb 7B11, eosinophils were assessed for  $[Ca^{2+}]_i$  following injection of mAb 7B11, or an irrelevant control mAb. Eosinophils incubated with the irrelevant mAb still produced changes in  $[Ca^{2+}]_i$  following injection of optimal  
25 amounts of eotaxin, RANTES, MCP-2, MCP-3 and MCP-4 (top panels, Figure 21). C5a, a potent stimulator of eosinophil  $[Ca^{2+}]_i$ , was used as a control.

Eosinophils incubated with 6.4  $\mu$ g/ml of 7B11 mAb for 40 seconds were unable to respond to eotaxin, RANTES,  
30 MCP-2, MCP-3 and MCP-4 (bottom panels, Figure 21). This inhibition was not due to receptor modulation from the cell surface, since this effect was rapid, and immunofluorescent staining of eosinophils incubated with mAb 7B11 at room temperature revealed intense staining. In addition, mAb

7B11 was antagonistic rather than agonistic, since concentrations as high as 10  $\mu$ g/ml of mAb failed to induce a change in  $[Ca^{2+}]_i$ . 7B11 treated eosinophils showed changes in  $[Ca^{2+}]_i$  to C5a (Figure 21). mAb 7B11 had no effect on the  $[Ca^{2+}]_i$  of butyrate differentiated HL-60 cells to MIP-1 $\alpha$  or RANTES, a response that is mediated through receptors other than CCR3.

IL-5 primed eosinophils respond to CC chemokines through CCR3 but upregulate IL-8 receptors. Eosinophils from eosinophilic individuals, and normal eosinophils primed in vitro with IL-5, respond to IL-8 in chemotaxis assays (Schweizer, R.C., et al., *Blood*, 83:3697-3704 (1994); Sehmi, R., et al., *Clin. Exp. Allergy*, 23:1027-1034 (1994)), suggesting that activated eosinophils have altered chemokine receptor expression. To test whether primed or activated eosinophils respond to CC chemokines in the same manner as do normal eosinophils, blocking experiments similar to those shown in Figures 20 and 21 were performed using day 5 to 7 IL-5 stimulated eosinophils, and eosinophils from an eosinophilic individual. The IL-8 receptors, CXCR1 and CXCR2, were undetectable by mAb staining on eosinophils from all normal individuals examined (n=12) (Figure 22A). However following 5-7 days culture in vitro with human IL-5, CXCR2 and (to a lesser degree) CXCR1 were detectable on the surface of eosinophils, as detected using anti-CXCR2 mAbs and flow cytometry (Figure 22B), and this expression paralleled the ability of these eosinophils to migrate to IL-8 in chemotaxis assays (not shown). In the one eosinophilic donor examined (18-25% of WBC were eosinophils, for >1 year), CXCR2 was expressed on eosinophils at a slightly lower level (Figure 22C).

mAb 7B11 was still able to block completely the calcium responses of both IL-5 primed eosinophils

(Figure 22D), and eosinophils from the eosinophilic donor, to eotaxin and RANTES (Figure 22D), as well as MCP-2, MCP-3, and MCP-4, in a similar fashion to that described for normal eosinophils. mAb 7B11 had no effect on IL-8  
5 responses (Figure 22D), and MIP-1 $\alpha$  responses were not evident in these experiments. CCR3 expression was assessed on the IL-5 primed eosinophils, and from eosinophils from numerous healthy individuals. The number of 7B11 binding  
10 sites per eosinophil from healthy individuals was calculated to be  $17,400 \pm 1600$  (n=12), and no significant differences were observed following IL-5 stimulation. However in the one eosinophilic donor analyzed, the number of 7B11 binding sites was found to be 26,000.

#### DISCUSSION

15 The functional effects of all of the efficacious chemokines for eosinophils characterized, including eotaxin, RANTES, MCP-2, MCP-3, and MCP-4, could be blocked completely with an anti-CCR3 mAb with potent antagonistic activity. This mAb was specific for CCR3, and no inhibitory  
20 effects on other chemoattractant receptors were observed. These results further establish that CCR3 is the principal receptor for eosinophil responses to CC chemokines, and questions an essential role for CCR1, CCR2, CCR4 or CCR5.

The predominant CC chemokine receptor on eosinophils  
25 is CCR3. This receptor is expressed at a high level, as shown by ligand binding studies and mAb staining. A recent study suggested that human eosinophils express MIP-1 $\alpha$  receptors, either CCR1, CCR4 or CCR5, at about 1-5% of the levels of CCR3 (Daugherty, B.L., et al., *J. Exp. Med.*,  
30 183:2349-2354 (1996)), and modest eosinophil chemotactic responses towards MIP-1 $\alpha$  have been observed in some individuals ( see above; Ponath, P.D., et al., *J. Exp. Med.*, 183:2437-2448 (1996); Ponath, P.D., et al., *J. Clin. Invest.*, 97:604-612 (1996)). However, the results using

MAB 7B11 indicate MIP-1 $\alpha$  receptor(s) contribute little to the functional responses of eosinophils to RANTES or MCP-3. Donor variation was observed in eosinophil responses to the CC chemokines, however these responses were blocked completely in all individuals, using mAb 7B11, indicating that if other CC chemokine receptors are present, they have a minor functional significance. In addition, responses of IL-5-stimulated eosinophils to CC chemokines could also be blocked by mAb 7B11, suggesting that no new receptors were upregulated on cytokine primed eosinophils, as happens for IL-2 primed T cells (Loetscher, P., et al., *J. Exp. Med.*, 184:569-577 (1996)). The relevance of IL-8 receptors on IL-5 primed or activated eosinophils is uncertain. The phenotypic and functional analyses described herein are consistent with previous reports showing that IL-5 stimulated eosinophils, or eosinophils from eosinophilic donors, respond to IL-8 in chemotaxis assays (Schweizer, R.C., et al., *Blood*, 83:3697-3704 (1994); Sehmi, R., et al., *Clin. Exp. Allergy*, 23:1027-1034 (1994)).

Thus, as described herein, a fully antagonistic mAb to a CC chemokine receptor has been identified. A CCR3 antagonist has application in the treatment of diseases such as asthma, where an inhibition of eosinophil migration to the airways is beneficial. The role of Eotaxin-CCR3 in eosinophil migration to the airways in asthma is suggested since a selective recruitment of eosinophils often occurs in this disease. Moreover, eotaxin and other chemokines are highly upregulated in the airways of asthma patients (J. Rottmann and D. Ringler), as well as in animal models of allergic airway disease (Jose, P.J., et al., *J. Exp. Med.*, 179:881-887 (1994); Gonzalo, J.-A., et al., *Immunity*, 4:1-14 (1996)).

Example 11 Blockade of eosinophil degranulation induced by eotaxin, RANTES and MCP-3 by anti-CCR3 monoclonal antibody 7B11. Effect of anti-CCR3 monoclonal antibody 7B11 on C5a-induced eosinophil degranulation.

5        Eosinophil degranulation stimulated by eotaxin, RANTES, MCP-3 or C5a was measured by the release of eosinophil peroxidase into the media (EPO) after stimulation with either eotaxin, RANTES, MCP-3 or C5a. EPO is an eosinophil enzyme present in eosinophilic specific  
10 granules.

      The present study shows that the anti-CCR3 monoclonal antibody 7B11 inhibits the eosinophil degranulation stimulated by the CCR3 chemokines eotaxin, RANTES and MCP-3, while it has no effect on eosinophil degranulation  
15 stimulated by C5a. C5a binds to a different receptor and thus it serves as a negative control.

**Materials and Methods**

      Hank's Balanced Salt Solution (HBSS, Cat. No. 14025-092) and Dulbecco's Phosphate Buffered Saline (PBS, Cat.  
20 No. 14190-144) were from Gibco BRL. Cytochalasin B (C-6762), Hydrogen Peroxide (H<sub>2</sub>O<sub>2</sub>, 3% solution, H-6520), DMSO (D-5879), Tris(hydroxymethyl)amino methane (T-1503) and o-phenylenediamine (P2903) were from Sigma Chemical Co., (St. Louis, MO). Polystyrene V or round bottom plates  
25 were from Costar. Purified human eosinophils were prepared as described above.

**Eosinophil degranulation assay and blockade by the monoclonal antibody 7B11.**

      7B11 antibody solutions were prepared in PBS at 1 and  
30 0.1 mg/ml (100 X assay final concentrations). Chemokine or C5a were dissolved in HBSS, 25 mM Hepes, 0.25% BSA buffer (assay buffer) at 2X assay final concentrations.



Eosinophils were resuspended at  $2.5 \times 10^6$ /ml in assay buffer (HBSS, 25 mM Hepes, 0.25% BSA). A 1:1000 volume of a 5 mg/ml cytochalasin B solution in 100% DMSO was added to the eosinophil suspension (5  $\mu$ g/ml final concentration).  
5 100  $\mu$ l of the cell suspension were then dispensed into 96 well V bottom plates ( $0.25 \times 10^6$  cells per well). 2  $\mu$ l of either PBS or antibody solution (1 or 0.1 mg/ml for the 10 or 1  $\mu$ g/ml final antibody concentrations, respectively) were added to the cells and the plates were placed in a  
10 37°C incubator for 10 min. After incubation, 100  $\mu$ l of chemokine solution or buffer alone were added to the cells and incubated for 30 min. After incubation the plates were centrifuged for 5 min at 160 g at 10°C. After centrifugation supernatants were collected and assayed for  
15 the presence of eosinophil peroxidase as described below. Assays were normally performed in duplicate.

#### Eosinophil peroxidase assay.

Analysis of EPO concentrations were carried out following the protocol described in White, S.R., et al., J.  
20 *Immunol. Meth.*, 44:257-263 (1991) with some modifications. This assay is based on the oxidation of o-phenylenediamine by EPO in the presence of  $H_2O_2$ . Assay final concentrations of substrate and  $H_2O_2$  were 16 mM and 0.01%, respectively. The substrate stock solution (27 mM substrate, 0.016%  $H_2O_2$ )  
25 was prepared immediately prior to use in 0.1 M Tris pH 8.0, 0.1% Triton X-100. Briefly, 75  $\mu$ l of substrate solution were combined with 50  $\mu$ l of sample in a flat bottom 96 well plate immediately prior to obtaining readings at 492 nm every 15 sec for 5 min. Spectrophotometric readings were  
30 performed in a microplate absorbance spectrophotometer (Dynatech MR 4000, Dynatech Laboratories, INC., Chantilly, Virginia). Data was collected and analyzed using the assay management software Biolinx TM version 2.1. The velocity

of the reaction was calculated by interpolation between successive 3 or 4 points. Horseradish peroxidase (HRP) was used as standard. Kinetic data were extrapolated to a standard curve obtained with 2, 5, 10 and 20 ng of HRP and the activity expressed in units of EPO per million cells, with one unit corresponding to the activity that is equivalent to the activity of 1 ng of HRP. Thus, a unit of EPO is defined as the amount of protein that would give the same activity as 1 ng of HRP.

## 10 RESULTS

In two separate experiments, the mAb 7B11 blocked eotaxin-induced peroxidase release from eosinophils. Figure 23A shows that 7B11 at a concentration of 10 µg/ml significantly inhibited the degranulation induced by 10 or 100 nM eotaxin and by 100 nM RANTES or MCP-3. Degranulation induced by 100 nM eotaxin, RANTES or MCP-3 was inhibited by 99, 77 and 72%, respectively. Degranulation induced by 10 nM eotaxin was inhibited to 65% and 85% by 1 and 10 µg/ml of 7B11, respectively. Significantly, as shown in Figure 23B, the mAb 7B11 did not inhibit the degranulation induced by C5a.

Previous studies showed that eotaxin stimulated release of EPO parallels the release of other eosinophilic granule enzymes and proteins such as eosinophil cationic protein (ECP) (Figure 24A), glucuronidase and arylsulfatase B (Figures 25-27). EPO, ECP and glucuronidase are present in eosinophil specific granules and arylsulfatase B is present in small granules. Thus, eotaxin induces degranulation of both specific and small granules. Figures 25-27 and show that the eotaxin dose response curves for EPO release parallel the dose response curves for the release of other eosinophilic proteins. These assays were essentially performed as described in the materials and methods for the eosinophil degranulation assay. The

supernatants were then assayed for the presence of eosinophil granule proteins using established procedures. For ECP a commercially available radioimmunoassay kit was used (Pharmacia Diagnostics, Cat. No. 10-9165-01). Enzyme  
5 assays for glucuronidase and arylsulfatase B are described in Kroegel, C., et al., *J. of Immunol.*, 142:3518-3526 (1989).

EPO was the enzyme of choice in eosinophil degranulation studies because of convenience of assay and  
10 quantitation. EPO release by eotaxin is a reflection of eosinophil degranulation in general. Because EPO release is paralleled by the release of other eosinophil proteins and enzymes, similarly, 7B11 blockade of degranulation induced by eotaxin as measured by blockade of EPO release,  
15 should also be reflected in blockade of release of other eosinophil proteins and enzymes.

#### Example 12 Basophils express CCR3

##### **Materials and Methods**

**Flow Cytometry.** Cells expressing CCR3 in whole blood  
20 were identified by flow cytometry. 100 $\mu$ l of heparinized whole blood was stained with 400 ng of a 7B11 (anti-CCR3)-FITC preparation and 500ng of biotin coupled anti-human IgE (PharMingen, San Diego, CA) in the presence of 100 $\mu$ l of PBS with 0.1% azide at room temperature for 20-30 minutes.  
25 Cells were washed once in PBS with azide and stained with 5 $\mu$ l Streptavidin-Quantum Red (Sigma Immuno Chemicals, St. Louis, MO) for 15-30 minutes at room temperature. Red cells were lysed using 2ml of an ammonium chloride lysing buffer and leukocytes were pelleted and resuspended in PBS  
30 for analysis on a FACScan flow cytometer (Becton Dickinson, Mountainview, CA). Visual analysis of cells from the stained populations was performed after sorting cells, stained as above, using a FACSVantage flow cytometer (Becton Dickinson), and preparing Diff Quik (Baxter

Scientific Products, McGaw Park, II) stained slides of the collected cells.

Enumeration of number of sites/cell. Cells were stained as above for flow cytometry. After analysis of the sample, tubes containing Quantum 26 beads (Flow Cytometry Standards Corp., San Juan, PR) were used to calibrate fluorescence. The MFSF/protein ratio for the 7B11/FITC preparation was determined using Simply Cellular beads (Flow Cytometry Standards Corp.). Median channel fluorescence of the stained cells was then used to calculate the mean number of bound antibody molecules/cell.

### Results

The monoclonal antibody 7B11 previously shown to recognize CCR3, recognized only two populations of cells from whole blood preparations (Figure 28). One of these populations could be shown to have high levels of IgE on its surface, the other did not. Sorted cells lacking IgE, but stained with 7B11 were 97.3%  $\pm$  0.6 eosinophils as identified on slides prepared from sorted cells. Cells bearing high levels of IgE on their surfaces and also stained by 7B11 appeared on stained preparations to be basophils (92%  $\pm$  4.6), although the method of IgE staining, cell lysis and sorting of the samples led to degranulation of the majority of the cells. Eosinophil consistently expressed slightly higher numbers of receptors/cell than basophils from a given individual ( $p < 0.001$ , paired t-test). From analysis of 30 individuals, the average number of 7B11 binding sites/eosinophil was found to be 24,700  $\pm$  5700; the average number of sites/basophils was 19,000  $\pm$  4500.

Whole blood was stained with 7B11-FITC and anti-human IgE-biotin followed by streptavidin Quantum red and analyzed by flow cytometry. Analysis of the two color staining from whole blood indicated two populations bearing

CCR3 (Figure 28), one of these populations was double stained with anti-human IgE. Comparisons of the intensity of staining by anti-CCR3 antibody indicated that eosinophils consistently stained more intensely than  
5 basophils for expression of CCR3. Identity of cells in these two populations was confirmed by conventional histological staining and the IgE<sup>(+)</sup> CCR3(+) population was found to be basophils (degranulated), while the IgE(-) CCR3(+) population was eosinophils. Forward and side  
10 scatter using backgating of the two populations indicated that these cells light scatter properties consistent with other indications of their cell type.

Example 13 Basophil chemotaxis to eotaxin and MCP-4 is blocked by anti-CCR3 mAb

15 Leukocytes were obtained from unselected healthy volunteers after informed consent, and were isolated and fractionated by discontinuous density centrifugation as described (Kurimoto, Y., et al., *J. Exp. Med.*, 170:467 (1989); Bischoff, S.C., et al., *Blood*, 79:2662 (1990)).  
20 Briefly, venous blood was anticoagulated with 10 mM EDTA, mixed with 0.25 volume of dextran (6% in NaCl 0.9%), and erythrocytes were allowed to sediment at room temperature. After 90 min, the leukocytes were collected and washed  
3 times in HA buffer (20 mM Hepes, 125 mM NaCl, 5 mM KCl, 25 0.5 mM glucose, 0.025% bovine serum albumin). To enrich for basophil granulocytes, leukocytes were fractionated by Ficoll Hypaque density centrifugation exactly as described (Kurimoto, Y., et al., *J. Exp. Med.*, 170:467 (1989)).  
Purified basophils were obtained by leukocyte fractionation  
30 by discontinuous Percoll gradient centrifugation (Bischoff, S.C., et al., *Blood*, 79:2662 (1990)). The basophil-rich cell layer was collected, washed in HA buffer, resuspended in 150 ul HA buffer, and incubated for 40 min with

paramagnetic beads coated with mAb against CD3 (12 ul), CD4 (15 ul), CD8 (12 ul), CD14 (5 ul), CD16 (5 ul) and CD19 (5 ul). The magnetically stained cell suspension was passed over a separation column placed in a strong magnetic field to eliminate contaminating cells (MACS system, Miltenyi Biotec GmbH, Bergisch Gladbach, FRG). The combination of Percoll gradient centrifugation and negative selection with immunomagnetic beads yielded basophil preparations of 80-95% purity (contaminated exclusively by small lymphocytes) with a recovery of 30-60% (as determined by cytocentrifuge slides stained with May Gruenwald/Giemsa and measurements of total histamine contents). Cells were finally washed 3 times in HA buffer and resuspended in HACM buffer (HA buffer supplemented with 1 mM  $MgCl_2$  and 1 mM  $CaCl_2$ ).

#### Histamine and $LTC_4$ release.

Basophil ( $80-180 \times 10^3/ml$ ) in 20 mM Hepes, pH 7.4 containing 125 mM glucose and 0.025% BSA were warmed to 37°C, exposed to IL-3 (10 ng/ml) with or without anti-CCR3 (5 ug/ml) and then challenged. After 20 min the tubes were placed on ice and histamine and  $LTC_4$  were measured in the supernatant (Dahinden, C.A., et al., *J. Exp. Med.*, 179:751 (1994)). Histamine release was expressed as percent of the total content of the sample (determined after cell lysis).  $LTC_4$  generation was expressed as picograms  $LTC_4/D_4/E_4$  per nanogram total histamine (which corresponds to 1,000 basophils).

As shown in Figure 29, basophils release histamine in response to chemokines, an histamine release can be blocked by MAb 7B11.

### **Chemotaxis**

Chemokines were added to the lower wells of a 48 well chemotactic chamber (Neuro Probe, Cabin John, MD). Cells were suspended in RPMI 1640, 20 mM Hepes and 1% PPL, pH 7.4  
5 with or without anti-CCR3 (5 ug/ml) and placed into the top wells (50,000 cells per well). Migration across as polycarbonate filter (polyvinyl pyrrolidone free, 5 um pore size; Nucleopore Corp., Pleasanton, CA) was assessed after an incubation at 37°C in 5% CO<sub>2</sub> for 50 min. Migrated cells  
10 were counted microscopically on the lower surface of the filter after staining with May-Gruenwald/Giemsa.

As shown in Figures 30A and 30B, basophils chemotax to eotaxin and MCP-4 and the response is blocked with anti-CCR3 mAb 7B11.

### **Equivalents**

Those skilled in the art will be able to recognize, or be able to ascertain, using no more than routine experimentation, many equivalents to the specific  
5 embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Gerard, Craig  
Gerard, Norma P.  
Mackay, Charles  
Ponath, Paul D.  
Post, Theodore W.  
Qin, Shixin
- (ii) TITLE OF INVENTION: G PROTEIN-COUPLED RECEPTOR GENE CCR3 AND  
ANTAGONISTS THEREOF
- (iii) NUMBER OF SEQUENCES: 18
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
  - (B) STREET: Two Militia Drive
  - (C) CITY: Lexington
  - (D) STATE: MA
  - (E) COUNTRY: USA
  - (F) ZIP: 02173
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Floppy disk
  - (B) COMPUTER: IBM PC compatible
  - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
  - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER:
  - (B) FILING DATE:
  - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
  - (A) APPLICATION NUMBER: US 08/375,199
  - (B) FILING DATE: 19-JAN-1995
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: Brook, David E.
  - (B) REGISTRATION NUMBER: 22,592
  - (C) REFERENCE/DOCKET NUMBER: LKS94-05A PCT
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: 617-861-6240
  - (B) TELEFAX: 617-861-9540

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 1689 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)



(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

AATCCTTTTC CTGGCACCTC TGATATCCTT TTGAAATTCA TGTTAAAGAA TCCCTAGGCT	60
GCTATCACAT GTGGCATCTT TGTGAGTAC ATGAATAAAT CAACTGGTGT GTTTTACGAA	120
GGATGATTAT GCTTCATTGT GGGATTGTAT TTTTCTTCTT CTATCACAGG GAGAAGTGAA	180
ATGACAACCT CACTAGATAC AGTTGAGACC TTTGGTACCA CATCCTACTA TGATGACGTG	240
GGCCTGCTCT GTGAAAAAGC TGATACCAGA GCACTGATGG CCCAGTTTGT GCCCCCGCTG	300
TACTCCCTGG TGTTCACTGT GGGCCTCTTG GGCAATGTGG TGGTGGTGAT GATCCTCATA	360
AAATACAGGA GGCTCCGAAT TATGACCAAC ATCTACCTGC TCAACCTGGC CATTTCCGAC	420
CTGCTCTTCC TCGTCACCCT TCCATTCTGG ATCCACTATG TCAGGGGGCA TAACTGGGTT	480
TTTGGCCATG GCATGTGTAA GTCCTCTCA GGGTTTTATC ACACAGGCTT GTACAGCGAG	540
ATCTTTTTCA TAATCCTGCT GACAATCGAC AGGTACCTGG CCATTGTCCA TGCTGTGTTT	600
GCCCTTCGAG CCCGGACTGT CACTTTTGGT GTCATACCA GCATCGTCAC CTGGGGCCTG	660
GCAGTGCTAG CAGCTCTTCC TGAATTTATC TTCTATGAGA CTGAAGAGTT GTTTGAAGAG	720
ACTCTTTGCA GTGCTCTTTA CCCAGAGGAT ACAGTATATA GCTGGAGGCA TTTCCACACT	780
CTGAGAATGA CCATCTTCTG TCTCGTTCTC CCTCTGCTCG TTATGGCCAT CTGCTACACA	840
GGAATCATCA AAACGCTGCT GAGGTGCCCC AGTAAAAAAA AGTACAAGGC CATCCGGCTC	900
ATTTTTGTCA TCATGGCGGT GTTTTTCATT TTCTGGACAC CCTACAATGT GGCTATCCTT	960
CTCTCTTCTT ATCAATCCAT CTTATTTGGA AATGACTGTG AGCGGACGAA GCATCTGGAC	1020
CTGGTCATGC TGGTGACAGA GGTGATCGCC TACTCCCACT GCTGCATGAA CCCGGTGATC	1080
TACGCCTTTG TTGGAGAGAG GTTCCGGAAG TACCTGCGCC ACTTCTTCCA CAGGCACTTG	1140
CTCATGCACC TGGGCAGATA CATCCCATTC CTTCTAGTG AGAAGCTGGA AAGAACCAGC	1200
TCTGTCTCTC CATCCACAGC AGAGCCGGAA CTCTCTATTG TGTTTTAGGT AGATGCAGAA	1260
AATTGCCTAA AGAGGAAGGA CCAAGGAGAT NAAGCAAACA CATTAGCCT TCCACACTCA	1320
CCTCTAAAC AGTCCTTCAA ACCTTCCAGT GCAACACTGA AGCTCTTAAG ACACTGAAAT	1380
ATACACACAG CAGTAGCAGT AGATGCATGT ACCCTAAGGT CATTACCACA GGCCAGGGCT	1440
GGGCAGCGTA CTCATCATCA ACCTAAAAAG CAGAGCTTTG CTTCTCTCTC TAAAATGAGT	1500
TACCTATATT TTAATGCACC TGAATGTTAG ATAGTTACTA TATGCCGCTA CAAAAGGTA	1560
AAACTTTTTA TATTTTATAC ATTAACCTCA GCCAGCTATT ATATAAATAA AACATTTTCA	1620
CACAATACAA TAAGTAACT ATTTTATTTT CTAATGTGCC TAGTTCTTTC CCTGCTTAAT	1680
GAAAAGCTT	1689

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 355 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met	Thr	Thr	Ser	Leu	Asp	Thr	Val	Glu	Thr	Phe	Gly	Thr	Thr	Ser	Tyr	1	5	10	15
Tyr	Asp	Asp	Val	Gly	Leu	Leu	Cys	Glu	Lys	Ala	Asp	Thr	Arg	Ala	Leu	20	25	30	
Met	Ala	Gln	Phe	Val	Pro	Pro	Leu	Tyr	Ser	Leu	Val	Phe	Thr	Phe	Gly	35	40	45	
Leu	Leu	Gly	Asn	Val	Val	Val	Val	Met	Ile	Leu	Ile	Lys	Tyr	Arg	Arg	50	55	60	
Leu	Arg	Ile	Met	Thr	Asn	Ile	Tyr	Leu	Leu	Asn	Leu	Ala	Ile	Ser	Asp	65	70	75	80
Leu	Leu	Phe	Leu	Val	Thr	Leu	Pro	Phe	Trp	Ile	His	Tyr	Val	Arg	Gly	85	90	95	
His	Asn	Trp	Val	Phe	Gly	His	Gly	Met	Cys	Lys	Leu	Leu	Ser	Gly	Phe	100	105	110	
Tyr	His	Thr	Gly	Leu	Tyr	Ser	Glu	Ile	Phe	Phe	Ile	Ile	Leu	Leu	Thr	115	120	125	
Ile	Asp	Arg	Tyr	Leu	Ala	Ile	Val	His	Ala	Val	Phe	Ala	Leu	Arg	Ala	130	135	140	
Arg	Thr	Val	Thr	Phe	Gly	Val	Ile	Thr	Ser	Ile	Val	Thr	Trp	Gly	Leu	145	150	155	160
Ala	Val	Leu	Ala	Ala	Leu	Pro	Glu	Phe	Ile	Phe	Tyr	Glu	Thr	Glu	Glu	165	170	175	
Leu	Phe	Glu	Glu	Thr	Leu	Cys	Ser	Ala	Leu	Tyr	Pro	Glu	Asp	Thr	Val	180	185	190	
Tyr	Ser	Trp	Arg	His	Phe	His	Thr	Leu	Arg	Met	Thr	Ile	Phe	Cys	Leu	195	200	205	
Val	Leu	Pro	Leu	Leu	Val	Met	Ala	Ile	Cys	Tyr	Thr	Gly	Ile	Ile	Lys	210	215	220	
Thr	Leu	Leu	Arg	Cys	Pro	Ser	Lys	Lys	Lys	Tyr	Lys	Ala	Ile	Arg	Leu	225	230	235	240
Ile	Phe	Val	Ile	Met	Ala	Val	Phe	Phe	Ile	Phe	Trp	Thr	Pro	Tyr	Asn	245	250	255	

CCDS10000.1

Val Ala Ile Leu Leu Ser Ser Tyr Gln Ser Ile Leu Phe Gly Asn Asp  
260 265 270  
Cys Glu Arg Thr Lys His Leu Asp Leu Val Met Leu Val Thr Glu Val  
275 280 285  
Ile Ala Tyr Ser His Cys Cys Met Asn Pro Val Ile Tyr Ala Phe Val  
290 295 300  
Gly Glu Arg Phe Arg Lys Tyr Leu Arg His Phe Phe His Arg His Leu  
305 310 315 320  
Leu Met His Leu Gly Arg Tyr Ile Pro Phe Leu Pro Ser Glu Lys Leu  
325 330 335  
Glu Arg Thr Ser Ser Val Ser Pro Ser Thr Ala Glu Pro Glu Leu Ser  
340 345 350  
Ile Val Phe  
355

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 1193 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:  
(A) NAME/KEY: CDS  
(B) LOCATION: 92..1156

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

TTGTGCTTAT CCGGGCAAGA ACTTATCGAA ATACAATAGA AGACCCACGC GTCCGGTTTT	60
TACTTAGAAG AGATTTTCAG GGAGAAGTGA A ATG ACA ACC TCA CTA GAT ACA	112
Met Thr Thr Ser Leu Asp Thr	
1 5	
GTT GAG ACC TTT GGT ACC ACA TCC TAC TAT GAT GAC GTG GGC CTG CTC	160
Val Glu Thr Phe Gly Thr Thr Ser Tyr Tyr Asp Asp Val Gly Leu Leu	
10 15 20	
TGT GAA AAA GCT GAT ACC AGA GCA CTG ATG GCC CAG TTT GTG CCC CCG	208
Cys Glu Lys Ala Asp Thr Arg Ala Leu Met Ala Gln Phe Val Pro Pro	
25 30 35	
CTG TAC TCC CTG GTG TTC ACT GTG GGC CTC TTG GGC AAT GTG GTG GTG	256
Leu Tyr Ser Leu Val Phe Thr Val Gly Leu Leu Gly Asn Val Val Val	
40 45 50 55	
GTG ATG ATC CTC ATA AAA TAC AGG AGG CTC CGA ATT ATG ACC AAC ATC	304
Val Met Ile Leu Ile Lys Tyr Arg Arg Leu Arg Ile Met Thr Asn Ile	
60 65 70	

TAC	CTG	CTC	AAC	CTG	GCC	ATT	TCG	GAC	CTG	CTC	TTC	CTC	GTC	ACC	CTT	352
Tyr	Leu	Leu	Asn	Leu	Ala	Ile	Ser	Asp	Leu	Leu	Phe	Leu	Val	Thr	Leu	
			75					80					85			
CCA	TTC	TGG	ATC	CAC	TAT	GTC	AGG	GGG	CAT	AAC	TGG	GTT	TTT	GGC	CAT	400
Pro	Phe	Trp	Ile	His	Tyr	Val	Arg	Gly	His	Asn	Trp	Val	Phe	Gly	His	
		90					95					100				
GGC	ATG	TGT	AAG	CTC	CTC	TCA	GGG	TTT	TAT	CAC	ACA	GGC	TTG	TAC	AGC	448
Gly	Met	Cys	Lys	Leu	Leu	Ser	Gly	Phe	Tyr	His	Thr	Gly	Leu	Tyr	Ser	
	105					110					115					
GAG	ATC	TTT	TTC	ATA	ATC	CTG	CTG	ACA	ATC	GAC	AGG	TAC	CTG	GCC	ATT	496
Glu	Ile	Phe	Phe	Ile	Ile	Leu	Leu	Thr	Ile	Asp	Arg	Tyr	Leu	Ala	Ile	
120					125					130					135	
GTC	CAT	GCT	GTG	TTT	GCC	CTT	CGA	GCC	CGG	ACT	GTC	ACT	TTT	GGT	GTC	544
Val	His	Ala	Val	Phe	Ala	Leu	Arg	Ala	Arg	Thr	Val	Thr	Phe	Gly	Val	
				140					145					150		
ATC	ACC	AGC	ATC	GTC	ACC	TGG	GGC	CTG	GCA	GTG	CTA	GCA	GCT	CTT	CCT	592
Ile	Thr	Ser	Ile	Val	Thr	Trp	Gly	Leu	Ala	Val	Leu	Ala	Ala	Leu	Pro	
			155					160					165			
GAA	TTT	ATC	TTC	TAT	GAG	ACT	GAA	GAG	TTG	TTT	GAA	GAG	ACT	CTT	TGC	640
Glu	Phe	Ile	Phe	Tyr	Glu	Thr	Glu	Glu	Leu	Phe	Glu	Glu	Thr	Leu	Cys	
		170					175					180				
AGT	GCT	CTT	TAC	CCA	GAG	GAT	ACA	GTA	TAT	AGC	TGG	AGG	CAT	TTC	CAC	688
Ser	Ala	Leu	Tyr	Pro	Glu	Asp	Thr	Val	Tyr	Ser	Trp	Arg	His	Phe	His	
	185					190					195					
ACT	CTG	AGA	ATG	ACC	ATC	TTC	TGT	CTC	GTT	CTC	CCT	CTG	CTC	GTT	ATG	736
Thr	Leu	Arg	Met	Thr	Ile	Phe	Cys	Leu	Val	Leu	Pro	Leu	Leu	Val	Met	
200					205					210					215	
GCC	ATC	TGC	TAC	ACA	GGA	ATC	ATC	AAA	ACG	CTG	CTG	AGG	TGC	CCC	AGT	784
Ala	Ile	Cys	Tyr	Thr	Gly	Ile	Ile	Lys	Thr	Leu	Leu	Arg	Cys	Pro	Ser	
				220					225					230		
AAA	AAA	AAG	TAC	AAG	GCC	ATC	CGG	CTC	ATT	TTT	GTC	ATC	ATG	GCG	GTG	832
Lys	Lys	Lys	Tyr	Lys	Ala	Ile	Arg	Leu	Ile	Phe	Val	Ile	Met	Ala	Val	
			235					240					245			
TTT	TTC	ATT	TTC	TGG	ACA	CCC	TAC	AAT	GTG	GCT	ATC	CTT	CTC	TCT	TCC	880
Phe	Phe	Ile	Phe	Trp	Thr	Pro	Tyr	Asn	Val	Ala	Ile	Leu	Leu	Ser	Ser	
		250					255					260				
TAT	CAA	TCC	ATC	TTA	TTT	GGA	AAT	GAC	TGT	GAG	CGG	AGC	AAG	CAT	CTG	928
Tyr	Gln	Ser	Ile	Leu	Phe	Gly	Asn	Asp	Cys	Glu	Arg	Ser	Lys	His	Leu	
	265					270					275					
GAC	CTG	GTC	ATG	CTG	GTG	ACA	GAG	GTG	ATC	GCC	TAC	TCC	CAC	TGC	TGC	976
Asp	Leu	Val	Met	Leu	Val	Thr	Glu	Val	Ile	Ala	Tyr	Ser	His	Cys	Cys	
280					285					290					295	
ATG	AAC	CCG	GTG	ATC	TAC	GCC	TTT	GTT	GGA	GAG	AGG	TTC	CGG	AAG	TAC	1024
Met	Asn	Pro	Val	Ile	Tyr	Ala	Phe	Val	Gly	Glu	Arg	Phe	Arg	Lys	Tyr	
				300					305					310		

CTG CGC CAC TTC TTC CAC AGG CAC TTG CTC ATG CAC CTG GGC AGA TAC	1072
Leu Arg His Phe Phe His Arg His Leu Leu Met His Leu Gly Arg Tyr	
315 320 325	
ATC CCA TTC CTT CCT AGT GAG AAG CTG GAA AGA ACC AGC TCT GTC TCT	1120
Ile Pro Phe Leu Pro Ser Glu Lys Leu Glu Arg Thr Ser Ser Val Ser	
330 335 340	
CCA TCC ACA GCA GAG CCG GAA CTC TCT ATT GTG TTT TAGGTAGATG	1166
Pro Ser Thr Ala Glu Pro Glu Leu Ser Ile Val Phe	
345 350 355	
CAGAAAATTG CCTAAAGAGG AAGGACC	1193

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 355 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Thr Thr Ser Leu Asp Thr Val Glu Thr Phe Gly Thr Thr Ser Tyr	
1 5 10 15	
Tyr Asp Asp Val Gly Leu Leu Cys Glu Lys Ala Asp Thr Arg Ala Leu	
20 25 30	
Met Ala Gln Phe Val Pro Pro Leu Tyr Ser Leu Val Phe Thr Val Gly	
35 40 45	
Leu Leu Gly Asn Val Val Val Val Met Ile Leu Ile Lys Tyr Arg Arg	
50 55 60	
Leu Arg Ile Met Thr Asn Ile Tyr Leu Leu Asn Leu Ala Ile Ser Asp	
65 70 75 80	
Leu Leu Phe Leu Val Thr Leu Pro Phe Trp Ile His Tyr Val Arg Gly	
85 90 95	
His Asn Trp Val Phe Gly His Gly Met Cys Lys Leu Leu Ser Gly Phe	
100 105 110	
Tyr His Thr Gly Leu Tyr Ser Glu Ile Phe Phe Ile Ile Leu Leu Thr	
115 120 125	
Ile Asp Arg Tyr Leu Ala Ile Val His Ala Val Phe Ala Leu Arg Ala	
130 135 140	
Arg Thr Val Thr Phe Gly Val Ile Thr Ser Ile Val Thr Trp Gly Leu	
145 150 155 160	
Ala Val Leu Ala Ala Leu Pro Glu Phe Ile Phe Tyr Glu Thr Glu Glu	
165 170 175	
Leu Phe Glu Glu Thr Leu Cys Ser Ala Leu Tyr Pro Glu Asp Thr Val	
180 185 190	

Tyr Ser Trp Arg His Phe His Thr Leu Arg Met Thr Ile Phe Cys Leu  
195 200 205

Val Leu Pro Leu Leu Val Met Ala Ile Cys Tyr Thr Gly Ile Ile Lys  
210 215 220

Thr Leu Leu Arg Cys Pro Ser Lys Lys Lys Tyr Lys Ala Ile Arg Leu  
225 230 235 240

Ile Phe Val Ile Met Ala Val Phe Phe Ile Phe Trp Thr Pro Tyr Asn  
245 250 255

Val Ala Ile Leu Leu Ser Ser Tyr Gln Ser Ile Leu Phe Gly Asn Asp  
260 265 270

Cys Glu Arg Ser Lys His Leu Asp Leu Val Met Leu Val Thr Glu Val  
275 280 285

Ile Ala Tyr Ser His Cys Cys Met Asn Pro Val Ile Tyr Ala Phe Val  
290 295 300

Gly Glu Arg Phe Arg Lys Tyr Leu Arg His Phe Phe His Arg His Leu  
305 310 315 320

Leu Met His Leu Gly Arg Tyr Ile Pro Phe Leu Pro Ser Glu Lys Leu  
325 330 335

Glu Arg Thr Ser Ser Val Ser Pro Ser Thr Ala Glu Pro Glu Leu Ser  
340 345 350

Ile Val Phe  
355

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1116 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CAGGGAGAAG TGAAATGACA ACCTCACTAG ATACAGTTGA GACCTTTGGT ACCACATCCT	60
ACTATGATGA CGTGGGCCTG CTCTGTGAAA AAGCTGATAC CAGAGCACTG ATGGCCCAGT	120
TTGTGCCCCC GCTGTACTCC CTGGTGTTC A CTGTGGGCCT CTTGGGCAAT GTGGTGGTGG	180
TGATGATCCT CATAAAATAC AGGAGGCTCC GAATTATGAC CAACATCTAC CTGCTCAACC	240
TGGCCATTTT GGACCTGCTC TTCCTCGTCA CCCTTCCATT CTGGATCCAC TATGTCAGGG	300
GGCATAACTG GGTTTTTGGC CATGGCATGT GTAAGCTCCT CTCAGGGTTT TATCACACAG	360
GCTTGTACAG CGAGATCTTT TTCATAATCC TGCTGACAAT CGACAGGTAC CTGGCCATTG	420
TCCATGCTGT GTTTGCCCTT CGAGCCCGGA CTGTCACTTT TGGTGTCTATC ACCAGCATCG	480
TCACCTGGGG CCTGGCAGTG CTAGCAGCTC TTCCTGAATT TATCTTCTAT GAGACTGAAG	540

AGTTGTTTGA AGAGACTMTT TGCAGTGCTC TTTACCCAGA GGATACAGTA TATAGCTGGA 600  
 GSSATTTCCTA CACTCTGAGA ATGACCATCT TCTGTCTCGT TCTCCCTCTG CTCGTTATGG 660  
 CCATCTGCTA CACAGGAATC ATCAAAACGC TGCTGAGGTG CCCCAGTAAA AAAAAGTACA 720  
 AGGCCATCCG GCTCATTTTT GTCATCATGG CGGTGTTTTT CATTTTCTGG ACACCCTACA 780  
 ATGTGGCTAT CCTTCTCTCT TSCYWYMAW YCATCTTATT TGGAAATGAC TGTGAGCGGM 840  
 MGARSMWYYK GGACCTGGTC ATGCTGGTGA CAGAGGTGAT CGCCTACTCC CACTGCTGCA 900  
 TGAACCCGGT GATCTACGCC TTTGTTGGAG AGAGGTTCCG GAAGTACCTG CGCCACTTST 960  
 TCCACAGGCA CTTGCTCATG CACCTGGGCA GATACATCCC ATTCCTTCCT AGTGAGAAGC 1020  
 TGGAAAGAAC CAGCTCTGTC TCTCCATCCA CAGCAGAGCC GGAAGTCTCT ATTGTGTTTT 1080  
 AGGTAGATGC AGAAAATTGC CTAAAGAGGA AGGACC 1116

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 355 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Met	Thr	Thr	Ser	Leu	Asp	Thr	Val	Glu	Thr	Phe	Gly	Thr	Thr	Ser	Tyr	1	5	10	15
Tyr	Asp	Asp	Val	Gly	Leu	Leu	Cys	Glu	Lys	Ala	Asp	Thr	Arg	Ala	Leu	20	25	30	
Met	Ala	Gln	Phe	Val	Pro	Pro	Leu	Tyr	Ser	Leu	Val	Phe	Thr	Val	Gly	35	40	45	
Leu	Leu	Gly	Asn	Val	Val	Val	Val	Met	Ile	Leu	Ile	Lys	Tyr	Arg	Arg	50	55	60	
Leu	Arg	Ile	Met	Thr	Asn	Ile	Tyr	Leu	Leu	Asn	Leu	Ala	Ile	Ser	Asp	65	70	75	80
Leu	Leu	Phe	Leu	Val	Thr	Leu	Pro	Phe	Trp	Ile	His	Tyr	Val	Arg	Gly	85	90	95	
His	Asn	Trp	Val	Phe	Gly	His	Gly	Met	Cys	Lys	Leu	Leu	Ser	Gly	Phe	100	105	110	
Tyr	His	Thr	Gly	Leu	Tyr	Ser	Glu	Ile	Phe	Phe	Ile	Ile	Leu	Leu	Thr	115	120	125	
Ile	Asp	Arg	Tyr	Leu	Ala	Ile	Val	His	Ala	Val	Phe	Ala	Leu	Arg	Ala	130	135	140	
Arg	Thr	Val	Thr	Phe	Gly	Val	Ile	Thr	Ser	Ile	Val	Thr	Trp	Gly	Leu	145	150	155	160

-139-

Ala Val Leu Ala Ala Leu Pro Glu Phe Ile Phe Tyr Glu Thr Glu Glu  
165 170 175  
Leu Phe Glu Glu Thr Xaa Cys Ser Ala Leu Tyr Pro Glu Asp Thr Val  
180 185 190  
Tyr Ser Trp Xaa Xaa Phe His Thr Leu Arg Met Thr Ile Phe Cys Leu  
195 200 205  
Val Leu Pro Leu Leu Val Met Ala Ile Cys Tyr Thr Gly Ile Ile Lys  
210 215 220  
Thr Leu Leu Arg Cys Pro Ser Lys Lys Lys Tyr Lys Ala Ile Arg Leu  
225 230 235 240  
Ile Phe Val Ile Met Ala Val Phe Phe Ile Phe Trp Thr Pro Tyr Asn  
245 250 255  
Val Ala Ile Leu Leu Ser Xaa Xaa Xaa Xaa Ile Leu Phe Gly Asn Asp  
260 265 270  
Cys Glu Arg Xaa Xaa Xaa Xaa Asp Leu Val Met Leu Val Thr Glu Val  
275 280 285  
Ile Ala Tyr Ser His Cys Cys Met Asn Pro Val Ile Tyr Ala Phe Val  
290 295 300  
Gly Glu Arg Phe Arg Lys Tyr Leu Arg His Xaa Phe His Arg His Leu  
305 310 315 320  
Leu Met His Leu Gly Arg Tyr Ile Pro Phe Leu Pro Ser Glu Lys Leu  
325 330 335  
Glu Arg Thr Ser Ser Val Ser Pro Ser Thr Ala Glu Pro Glu Leu Ser  
340 345 350  
Ile Val Phe  
355

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: modified\_base
- (B) LOCATION: 19
- (D) OTHER INFORMATION: /mod\_base= i

(ix) FEATURE:

- (A) NAME/KEY: modified\_base
- (B) LOCATION: 24
- (D) OTHER INFORMATION: /mod\_base= i

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

TACCTGCTSA ACCTGGCCNT GGCNG



(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 25 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

- (ix) FEATURE:  
 (A) NAME/KEY: modified\_base  
 (B) LOCATION: 9  
 (D) OTHER INFORMATION: /mod\_base= i

- (ix) FEATURE:  
 (A) NAME/KEY: modified\_base  
 (B) LOCATION: 14  
 (D) OTHER INFORMATION: /mod\_base= i

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

ACCTGGCCNT GGCNGACCTM CTCTT

25

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 27 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

- (ix) FEATURE:  
 (A) NAME/KEY: modified\_base  
 (B) LOCATION: 18  
 (D) OTHER INFORMATION: /mod\_base= i

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

GACCGYTACC TGGCCATNGT CCAYGCC

27

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 27 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

- (ix) FEATURE:  
 (A) NAME/KEY: modified\_base  
 (B) LOCATION: 10  
 (D) OTHER INFORMATION: /mod\_base= i

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

GGCRTGGACN ATGGCCAGGT ARCGGTC

27

CCCTGGCCNT GGCNGACCTM CTCTT

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 27 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

- (ix) FEATURE:  
 (A) NAME/KEY: modified\_base  
 (B) LOCATION: 1  
 (D) OTHER INFORMATION: /mod\_base= i

- (ix) FEATURE:  
 (A) NAME/KEY: modified\_base  
 (B) LOCATION: 6  
 (D) OTHER INFORMATION: /mod\_base= i

- (ix) FEATURE:  
 (A) NAME/KEY: modified\_base  
 (B) LOCATION: 16  
 (D) OTHER INFORMATION: /mod\_base= i

- (ix) FEATURE:  
 (A) NAME/KEY: modified\_base  
 (B) LOCATION: 18  
 (D) OTHER INFORMATION: /mod\_base= i

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

NACCANRTTG TAGGGNRNCC ARMARAG

27

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 28 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

- (ix) FEATURE:  
 (A) NAME/KEY: modified\_base  
 (B) LOCATION: 8  
 (D) OTHER INFORMATION: /mod\_base= i

- (ix) FEATURE:  
 (A) NAME/KEY: modified\_base  
 (B) LOCATION: 10  
 (D) OTHER INFORMATION: /mod\_base= i

- (ix) FEATURE:  
 (A) NAME/KEY: modified\_base  
 (B) LOCATION: 23  
 (D) OTHER INFORMATION: /mod\_base= i

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

TGTAGGGNRN CCARMARAGR AGNARGAA

28

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 27 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

- (ix) FEATURE:  
 (A) NAME/KEY: modified\_base  
 (B) LOCATION: 12  
 (D) OTHER INFORMATION: /mod\_base= i

- (ix) FEATURE:  
 (A) NAME/KEY: modified\_base  
 (B) LOCATION: 15  
 (D) OTHER INFORMATION: /mod\_base= i

- (ix) FEATURE:  
 (A) NAME/KEY: modified\_base  
 (B) LOCATION: 16  
 (D) OTHER INFORMATION: /mod\_base= i

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

GAAGGCGTAG ANSANNGGGT TGASGCA

27

(2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 25 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

- (ix) FEATURE:  
 (A) NAME/KEY: modified\_base  
 (B) LOCATION: 4  
 (D) OTHER INFORMATION: /mod\_base= i

- (ix) FEATURE:  
 (A) NAME/KEY: modified\_base  
 (B) LOCATION: 7  
 (D) OTHER INFORMATION: /mod\_base= i

- (ix) FEATURE:  
 (A) NAME/KEY: modified\_base  
 (B) LOCATION: 8  
 (D) OTHER INFORMATION: /mod\_base= i

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

AGANSANNGG GTTGASGCAG CWGTG

25

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 48 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear

- (ix) FEATURE:  
 (A) NAME/KEY: CDS  
 (B) LOCATION: 16..48

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

AAGCTTCCAG CAGCC ATG GAC TAC AAG GAC GAC GAT GAC AAA GAA TTC  
Met Asp Tyr Lys Asp Asp Asp Asp Lys Glu Phe  
1 5 10

48

(2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 11 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

Met Asp Tyr Lys Asp Asp Asp Asp Lys Glu Phe  
1 5 10

(2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 27 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

TTAAGAATTG ACAACCTCAC TAGATAC

27

(2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 18 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

CATAGTGGAT CCAGAATG

18

CLAIMS

What is claimed is:

1. An isolated nucleic acid, wherein said isolated nucleic acid hybridizes to a nucleic acid selected from the group consisting of:
  - a) a nucleic acid having the sequence set forth in SEQ ID NO: 1 or a portion thereof comprising the coding sequence;
  - b) a nucleic acid having the sequence set forth in SEQ ID NO: 3 or a portion thereof comprising the coding sequence ;
  - c) a nucleic acid having the sequence set forth in SEQ ID NO: 5 or a portion thereof comprising the coding sequence;
  - d) the complement of any one of (a) through (c); and
  - e) the RNA counterpart of any one of (a) through (d), wherein U is substituted for T.
2. The isolated nucleic acid of Claim 1, wherein the isolated nucleic acid is essentially pure.
3. The isolated nucleic acid of Claim 1, wherein the isolated nucleic acid hybridizes to any one of the nucleic acids set forth in a) through e) under stringent conditions.
4. The isolated nucleic acid of Claim 1, wherein the isolated nucleic acid encodes at least a functional portion of a mammalian chemokine receptor 3.
5. The isolated nucleic acid of Claim 4, wherein the mammal is a human.

6. The isolated nucleic acid of Claim 4, wherein the isolated nucleic acid is recombinant.
7. An isolated, recombinant nucleic acid which encodes a mammalian chemokine receptor-3.
- 5 8. An isolated, recombinant nucleic acid of Claim 7, wherein the mammal is a primate.
9. An isolated, recombinant nucleic acid of Claim 8, wherein the primate is a human.
- 10 10. An isolated nucleic acid, wherein said nucleic acid encodes a polypeptide selected from the group consisting of:
  - a) a polypeptide having the amino acid sequence set forth in SEQ ID NO:2;
  - 15 b) a polypeptide having the amino acid sequence set forth in SEQ ID NO:4;
  - c) a polypeptide having the amino acid sequence set forth in SEQ ID NO:6; and
  - 20 d) a functional portion of any one of (a) through (c), said portion having at least one function characteristic of a mammalian C-C chemokine receptor.
11. The isolated nucleic acid of Claim 10, wherein said nucleic acid is essentially pure.
12. The isolated nucleic acid of Claim 10, which is a recombinant nucleic acid.
- 25 13. The nucleic acid of Claim 10, wherein the polypeptide binds one or more of RANTES, MCP-3, and eotaxin.

14. The nucleic acid of Claim 10, wherein the polypeptide binds RANTES.
15. A recombinant construct comprising a recombinant nucleic acid which hybridizes to a nucleic acid selected from the group consisting of:
- a) a nucleic acid having the sequence set forth in SEQ ID NO: 1 or a portion thereof comprising the coding sequence;
  - b) a nucleic acid having the sequence set forth in SEQ ID NO: 3 or a portion thereof comprising the coding sequence ;
  - c) a nucleic acid having the sequence set forth in SEQ ID NO: 5 or a portion thereof comprising the coding sequence;
  - d) the complement of any one of (a) through (c); and
  - e) the RNA counterpart of any one of (a) through (d), wherein U is substituted for T.
16. The recombinant construct of Claim 15, wherein the recombinant nucleic acid is operably linked to an expression control sequence.
17. The recombinant construct of Claim 15, wherein the recombinant nucleic acid encodes at least a functional portion of a mammalian chemokine receptor-3.
18. The recombinant construct of Claim 17, wherein the mammal is a human.
19. A recombinant construct comprising a nucleic acid which encodes a mammalian chemokine receptor 3.
20. The recombinant construct of Claim 19, wherein the mammal is a primate.

21. The recombinant construct of Claim 20, wherein the primate is a human.

22. A recombinant construct comprising a nucleic acid, wherein said nucleic acid encodes a polypeptide selected from the group consisting of:

- a) a polypeptide having the amino acid sequence set forth in SEQ ID NO:2;
- b) a polypeptide having the amino acid sequence set forth in SEQ ID NO:4;
- c) a polypeptide having the amino acid sequence set forth in SEQ ID NO:6;
- d) a functional portion of any one of (a) through (c), said portion having at least one function characteristic of a mammalian C-C chemokine receptor; and
- e) a functional equivalent of any one of (a) through (c).

23. The recombinant construct of Claim 22, wherein the nucleic acid is operably linked to an expression control sequence.

24. An isolated, recombinant mammalian chemokine receptor 3 or portion thereof, said portion having at least one function characteristic of a mammalian chemokine receptor or an immunological property.

25. An isolated, recombinant receptor of Claim 24, wherein the mammal is a human.

26. An essentially pure mammalian chemokine receptor 3 or portion thereof, having at least one function characteristic of a mammalian chemokine receptor, for example, exotaxin binding.



27. A host cell containing an isolated, recombinant nucleic acid encoding a mammalian CKR-3 receptor protein or functional portion thereof.
- 5 28. A host cell of Claim 27, wherein the nucleic acid is operably linked to an expression control sequence, whereby the encoded receptor protein or functional portion thereof is expressed when the host cell is maintained under conditions suitable for expression.
- 10 29. A host cell of Claim 28, wherein the expressed protein binds one or more of RANTES, MCP-3, and eotaxin.
- 15 30. A fusion protein containing a mammalian chemokine receptor 3 protein or portion thereof, said portion having at least one functional characteristic of a mammalian chemokine receptor or an immunological property.
31. The fusion protein of Claim 30 wherein the mammalian chemokine receptor protein or portion thereof binds one or more of RANTES, MCP-3, and eotaxin.
- 20 32. The fusion protein of Claim 30, wherein the polypeptide binds RANTES.
33. The fusion protein of Claim 30, wherein the mammal is a human.
- 25 34. A nucleic acid construct, wherein said construct is an expression vector comprising a nucleic acid encoding a fusion protein of Claim 30, said nucleic acid comprising all or part of the coding sequence for a mammalian chemokine receptor 3 protein, wherein the

coding sequence is under the control of an expression control sequence.

- 5 35. A method for producing a mammalian chemokine receptor 3 protein or functional portion thereof comprising maintaining a host cell containing a recombinant nucleic acid encoding said receptor or functional portion thereof under conditions suitable for expression of the nucleic acid, whereby the encoded protein is expressed and said receptor or portion thereof is produced.
- 10 36. A method for producing a mammalian chemokine receptor 3 protein or functional portion thereof comprising the following steps:
- 15 a) providing a recombinant nucleic acid construct comprising a nucleic acid which encodes all or part of a coding sequence for a mammalian chemokine receptor 3 protein wherein the coding sequence is operably linked to at least one expression control sequence;
- 20 b) introducing the construct into a suitable host cells; and
- c) maintaining the host cells in suitable medium under conditions whereby the nucleic acid is expressed.
- 25 37. The method of Claim 36, further comprising the step of isolating a mammalian chemokine receptor 3 protein or functional portion thereof from said cell or the medium of its growth.
- 30 38. An antibody or functional portion thereof which binds to a mammalian chemokine receptor 3 protein or portion of said receptor protein.

39. An antibody of Claim 38, wherein the mammalian chemokine receptor 3 protein is a human mammalian chemokine receptor 3 protein.
- 5 40. A method of detecting a ligand of a mammalian chemokine receptor 3 protein or portion thereof comprising the steps of combining a compound to be tested with an active, isolated mammalian chemokine receptor 3 protein under conditions suitable for binding of ligand thereto, and detecting or measuring the formation of a complex between said compound and the active, isolated protein.
- 10 41. A method of identifying a ligand of a mammalian chemokine receptor 3 protein or portion thereof comprising the steps of:
- 15 a) combining a compound to be tested with a host cell expressing an active, recombinant mammalian chemokine receptor 3 protein under conditions suitable for binding of ligand thereto; and
- 20 b) detecting or measuring the formation of a complex between said compound and the active, isolated protein.
- 25 42. The method of Claim 41, wherein the formation of a complex is monitored by detecting or measuring a signalling activity or cellular response by said active receptor in response to binding of a ligand thereto.
- 30 43. A method of identifying an inhibitor of a mammalian chemokine receptor 3 protein or portion thereof comprising the steps of:
- a) combining a compound to be tested with a host cell expressing an active, recombinant mammalian

chemokine receptor 3 protein under conditions suitable for binding of ligand thereto in the presence of a ligand; and

- b) detecting or measuring the formation of a complex between said ligand and the active, isolated protein.

44. An inhibitor of at least one function characteristic of a mammalian chemokine receptor 3 protein.

45. An inhibitor of Claim 44, which is an antibody or portion thereof.

46. Antisense nucleic acid comprising a nucleic acid having a sequence that hybridizes to a nucleic acid having a sequence selected from the group consisting of:

- a) SEQ ID NO: 1;  
b) SEQ ID NO: 3;  
c) SEQ ID NO: 5;  
b) an RNA counterpart of any one of a) through c).

47. A method of modulating at least one function of a mammalian chemokine receptor 3 protein, comprising the step of contacting said protein with an inhibitor or promoter of at least one function of said protein.

48. A method for treating an inflammatory disease or condition, comprising administering to a mammal a therapeutically effective amount of an inhibitor of a mammalian chemokine receptor 3 protein, whereby inflammation is reduced.

49. An antibody having binding specificity for a mammalian chemokine receptor 3 protein or portion thereof,

wherein the antibody blocks binding of a ligand to the receptor and inhibits function associated with binding of the ligand to the receptor.

- 5      50.    The antibody of Claim 49 wherein the antibody can compete with monoclonal antibody 7B11 for binding to a human chemokine receptor 3 protein or portion thereof.
51.    The antibody of Claim 49 wherein the antibody is 7B11.
52.    An antigen binding fragment of the antibody of Claim 49.

G PROTEIN-COUPLED RECEPTOR GENE CCR3 AND  
ANTAGONISTS THEREOF

Abstract of the Disclosure

5 The present invention relates to isolated and/or  
recombinant nucleic acids which encode a mammalian (e.g.,  
human) receptor protein designated C-C Chemokine Receptor 3  
(CKR-3) or Eos L2, and to proteins or polypeptides,  
referred to herein as isolated, recombinant mammalian CKR-3  
10 receptors. The invention further relates to recombinant  
nucleic acid constructs, comprising a nucleic acid which  
encodes a receptor protein of the present invention or a  
portion thereof; to host cells comprising such constructs,  
useful for the production of recombinant CKR-3 receptors or  
polypeptides; and to antibodies reactive with the  
15 receptors, which are useful in research and diagnostic  
applications.

Also provided are methods of use of the nucleic acids,  
proteins, and host cells to identify ligands, inhibitors  
(e.g., antagonists) or promoters (agonists) of receptor  
20 function. Administration of a compound which inhibits or  
promotes receptor function to an individual in need of  
therapy provides a new approach to selective modulation of  
leukocyte function, which is useful in a variety of  
inflammatory and autoimmune diseases, or in the treatment  
25 of infections. As a major leukocyte chemokine receptor  
present in leukocytes such as eosinophils and lymphocytes,  
the receptor provides a key target for drug screening and  
design.

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Declaration for Patent Application

As a named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated next to my name;

I believe I am the original, first and sole inventor (if only one name is listed) or an original, first and joint inventor (if plural names are listed in the signatory page(s) commencing at page 3 hereof) of the subject matter which is claimed and for which a patent is sought on the invention entitled

G PROTEIN-COUPLED RECEPTOR GENE CCR3 AND ANTAGONISTS THEREOF

the specification of which (check one)

☐ is attached hereto.

☒ was filed on September 30, 1996 as  
Application Serial No. 08/720,565  
and was amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is known by me to be material to patentability as defined in 37 C.F.R. §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

Priority  
Not  
Claimed

_____ (Number)	_____ (Country)	_____ (Day/Month/Year filed)	[ <input type="checkbox"/> ]
_____ (Number)	_____ (Country)	_____ (Day/Month/Year filed)	[ <input type="checkbox"/> ]
_____ (Number)	_____ (Country)	_____ (Day/Month/Year filed)	[ <input type="checkbox"/> ]

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

_____ (Application Number)	_____ (Filing Date)
-------------------------------	------------------------

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information known by me to be material to patentability as defined in 37 C.F.R. §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

<u>PCT/US96/00608</u>	<u>01-19-96</u>	<u>Pending</u>
(Application Serial No.)	(Filing date)	(Status, patented, pending, abandoned)
<u>08/375,199</u>	<u>01-19-95</u>	<u>Pending</u>
(Application Serial No.)	(Filing date)	(Status, patented, pending, abandoned)

As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

I also hereby grant additional Powers of Attorney to the following attorney(s) and/or agent(s) to file and prosecute an international application under the Patent Cooperation Treaty based upon the above-identified application, including a power to meet all designated office requirements for designated states.

David E. Brook	Registration No. 22,592
James M. Smith	Registration No. 28,043
Leo R. Reynolds	Registration No. 20,884
Richard A. Wise	Registration No. 18,041
Patricia Granahan	Registration No. 32,227
Mary Lou Wakimura	Registration No. 31,804
Thomas O. Hoover	Registration No. 32,470
Alice O. Carroll	Registration No. 33,542
N. Scott Pierce	Registration No. 34,900
Helen E. Wendler	Registration No. 37,964

all of Hamilton, Brook, Smith and Reynolds, P.C., Two Militia Drive, Lexington, Massachusetts 02173;

and

Send correspondence to: David E. Brook, Esq.

Hamilton, Brook, Smith & Reynolds, P.C.  
Two Militia Drive, Lexington, Massachusetts 02173

Direct telephone calls to: David E. Brook, Esq.

617-861-6240

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.



I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first  
inventor, if any Craig J. Gerard  
First Inventor's  
Signature [Signature] Date 12/18/96  
Residence 117 Walpole Street  
Dover, Massachusetts 02030  
Citizenship United States  
Post Office Address Same as above

Full name of second  
joint inventor Norma P. Gerard  
Inventor's  
Signature [Signature] Date 12/16/96  
Residence 117 Walpole Street  
Dover, Massachusetts 02030  
Citizenship United States  
Post Office Address Same as above

Full name of third  
joint inventor Charles R. Mackay  
Inventor's  
Signature \_\_\_\_\_ Date \_\_\_\_\_  
Residence 126 Church Street  
Watertown, Massachusetts 02172  
Citizenship Australia  
Post Office Address Same as above

Full name of fourth joint  
inventor, if any Paul D. Ponath  
Third Inventor's  
Signature \_\_\_\_\_ Date \_\_\_\_\_  
Residence 45 Upton #3  
Boston, Massachusetts 02118  
Citizenship United States  
Post Office Address Same as above

Full name of fifth joint  
inventor, if any Theodore W. Post  
Third Inventor's  
Signature \_\_\_\_\_ Date \_\_\_\_\_  
Residence 14 Mandalay Road  
Newton, Massachusetts 02159  
Citizenship United States  
Post Office Address Same as above

Full name of sixth joint  
inventor, if any Shixin Qin  
Second Inventor's  
Signature \_\_\_\_\_ Date \_\_\_\_\_  
Residence 14 Taft Avenue  
Lexington, Massachusetts 02173  
Citizenship China  
Post Office Address Same as above  
\_\_\_\_\_  
\_\_\_\_\_

AJC50:1ks945a2.DEC

SECRET

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Declaration for Patent Application

As a named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated next to my name;

I believe I am the original, first and sole inventor (if only one name is listed) or an original, first and joint inventor (if plural names are listed in the signatory page(s) commencing at page 3 hereof) of the subject matter which is claimed and for which a patent is sought on the invention entitled

G PROTEIN-COUPLED RECEPTOR GENE CCR3 AND ANTAGONISTS THEREOF

the specification of which (check one)

☐ is attached hereto.

☒ was filed on September 30, 1996 as  
Application Serial No. 08/720,565  
and was amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is known by me to be material to patentability as defined in 37 C.F.R. §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

<u>Prior Foreign Application(s)</u>			Priority Not Claimed
_____ (Number)	_____ (Country)	_____ (Day/Month/Year filed)	<input type="checkbox"/>
_____ (Number)	_____ (Country)	_____ (Day/Month/Year filed)	<input type="checkbox"/>
_____ (Number)	_____ (Country)	_____ (Day/Month/Year filed)	<input type="checkbox"/>

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

_____ (Application Number)	_____ (Filing Date)
-------------------------------	------------------------

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information known by me to be material to patentability as defined in 37 C.F.R. §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

<u>PCT/US96/00608</u>	<u>01-19-96</u>	<u>Pending</u>
(Application Serial No.)	(Filing date)	(Status, patented, pending, abandoned)
<u>08/375,199</u>	<u>01-19-95</u>	<u>Pending</u>
(Application Serial No.)	(Filing date)	(Status, patented, pending, abandoned)

As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

I also hereby grant additional Powers of Attorney to the following attorney(s) and/or agent(s) to file and prosecute an international application under the Patent Cooperation Treaty based upon the above-identified application, including a power to meet all designated office requirements for designated states.

David E. Brook	Registration No. 22,592
James M. Smith	Registration No. 28,043
Leo R. Reynolds	Registration No. 20,884
Richard A. Wise	Registration No. 18,041
Patricia Granahan	Registration No. 32,227
Mary Lou Wakimura	Registration No. 31,804
Thomas O. Hoover	Registration No. 32,470
Alice O. Carroll	Registration No. 33,542
N. Scott Pierce	Registration No. 34,900
Helen E. Wendler	Registration No. 37,964

all of Hamilton, Brook, Smith and Reynolds, P.C., Two Militia Drive, Lexington, Massachusetts 02173;

and

Send correspondence to: David E. Brook, Esq.

Hamilton, Brook, Smith & Reynolds, P.C.  
Two Militia Drive, Lexington, Massachusetts 02173

Direct telephone calls to: David E. Brook, Esq.

617-861-6240

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.


Full name of sole or first  
inventor, if any Craig J. Gerard  
First Inventor's  
Signature \_\_\_\_\_ Date \_\_\_\_\_  
Residence 117 Walpole Street  
Dover, Massachusetts 02030  
Citizenship United States  
Post Office Address Same as above

Full name of second  
joint inventor Norma P. Gerard  
Inventor's  
Signature \_\_\_\_\_ Date \_\_\_\_\_  
Residence 117 Walpole Street  
Dover, Massachusetts 02030  
Citizenship United States  
Post Office Address Same as above

Full name of third  
joint inventor Charles R. Mackay  
Inventor's  
Signature Chas Mackay Date 12/17/96  
Residence 126 Church Street  
Watertown, Massachusetts 02172  
Citizenship Australia  
Post Office Address Same as above

Full name of fourth joint  
inventor, if any Paul D. Ponath  
Third Inventor's  
Signature Paul D Ponath Date 12-17-96  
Residence 45 Upton #3  
Boston, Massachusetts 02118  
Citizenship United States  
Post Office Address Same as above

Full name of fifth joint  
inventor, if any Theodore W. Post  
Third Inventor's  
Signature \_\_\_\_\_ Date \_\_\_\_\_  
Residence 14 Mandalay Road  
Newton, Massachusetts 02159  
Citizenship United States  
Post Office Address Same as above

Full name of sixth joint  
inventor, if any Shixin Qin  
Second Inventor's  
Signature  Date 12-17-96  
Residence 14 Taft Avenue  
Lexington, Massachusetts 02173  
Citizenship China  
Post Office Address Same as above  
-----  
-----

AJC50:lls945a2.DEC

2025 RELEASE UNDER E.O. 14176

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Declaration for Patent Application

As a named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated next to my name;

I believe I am the original, first and sole inventor (if only one name is listed) or an original, first and joint inventor (if plural names are listed in the signatory page(s) commencing at page 3 hereof) of the subject matter which is claimed and for which a patent is sought on the invention entitled

G PROTEIN-COUPLED RECEPTOR GENE CCR3 AND ANTAGONISTS THEREOF

the specification of which (check one)

☐ is attached hereto.

☒ was filed on September 30, 1996 as  
Application Serial No. 08/720,565  
and was amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is known by me to be material to patentability as defined in 37 C.F.R. §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

Priority  
Not  
Claimed

_____ (Number)	_____ (Country)	_____ (Day/Month/Year filed)	[ <input type="checkbox"/> ]
_____ (Number)	_____ (Country)	_____ (Day/Month/Year filed)	[ <input type="checkbox"/> ]
_____ (Number)	_____ (Country)	_____ (Day/Month/Year filed)	[ <input type="checkbox"/> ]

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

_____ (Application Number)	_____ (Filing Date)
-------------------------------	------------------------

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information known by me to be material to patentability as defined in 37 C.F.R. §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

<u>PCT/US96/00608</u>	<u>01-19-96</u>	<u>Pending</u>
(Application Serial No.)	(Filing date)	(Status, patented, pending, abandoned)
<u>08/375,199</u>	<u>01-19-95</u>	<u>Pending</u>
(Application Serial No.)	(Filing date)	(Status, patented, pending, abandoned)

As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

I also hereby grant additional Powers of Attorney to the following attorney(s) and/or agent(s) to file and prosecute an international application under the Patent Cooperation Treaty based upon the above-identified application, including a power to meet all designated office requirements for designated states.

David E. Brook	Registration No. 22,592
James M. Smith	Registration No. 28,043
Leo R. Reynolds	Registration No. 20,884
Richard A. Wise	Registration No. 18,041
Patricia Granahan	Registration No. 32,227
Mary Lou Wakimura	Registration No. 31,804
Thomas O. Hoover	Registration No. 32,470
Alice O. Carroll	Registration No. 33,542
N. Scott Pierce	Registration No. 34,900
Helen E. Wendler	Registration No. 37,964

all of Hamilton, Brook, Smith and Reynolds, P.C., Two Militia Drive, Lexington, Massachusetts 02173;

and

Send correspondence to: David E. Brook, Esq.

Hamilton, Brook, Smith & Reynolds, P.C.  
Two Militia Drive, Lexington, Massachusetts 02173

Direct telephone calls to: David E. Brook, Esq.

617-861-6240

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.



I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first  
inventor, if any Craig J. Gerard  
First Inventor's  
Signature \_\_\_\_\_ Date \_\_\_\_\_  
Residence 117 Walpole Street  
Dover, Massachusetts 02030  
Citizenship United States  
Post Office Address Same as above

Full name of second  
joint inventor Norma P. Gerard  
Inventor's  
Signature \_\_\_\_\_ Date \_\_\_\_\_  
Residence 117 Walpole Street  
Dover, Massachusetts 02030  
Citizenship United States  
Post Office Address Same as above

Full name of third  
joint inventor Charles R. Mackay  
Inventor's  
Signature \_\_\_\_\_ Date \_\_\_\_\_  
Residence 126 Church Street  
Watertown, Massachusetts 02172  
Citizenship Australia  
Post Office Address Same as above

Full name of fourth joint  
inventor, if any Paul D. Ponath  
Third Inventor's  
Signature \_\_\_\_\_ Date \_\_\_\_\_  
Residence 45 Upton #3  
Boston, Massachusetts 02118  
Citizenship United States  
Post Office Address Same as above

Full name of fifth joint  
inventor, if any Theodore W. Post  
Third Inventor's  
Signature Theodore W. Post Date 12/12/96  
Residence 14 Mandalay Road  
Newton, Massachusetts 02159  
Citizenship United States  
Post Office Address Same as above

Full name of sixth joint  
inventor, if any Shixin Qin  
Second Inventor's  
Signature \_\_\_\_\_ Date \_\_\_\_\_  
Residence 14 Taft Avenue  
Lexington, Massachusetts 02173  
Citizenship China  
Post Office Address Same as above  
-----

AJC50:lks945a2.DEC

Sequence Range: 1 to 1689

```

      10      20      30      40
AAT CCT TTT CCT GGC ACC TCT GAT ATC CTT TTG AAA TTC ATC TTA AAG
50      60      70      80      90
AAT CCC TAG GCT GCT ATC ACA TGT GGC ATC TTT GTT GAG TAC ATG AAT
100     110     120     130     140
AAA TCA ACT GGT GTG TTT TAC GAA GGA TGA TTA TGC TTC ATT GTG GGA
150     160     170     180     190
TTG TAT TTT TCT TCT TCT ATC ACA GGG AGA AGT GAA ATG ACA ACC TCA
Met Thr Thr Ser>
200     210     220     230     240
CTA GAT ACA GTT GAG ACC TTT GGT ACC ACA TCC TAC TAT GAT GAC GTG
Leu Asp Thr Val Glu Thr Phe Gly Thr Thr Ser Tyr Tyr Asp Asp Val>
250     260     270     280
GGC CTG CTC TGT GAA AAA GCT GAT ACC AGA GCA CTG ATG GCC CAG TTT
Gly Leu Leu Cys Glu Lys Ala Asp Thr Arg Ala Leu Met Ala Gln Phe>
290     300     310     320     330
GTG CCC CCG CTG TAC TCC CTG GTG TTC ACT GTG GGC CTC TTG GGC AAT
Val Pro Pro Leu Tyr Ser Leu Val Phe Thr Val Gly Leu Leu Gly Asn>
340     350     360     370     380
GTG GTG GTG GTG ATG ATC CTC ATA AAA TAC AGG AGG CTT CGA ATT ATG
Val Val Val Val Met Ile Leu Ile Lys Tyr Arg Arg Leu Arg Ile Met>
390     400     410     420     430
ACC AAC ATC TAC CTG CTC AAC CTG GCC ATT TCG GAC CTG CTC TTC CTC
Thr Asn Ile Tyr Leu Leu Asn Leu Ala Ile Ser Asp Leu Leu Phe Leu>
440     450     460     470     480
GTC ACC CTT CCA TTC TGG ATC CAC TAT GTC AGG GGG CAT AAC TGG GTT
Val Thr Leu Pro Phe Trp Ile His Tyr Val Arg Gly His Asn Trp Val>
490     500     510     520
TTT GGC CAT GGC ATG TGT AAG CTC CTC TCA GGG TTT TAT CAC ACA GGC
Phe Gly His Gly Met Cys Lys Leu Leu Ser Gly Phe Tyr His Thr Gly>
530     540     550     560     570
TTG TAC AGC GAG ATC TTT TTC ATA ATC CTG CTG ACA ATC GAC AGG TAC
Leu Tyr Ser Glu Ile Phe Phe Ile Ile Leu Leu Thr Ile Asp Arg Tyr>
580     590     600     610     620
CTC GCC ATT GTC CAT GCT GTG TTT GCC CTT CGA GCC CGG ACT GTC ACT

```

FIGURE 1A

005365-1039

Leu Ala Ile Val His Ala Val Phe Ala Leu Arg Ala Arg Thr Val Thr>  
 630 640 650 660 670  
 \* \* \* \* \*  
 TTT GGT GTC ATC ACC ASC ATC GTC ACC TGG CGC CTG GCA GTG CTA GCA  
 Phe Gly Val Ile Thr Ser Ile Val Thr Trp Gly Leu Ala Val Leu Ala>  
 680 690 700 710 720  
 \* \* \* \* \*  
 GCT CTT CCT GAA TTT ATC TTC TAT CAG ACT GAA CAG TTG TTT GAA GAG  
 Ala Leu Pro Glu Phe Ile Phe Tyr Glu Thr Glu Glu Leu Phe Glu Glu>  
 730 740 750 760  
 \* \* \* \* \*  
 ACT CTT TGC AGT GCT CTT TAC CCA GAG CAT ACA GTA TAT AGC TGG AGG  
 Thr Leu Cys Ser Ala Leu Tyr Pro Glu Asp Thr Val Tyr Ser Trp Arg>  
 770 780 790 800 810  
 \* \* \* \* \*  
 CAT TTC CAC ACT CTG AGA ATG ACC ATC TTC TGT CTC GTT CTC CCT CTG  
 His Phe His Thr Leu Arg Met Thr Ile Phe Cys Leu Val Leu Pro Leu>  
 820 830 840 850 860  
 \* \* \* \* \*  
 CTC GTT ATG GCC ATC TGC TAC ACA GGA ATC ATC AAA ACG CTG CTG AGG  
 Leu Val Met Ala Ile Cys Tyr Thr Gly Ile Ile Lys Thr Leu Leu Arg>  
 870 880 890 900 910  
 \* \* \* \* \*  
 TGC CCC AGT AAA AAA AAG TAC AAG GCC ATC CGG CTC ATT TTT GTC ATC  
 Cys Pro Ser Lys Lys Lys Tyr Lys Ala Ile Arg Leu Ile Phe Val Ile>  
 920 930 940 950 960  
 \* \* \* \* \*  
 ATG GCG CTG TTT TTC ATT TTC TGG ACA CCC TAC AAT GTG GCT ATC CTT  
 Met Ala Val Phe Phe Ile Phe Trp Thr Pro Tyr Asn Val Ala Ile Leu>  
 970 980 990 1000  
 \* \* \* \* \*  
 CTC TCT TCC TAT CAA TCC ATC TTA TTT GGA AAT GAC TGT GAG CGG ACG  
 Leu Ser Ser Tyr Gln Ser Ile Leu Phe Gly Asn Asp Cys Glu Arg Thr>  
 1010 1020 1030 1040 1050  
 \* \* \* \* \*  
 AAG CAT CTG GAC CTG GTC ATG CTG GTG ACA GAG GTG ATC GCC TAC TCC  
 Lys His Leu Asp Leu Val Met Leu Val Thr Glu Val Ile Ala Tyr Ser>  
 1060 1070 1080 1090 1100  
 \* \* \* \* \*  
 CAC TGC TGC ATG AAC CCG GTG ATC TAC GCC TTT GTT GGA GAG AGG TTC  
 His Cys Cys Met Asn Pro Val Ile Tyr Ala Phe Val Gly Glu Arg Phe>  
 1110 1120 1130 1140 1150  
 \* \* \* \* \*  
 CGG AAG TAC CTG CGC CAC TTC TTC CAC AGG CAC TTG CTC ATG CAC CTG  
 Arg Lys Tyr Leu Arg His Phe Phe His Arg His Leu Leu Met His Leu>  
 1160 1170 1180 1190 1200  
 \* \* \* \* \*  
 GGC AGA TAC ATC CCA TTC CTT CCT AGT GAG AAG CTG GAA AGA ACC AGC  
 Gly Arg Tyr Ile Pro Phe Leu Pro Ser Glu Lys Leu Glu Arg Thr Ser>

FIGURE 1B

1210                      1220                      1230                      1240  
 \*                      \*                      \*                      \*  
 TCT GTC TCT CCA TCC ACA GCA GAG CCG GAA CTC TCT ATT GTG TTT TAG  
 Ser Val Ser Pro Ser Thr Ala Glu Pro Glu Leu Ser Ile Val Phe \*\*\*>

1250                      1260                      1270                      1280                      1290  
 \*                      \*                      \*                      \*                      \*  
 GTA GAT GCA GAA AAT TGC CTA AAG AGG AAG GAC CAA CGA GAT NAA GCA

1300                      1310                      1320                      1330                      1340  
 \*                      \*                      \*                      \*                      \*  
 AAC ACA TTA AGC CTT CCA CAC TCA CCT CTA AAA CAG TCC TTC AAA CCT

1350                      1360                      1370                      1380                      1390  
 \*                      \*                      \*                      \*                      \*  
 TCC AGT GCA ACA CTG AAG CTC TTA ACA CAC TGA AAT ATA CAC ACA GCA

1400                      1410                      1420                      1430                      1440  
 \*                      \*                      \*                      \*                      \*  
 GTA GCA GTA GAT GCA TGT ACC CTA AGG TCA TTA CCA CAG GCC AGG CCT

1450                      1460                      1470                      1480  
 \*                      \*                      \*                      \*  
 GGG CAG CGT ACT CAT CAT CAA CCT AAA AAG CAG AGC TTT GCT TCT CTC

1490                      1500                      1510                      1520                      1530  
 \*                      \*                      \*                      \*                      \*  
 TCT AAA ATG AGT TAC CTA TAT TTT AAT GCA CCT GAA TGT TAG ATA GTT

1540                      1550                      1560                      1570                      1580  
 \*                      \*                      \*                      \*                      \*  
 ACT ATA TGC CGC TAC AAA AAG GTA AAA CTT TTT ATA TTT TAT ACA TTA

1590                      1600                      1610                      1620                      1630  
 \*                      \*                      \*                      \*                      \*  
 ACT TCA GCC AGC TAT TAT ATA AAT AAA ACA TTT TCA CAC AAT ACA ATA

1640                      1650                      1660                      1670                      1680  
 \*                      \*                      \*                      \*                      \*  
 AGT TAA CTA TTT TAT TTT CTA ATG TGC CTA GTT CTT TCC CTG CTT AAT

GAA AAG CTT

FIGURE 1C


10 20 30 40 50 60  
 \* \* \* \* \*  
 TTGTGCTTAT CCGGGCAAGA ACTTATCGAA ATACAATAGA AGACCCACGC GTCCGGTTTT  
 70 80 90 100 110  
 \* \* \* \* \*  
 TACTTAGAAG AGATTTTCAG GGAGAAGTGA A ATG ACA ACC TCA CTA GAT ACA GTT  
 M T T S L D T V>  
 120 130 140 150 160  
 \* \* \* \* \*  
 GAG ACC TTT GGT ACC ACA TCC TAC TAT GAT GAC GTG GGC CTG CTC TGT  
 E T F G T T S Y Y D D V G L L C>  
 170 180 190 200 210  
 \* \* \* \* \*  
 GAA AAA GCT GAT ACC AGA GCA CTG ATG GCC CAG TTT GTG CCC CCG CTG  
 E K A D T R A L M A Q F V P P L>  
 220 230 240 250  
 \* \* \* \* \*  
 TAC TCC CTG GTG TTC ACT GTG GGC CTC TTG GGC AAT GTG GTG GTG GTG  
 Y S L V F T V G L L G N V V V V>  
 260 270 280 290 300  
 \* \* \* \* \*  
 ATG ATC CTC ATA AAA TAC AGG AGG CTC CGA ATT ATG ACC AAC ATC TAC  
 M I L I K Y R R L R I M T N I Y>  
 310 320 330 340 350  
 \* \* \* \* \*  
 CTG CTC AAC CTG GCC ATT TCG GAC CTG CTC TTC CTC GTC ACC CTT CCA  
 L L N L A I S D L L F L V T L P>  
 360 370 380 390 400  
 \* \* \* \* \*  
 TTC TGG ATC CAC TAT GTC AGG GGG CAT AAC TGG GTT TTT GGC CAT GGC  
 F W I H Y V R G H N W V F G H G>  
 410 420 430 440 450  
 \* \* \* \* \*  
 ATG TGT AAG CTC CTC TCA GGG TTT TAT CAC ACA GGC TTG TAC AGC GAG  
 M C K L L S G F Y H T G L Y S E>  
 460 470 480 490  
 \* \* \* \* \*  
 ATC TTT TTC ATA ATC CTG CTG ACA ATC GAC AGG TAC CTG GCC ATT GTC  
 I F F I I L L T I D R Y L A I V>  
 500 510 520 530 540  
 \* \* \* \* \*  
 CAT GCT GTG TTT GCC CTT CGA GCC CGG ACT GTC ACT TTT GGT GTC ATC  
 H A V F A L R A R T V T F G V I>  
 550 560 570 580 590  
 \* \* \* \* \*  
 ACC AGC ATC GTC ACC TGG GGC CTG GCA GTG CTA GCA GCT CTT CCT GAA  
 T S I V T W G L A V L A A L P E>

FIGURE 2A

600                      610                      620                      630                      640  
 \*                      \*                      \*                      \*                      \*  
 TTT ATC TTC TAT GAG ACT GAA GAG TTG TTT GAA GAG ACT CTT TGC AGT  
 F I F Y E T E E L F E E T L C S>  
 650                      660                      670                      680                      690  
 \*                      \*                      \*                      \*                      \*  
 GCT CTT TAC CCA GAG GAT ACA GTA TAT AGC TGG AGG CAT TTC CAC ACT  
 A L Y P E D T V Y S W R H F H T>  
 700                      710                      720                      730  
 \*                      \*                      \*                      \*  
 CTG AGA ATG ACC ATC TTC TGT CTC GTT CTC CCT CTG CTC GTT ATG GCC  
 L R M T I F C L V L P L L V M A>  
 740                      750                      760                      770                      780  
 \*                      \*                      \*                      \*                      \*  
 ATC TGC TAC ACA GGA ATC ATC AAA ACG CTG CTG AGG TGC CCC AGT AAA  
 I C Y T G I I K T L L R C P S K>  
 790                      800                      810                      820                      830  
 \*                      \*                      \*                      \*                      \*  
 AAA AAG TAC AAG GCC ATC CGG CTC ATT TTT GTC ATC ATG GCG GTG TTT  
 K K Y K A I R L I F V I M A V F>  
 840                      850                      860                      870                      880  
 \*                      \*                      \*                      \*                      \*  
 TTC ATT TTC TGG ACA CCC TAC AAT GTG GCT ATC CTT CTC TCT TCC TAT  
 F I F W T P Y N V A I L L S S Y>  
 890                      900                      910                      920                      930  
 \*                      \*                      \*                      \*                      \*  
 CAA TCC ATC TTA TTT GGA AAT GAC TGT GAG CGG AGC AAG CAT CTG GAC  
 Q S I L F G N D C E R S K H L D>  
 940                      950                      960                      970  
 \*                      \*                      \*                      \*  
 CTG GTC ATG CTG GTG ACA GAG GTG ATC GCC TAC TCC CAC TGC TGC ATG  
 L V M L V T E V I A Y S H C C M>  
 980                      990                      1000                      1010                      1020  
 \*                      \*                      \*                      \*                      \*  
 AAC CCG GTG ATC TAC GCC TTT GTT GGA GAG AGG TTC CGG AAG TAC CTG  
 N P V I Y A F V G E R F R K Y L>  
 1030                      1040                      1050                      1060                      1070  
 \*                      \*                      \*                      \*                      \*  
 CGC CAC TTC TTC CAC AGG CAC TTG CTC ATG CAC CTG GGC AGA TAC ATC  
 R H F F H R H L L M H L G R Y I>  
 1080                      1090                      1100                      1110                      1120  
 \*                      \*                      \*                      \*                      \*  
 CCA TTC CTT CCT AGT GAG AAG CTG GAA AGA ACC AGC TCT GTC TCT CCA  
 P F L P S E K L E R T S S V S P>  
 1130                      1140                      1150                      1160                      1170  
 \*                      \*                      \*                      \*                      \*  
 TCC ACA GCA GAG CCG GAA CTC TCT ATT GTG TTT TAG G TAGATGCAGA  
 S T A E P E L S I V F \*>  
 1180                      1190  
 \*                      \*  
 AAATTGCCTA AAGAGGAAGG ACC

FIGURE 2B

# A simple leukocyte transendothelial assay for measuring chemotaxis



Insert (cells)

polycarbonate membrane, ECV304 endothelial cells

Bottom chamber (chemokine)

analysis

FIGURE 3






FIGURE 4

# Expression of Eos L2 on stably transfected L1-2 cells

## Flag staining of different clones




FIGURE 5




FIGURE 6




FIGURE 7




FIGURE 8




FIGURE 9A




FIGURE 9B




FIGURE 9C




FIGURE 9D

Fluorescence intensity →




FIGURE 10A




FIGURE 10B




FIGURE 10C




FIGURE 11A




FIGURE 11B




FIGURE 11C




FIGURE 11D






FIGURE 12




FIGURE 13A




FIGURE 13B




FIGURE 13C




FIGURE 14A




FIGURE 14B




FIGURE 15




FIGURE 16




FIGURE 17

7B11: a monoclonal antibody that specifically recognizes CCR3 and stains eosinophils

L1.2 Transfectants

Leukocytes

FIGURE 18A





FIGURE 18B



Fluorescence intensity 7B11 →




FIGURE 18C







FIGURE 19



# Inhibition of eosinophil chemotaxis to CC chemokines by mAb 7B11

FIGURE 20A eotaxin migration      FIGURE 20B other eos. chemoattractants





Time (sec)

FIGURE 21

FIGURE 22A




FIGURE 22B




FIGURE 22C




FIGURE 22D




FIGURE 23A





FIGURE 23B



Downloaded from www.sagepub.com at UNIV OF CALIF SAN DIEGO on June 11, 2015




FIGURE 24A




FIGURE 24B

Enzyme release from eosinophil specific granules by eotaxin




FIGURE 25




FIGURE 26

Enzyme release from eosinophil small granules by eotaxin




FIGURE 27

46011 333330




FIGURE 28



# Histamine release by human basophils in response to chemokines




FIGURE 29

# Basophils chemotax to eotaxin and MCP-4

Blockade with anti-CCR3 mAb 7B11




FIGURE 30A




FIGURE 30B